Evaluation of process simulators for an integrated bioprocess design by Rouf, Sabina Ahmad
EVALUATION OF PROCESS SIMULATORS FOR AN 
MTEGRATED BIOPROCESS DESIGN 
by 
Sabina Ahmad Rouf 
A thesis 
presented to the University of Waterloo 
in fiilfiIlment of the 
thesis requirement for the degree of 
Doctor of Philosophy 
in 
Chernical Engineering 
Waterloo, Ontario, Canada, 1999 
S Sabina Ahmad Rouf, 1999 
uisitions and 9- Acquisitions et Bb iogaphic Services services bibliographiques 
395 W- Street 395. W43Uingm 
OüawaON K l A W  OltawaûN K 1 A W  
canas Canada 
The author has granted a non- 
exclusive licence allowing the 
National Lib~ary of Canada to 
reproduce, loan, distriiute or sell 
copies of this thesis in microforrn, 
papa or electronic formats. 
The a d o r  retains ownership of the 
copyright in this thesis. Neither the 
thesis nor substantiai extracts fiom it 
may be printed or otherwise 
reproduced without the author's 
permission. 
L'auteur a accordé une licence non 
exclusive permettant a La 
Bibliothèque nationale du Canada de 
reproduire, prêter, distriiuer ou 
vendre des copies de cette thèse sous 
la forme de microfiche/film, de 
reproduction sur papier ou sur format 
électronique. 
L'auteur conserve la propriété du 
droit d'auteur qui protége cette thése. 
Ni la thèse ni des extraits substantie1s 
de celle-ci ne doivent être imprimés 
ou autrement reproduits sans son 
autorisation. 
The University of Waterloo requires the signatures of al1 pmons using or photocopying 
this thesis. PIease sign below, and give address and date. 
iii 
Evaluation of Process Sirnulators 
for an Integrated Bioprocess Design 
ABSTRACT 
Several altemate flowsheets for the production of tissue plasrninogen activator (t-PA) in 
Chinese hamster ovary (CHO) cells were simulated using "BioProcess Simulatorw' 
(BPS) of Aspen Technology Inc. The flowsheet developed for typical conditions 
reported for laboratory-scale production and purification of t-PA was defined as the base 
case. The altemate flowsheets differed in the fermentation media, type and mode of 
operation of the bioreactor and scaie-up strategy. A triai and enor method was used to 
design the downstream processing train so that the required purity and specified ovedl  
recovery are met within a predetemiineed batch time. The simulator was also used to 
cary out economic evaluation of process alternatives. Overail economic performance 
was measured in ternis of return on investment (ROI) and gross margin (GM). The 
flowsheet that used a fed-batch mode of operation for the bioreactor was found to r e d t  
in the larges ROI. This was followed by a multiple bioreactor flowsheet, where the 
downstream train was much mialler compared to the base case. A two-stage ce11 culture 
process increased the ROI of the process by 44% whereas, the ROI increased only 
marginaily by replacing the stirred ta& bioreactor with an airlift bioreactor. 
Simulation of the base case was also d e d  out with "SuperPro Designer@" of 
Intelligen Inc. The simulation was found to be simpler and faster using the short cut unit 
operation models. However, due to flexibility and thoroughness of the simulation, as 
weli as analyticd abiiity, BPS was found to be more suitable for a detailed process 
design. On the other han& contmy to experimental obsewations, the rigorous models of 
BPS for some units (e.g. chromatography) generated results which were found to be 
insensitive to variations in process parameters. 
To backup the simulation results, a sensitivity hidy of the process performance to 
uncertain parameters and variables was carried out using BioProcess SimulatorTM. The 
membrane separation units were found to be most sensitive to flow velocity and 
exponent 'b', that accounts for dependence of gel resistance on Reynolds number. Both 
of these quantities affect the thickness of the boundary layer, thereby reducing gel 
resistance. For the chromatography columns, solute capacity was found to be the cntical 
parameter. The performance of the affkity chromatography was sensitive to the choice 
of the Langmuir isotherm constant, whereas the ion exchange column was sensitive to 
charge on the t-PA molecule. Resolution in the gel filtration column was most 
significantly affected by column length and to a lesser extent, by load volume and flow 
rate within the range studied. Among the economic parameters, ROI was found to be 
most sensitive to changes in equipment cost, followed by raw materials cos. A large 
increase in ROI was observed with improvements in overall recovery and could serve as 
an incentive to optimize the operation of the processes. 
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1 .l . Design of Large Scale Process for Blopharrnaceuticals 
As biotechnology moves h m  the nscarch laboratory to the marketplace (Table 1.1.1). 
the developmcnt of large-scale production professes for biopharmactuticals becoms 
inentable. Biopharmccuticais, particuiarly giycosylated proteins, are mostly produced in 
animrl ceiis bccausc of the fidtiity with whkh animai cc& can produce authcntrdy 
processed hurnan prote&. The swxcss of the overaii production process depends to a 
grrat exteut on the successfui integration of the expression systeq the c d  culnirr system 
and the processing methods appkd to produce the hished proâuct (Canwnght, 1994). 
Tabk 1.1.1: Thcraptutic product stanis ( S b 1  and Qiow, 1989) 
On Market 
humaninsuün(hmsiilin) 
huniaa mwth horxmnt (h GH) 
alpha intcrfkron (A-INF) 
L 
OICI3 
hepatitis-B vaccine (HEP-B VAC) 
tissue plasminogen activator (t-PA) 
E r y t h r o p ~ t i n ( E P 0 )  
Year of Entry 
'83 a 






The purity requirement of biopharmaceuticals is very seingent. In general, the final 
product should be fke of infectious agents and meet the specifïed limits for other 
con taminants such as DNA, cell and media proteins, endotoxin, etc. (Anicetti et al., 
1989). In addition, chemicd con taminants such as antifoam agents, antibiotics, leached 
chromatographie ligands and so on should be eliminated fiom the finished product. 
Downstream processing, therefore, serves as the primary guardian for safety, purity, 
potency and consistency of the product as required by regdatory agencies. 
Purification of products fiom animal cells to the required puity is extrernely challenging 
because some of the impurities have properties similar to the required product. The use 
of complex medium provides a hi& level of background protein, often globally sirnilar 
in physicochemical properties to the product. Generation of closely related product 
variants cm m e r  complicate the situation. Product variants can fonn due to 
differential glycosylation in which changing culture conditions during the fermentation 
nui result in the synthesis of a preponderance of different glycofonns at different stages. 
Variants may also r e d t  fiom partial proteolytic cleavage due either to the variable 
activity of cellular processing enzyme, the induction of extracellular protease, or to ce11 
lysis. Interaction between the product and macromolecular medium components can give 
rise to high molecuiar weight complexes. These complexes, although inactive, can co- 
puXy with the product (Cartwright, 1994). 
Since the required protein is unially of a labile nature, ody mild purification techniques 
can be applied. Therefore, the maintenance of a sterile atmosphere to exclude infectious 
agents and produce apyrogenic product becomes clifficuit. In addition, the level at which 
animal ceLls secrete proteins is low in most cases and the harvested supernatant contains 
only a low concentration of the secreted pduct .  Purification techniques work less 
efficiently in this situation and if the product is present at too low a concentration or as a 
very low percentage of the total protein, purification may not be practid either 
technicalIy or economically. 
Downstrram processing, therefore, plays a detenninant role in achieving the purity and 
assuring the d e t y  of biopharmaceutical products derived h m  animal cells. For high 
value products, downstream processing accounts for at least 70 to 80% of the o v d l  
costs. Hence, it is usually the effdveness of downstream processing which determines 
the economic viability of such a process (Cartwright, 1994). 
There is no algorithm or procedure by which one can proceed, step by step, to develop a 
foolproof large-scale design. The number of options for protein purification is so large 
that one cannot say that there is only one right method or one best process. Each protein 
is different and these differences preclude the formal development of an algorithm for 
designing downstream processes (Wheelwright, I W l )  although the strategy is sirnilar. 
The design of bioprocesses is complicated by its impact on the competitive advantage. 
Anything that provides an edge over cornpetitors or serves to differentiate the product 
nom similar products is a source of advantage. There are three main sources of 
competitive advantage in the manufacture and sale of high value products: fm to 
market, high quality and low coa (Figure 1.1). Each of these offers advantages that can 
be realized only at the expense of the others. The optimal process is that which gives the 
best performance with respect to the desired advantage. Early market penetration is often 
critical for economic success of a new biophannaceutical product. The Company 
First to Market 
Low Cost 
Figure 1.1 : The competitive advantage for optimal bioprocess design 
that is the first to market a new protein enjoys a substantid advantage over the 
competitors, particularly if k ing  first to market includes king first with patent 
protection. The Company that fuids itself in second place rnay manage only one-tenth the 
sales of the company that got there first. With this difference, it obviously makes little 
sense to spend years developing the lowest cost process if long term development means 
losing the race. On the other hand, if the product is not unique or if it can exist in many 
forms, then a greater advantage rnay be obtained by differentiation of quality tban by 
king first to market. 
Many products must share the market with competitors for v ~ o u s  reasons, such as 
insufficient patent protection to keep al1 competition off the market. In such w e s  king 
first to market rnay not be enough to ensure competitive advantage and product 
differentiation rnay be obtained by varying the characteristics of the product. A protein 
that is more pure, is more active, has greater lot-to-lot consistency or is improved by 
some other measure of performance rnay outshine the competition. Similarly, a company 
that cm configure its product in more alternatives to suit individual customers, shows 
greater flexibility and rnay gain an advantage. 
As a product acquires competitors, price becomes a greater issue with customers and 
lower cost products gain an advantage. Of course, the lower the cost is fiom the 
beginning, the higher the margin and the p a t e r  the profit. Thus the company whose 
process designer has initially developcd a lower cost process prevails over the company 
that must redesign to lower its cost. Regulatory restrictions impose such a high coa on 
process change that good original design provides a competitive edge. 
Once the competitive edge has ken  identined, it must be maintaineci as the criterion for 
evaluation of process design because it defines the goal. The moa profitable process is 
the one that minimizes time to market, m a x h k s  a differentiating characteristic or 
minimizes c o s  within the constraints of product specincations and available resources. 
In a regulated industry changes in rnanufacturing methods tend to be expensive as they 
often require repeated studies of safety and efficacy as well as delays resulting fiom 
seeking approval for the changes. Builder et al. (1988) estimates, for a licemed product, 
a minimum of two years frorn the t h e  of conception of a process change until the point 
when a liceme amendment rnay be granted. The cost for the entire effort could be 
millions of dollars. Thus design may be difficult to alter once a validated process has 
been established. Rushing in with an incomplete or illdefined process may cause 
considerable difficulties once the product is on the market (Wheelwright, 19%). 
Process design and scale up may be divided into three distinct steps: selection of unit 
operations, optimization of operating parameters at the small scale and increase of 
equipment size while maintaining the same operating parameters. The design of a large- 
scale protein purification process is an evolutionary method as s h o w  in Figure 1.2. 
The most cornmon approach to d o m  process design is to adapt a standard 
purification strategy. The advantage of copying an existing process is that the 
development t h e  is less. If the protein at hand is similar in nature, characteristics and 
properties to other proteins for which purification process exists, then copying the 
existing method rnay be very seaightforward and simple. But every protein is ciiffernit 
and there is no guarantee that this will produce acceptable material. The product rnay 
also be unrepresented in the literature. In these cases, another method of process 
development must be looked for. 
The second method, both in terms of most common application and in order of 
complexity, is cailed "heuristics " or d e s  of thumb. Heuristics serve as guidelines ody  
for approximate design. The purpose of heuristics is to n m w  the list of possible 
separation steps based on general experience. 
Process Synthesis 
Design Basis 
(product specification) - Design Strategy 
Scale-down lab trial 1 (mas balances, data collection) 
l financial anal y sis 
compare against 
Transfer to manufacturing 
Figure 1.2: Process synthesis flowchart (Wheelwright, 199 1 ) 
A third approach in the process design is the use of expert systems. The idea here is to 
follow the pattern of thought of the expert designer through a series of if-then postdates. 
Expert systems are based on models describing the expert; they do not necessarily follow 
a strict algorithm but rather rely more on qualitative judgments for chwsing among the 
competing alternatives. Leser and Asenjo (1994) have developed an expert system to 
assist the rational sekction of large-scale protein purification processes. This knowledge- 
based expert system is capable of selecting protein recovery, separation and purification 
processes by using a fundamental database conlainhg characteristics of the protein 
molecules. The development of the database for BaculoWus-derived proteins has also 
been described (Turner et al., 1994). The rationale for choosing high-resolution 
separation methods for multicomponent mixtures is based on equations desdbing 
heuristics and the behavior of proteins in chromatographie separations. Siletti and 
Stephanopoulos (1986) also carried out some earlier work in this area. 
The fourth design method is the use of algorithm or mathematical models. The use of a 
mode1 allows investigation of the effects of operating condition changes on the process 
output. The availability of cornputer simulation techniques for process design can greatiy 
facilitate process design using mathematical modeis. Flowsheet simulation offers the 
opportunity to significantly shorten the time required for process development (Cooney 
et al., 1988). Cornputer simulation can be used as a usefiai tool to compare process 
alternatives on a consistent bais and to synthesize and analyze interactively a large 
number of project ideas in a short the .  It can help to screen project ideas by identifying 
the most promishg ones. It can be used to interpret pilot plant data and substantially 
reduce the time and cost for pilot plant development (Grob, 1993). Interactions exist 
among the different stages of a process and early evaluation greatly fafilitates successful 
process design. Performing process design in an integrated manner also results in grrat 
savings in t h e  and cost (Zhou et al., 1997). For example, before finaiking the ceii 
culture system, the impact of medium composition or possible cell lysis on the quaiity of 
the product stream destined for purification, couid be taken into account. Another 
advantage of using process simulation is that al1 aspects of a process (e.g. yields, 
scheduling, economics etc.) are accounted for simultaneously and when changes are 
made to one aspect of the process the impact on al1 other areas is automatically 
determined (Shanklin et al., 1999). 
hocess optbhation by simulation can reduce manufacturhg costs by up to 30 percent 
depending on the process, largely by improwig product recovery yields (Evans, 1988). 
Process development and simultaneous economic evaluation by a sirnulator will result in 
faster, rigorous and consistent economic and technical justification analysis for the 
process. 
The only difficulty with using models to describe highly complex systems is that a 
highly complex model may be required. However, even a simple fundamentai model will 
contribute in the development of heuristics and empiricism. 
The fifth approach can be defined as a hybnd of the preceding metho&. Process 
synthesis may consist of following an existing example, modifying it by means of 
heuristics, following a modified expert system that relies mainly on heuristics or having 
an algorithm for part of the design and using these techniques to combine the unit 
operation in a stepwise fashion. 
1.2. The Present State of Bioprocess Simulation 
The use of cornputer aided-design packages for process simulation, cost estimation, 
equipment sizing and process optimization is widespread for chedcal processes. The 
advantages include reduction of t h e  taken to develop a process design and increase in 
productivity, efficiency and the level of contml of the selected process option (Gntsis 
and Titchener-Hooker, 1 989). 
Cornputer-assisted techniques in biochemicd process industries, however, have not 
found general application aithough the benefits achievable by process simulation in this 
area have been stressed by several investigators (Evans and Field, 1986; Evans, 1988; 
Gritsis and Titchener-Hooker, 1989; Grob, 1993; Petrides, 1994; Aelion and Petrides, 
1994; Petrides et ai., 1996; Zimmermann, 1997). 'T'hem are some significant ciifferences 
between chemical and biochemical processes that necessitated special featiues for 
biochemicai process simulators. First, biochemicd processes use living organism to 
synthesize the desired product. The microbid kinetics is much l e s  understood and 
requim the development of specific biochemical models. D e t e d t i o n  of their rate of 
growth, metabolimi of substrate and product formation requires an understanding of the 
ceIl physiology and biochemistry. The effect of overall process environment and 
operating parameters on the ce11 and its production are much more complicated 
compared to a chemicai process. For example, the level and range of shear force within a 
bioreactor can have a profound effect upon the rate of growth and productivity of some 
organimis (e.g. PeniciIZium chrysogerzum) (Gritsis and Titchener-Hooker, 1989). 
A second feature of biochemicai processes is the heavy use of batch or semi-continuous 
processes (Evans and Field, 1986; Evans, 1988). It is M e r  complicated by the 
combination of batch, semi-continuous and truly continuous modes of operation within 
the same ovemll process. For exarnple. the bioreactor is fiequently operated in a batch 
mode whereas a chromatography column in a cyclic mode. DifXerential equations must 
be used to describe the tirne-dependent batch biochemical processes. ûverlap between 
batch and semi-continuous steps can prove difficult to accmtely simulate (Shanklin, 
1999). Specialized mathematical routines and substantid propmmhg effort is required 
to generate suitable simulaton to solve the systems of differentid and algebraic 
equations (for continuous or equilibrium unit operations), which result fiom the mixed 
mode of operation, over different time domains. The specification of the sequence of 
operation within a unit operation also complicates such a process. For example, the 
sequencing of loading, washing and elution stage of a chromatography column requires 
the specification of an independent variable for each step. 
Finally, many unit operations unique to biochemical engineering are poorly understood 
Thete are predictive models for these operations but quantitative models kquently do 
not exist (e.g. homogenization). A bioprocess simulator must be flexible enough to 
accommodate improved and more sophisticated models, as they are developed (Evans 
and Field, 1986; Evans, 1988). Experimental data and curve fitting provides the simplest 
mode1 for simulation purposes. Empirical models may be developed with parameters and 
constants estimated fiom experimental data (or fiom literahire sources). The most 
sophisticated models, derived fiom first principles, often require detailed thermodynamic 
data on d l  the components. Under this situation prediction of relatively simple 
parameters such as viscosity, becomes difficult. Physicai property information is lacking 
for many typical materials in a bioprocess. 
Nevertheless, several investigaton pumed the development of bioprocess simulators 
adopting two alternative routes. The fm approach was to modify an existing package of 
conventional chernical process simulator. The alternate route has been the use of 
research information and data in order to develop models, which describe individual 
biochemical engineering unit operations and processes. 
The unique requirements of a bioprocess simulator, outlined in the literature (Evans and 
Field, 1986; Evans, 1988; Cooney et al., 1988) and necessitateci by the unique features of 
bioprocesses, are the following: 
Unit operation model: A bioprocess involves unit operations, many of which are not 
avaiiable in conventional chemicai process simulators. Moreover, there are often 
insufEcient data available to develop predictwe models based on first principles. 
Therefore, a bioprocess simulator must provide models at various levels of rigor. 
Initially, the shulator will rely on empincal and semi empirical models requiring user 
nipplied data. Each increase in rigor will require more fwidamental data. The user may 
select the suitable mode1 depending on the need and availability of data The simulator 
must also be flexible enough to accommodate for improved and more sophisticated 
models, as they become available. 
Physical properties: In contrast to chemical process simulaton that deal with liquid and 
vapor only, a biochemicai process involves biomateriaîs such as cells, ce11 debris, 
organic and inorganic solids, proteins and polymers. For best simulation results these 
biomaterials must be characterized according to biological activity, viscosity, solubility, 
diffusivities etc. The physical properties systems should be developed on a rigorous 
framework to provide compatibility with unit operation models that are more dependent 
on physical properties, such as precipitation. The bioprocess simulator should contain a 
collection of methods and modeis to calculate thennodynamic and transport properties of 
conventionai and non-conventional (e.g. proteins, cells, polysaccharides etc.) 
components. This will enable the unit operation models to determine property dependent 
performance and also help to characteriz the process Stream. 
Batch and qcüc processes: The mixed mode of operation that is typical of biochemical 
processes requk development and solution of steady state as well as dynamic models of 
unit operations Dynamic models are usually in the form of non-linear diffmntiai 
equations, which must be integrated over a period of t h e  whereas the steady state 
models are algebraic. The bioprocess simulator mut  be capable of handling these mked 
types of equations and properly integrate the batch processes with the continuous ones. 
Besides the above requirements a bioprocess simulator should also be equipped with a 
fast and effective method for equipment sizing and costing, data regression system and 
an interactive user i n t d c e  (Evans and Field, 1986). 
The fkt attempt at bioprocess simulation was cmied out with Aspen Plus (a chernical 
process simulator) to test its ability to handle biochemical flowsheet (Acetone-Butanol- 
Ethanol process) simulation. (Marlatt and Datta, 1986). This was followed by 
Bhattacharya and Motard (1986), who carried out steady state simulation of the same 
process with ASEPN PLUS modified by addition of some appropriate modules. They 
also studied economics of several process alternatives. 
Its applicability was next explored for simulation and optimization of recovery of 
penicillin G nom fermentation broth (Evans, 1988). Since the recovery process involves 
conventional unit operations such as filtration, solvent extraction, crystallization, drying 
etc., no dificulty was encountered in simulating this process with ASPEN PLUS. The 
authoa also reported the optimization of the solvent extractor performance by 
manipulating the pH and solvent flow rate. The optimum pH thus calculated was found 
to match the actual pH w d  in the process. ASPEN PLUS was used again to demonstrate 
the economic impact of alternative processing stnitegies. An alternate recovery process 
that uses a second extractor to back extract the penicillin to remove impurities was 
evaluated against the standard process. Simulated resdts showed that the two extractor 
mode1 would increase the net recovery cost by 30 percent. 
The same group also simulated the downstrearn processing of a proteolytic enzyme 
(Cooney et al., 1988). The flowsheet for protease recovery involved vacuum filtration 
followed by ultrafiltration to concentrate the product and then spray drying. Since 
models for ultrafiltration and spray drying are not available in ASPEN PLUS, user 
defined blocks were written for these units. The effect of wash water flow rate to the 
filter and the quantity of water removal by the uitrafilter were ais0 studied. 
With these successful results, modification of ASPEN PLUS simdator to a complete 
bioprocess simulator (Aspen Biohcess Simulatory was carried out by including 
typical biochemical unit operations such as chromatography, membraue separation etc. 
The architecture and flow of information in this simulator is shown in Figure 1.3. The 
developers tried to meet most of the aforementioned unique requirements of bio- 
simulators in Aspen BioProcess ShdatorTN. 
Mon of the biochernicai unit operation blocks are available in BioProcess Simulator~ 
(Grob, 1993). There are options for adding user-supplied subroutines to modify the unit 
operation models. There are dynamic models in addition to steady state ones for some of 
the unit operation blocks that normally operate in batch mode (e.g. fermenter, membrane 
separator etc.). To combine the batch operation with the continuous mode, the simulator 
time averages the output of the batch blocks. The average performance is then used to 
treat the batch operation as a "pseudo continuous" unit operation. The simulator accepts 
user supplied panuneter estimation methods. It also accepts wr-defined properties. 
Built in methods are available for the calculation of density and enthalpy with user 
supplied coefficients. 
The application of BioProcess SimulatorM has been demonstrated in the area of process 
development. As an exercise in bioprocess simulation, Petrides et al. (1989) simuiated 
the conceptual design of down stream processing of porcine growth hormone (pGH) 
using BioProcess SimulatorT". A plant was designed to produce 6000 kg/year of purifïed 
pGH. pGH is produced as an intracellular product in recombinant E. d i .  Therefore ce11 
disruption, solubilization, protein refolding etc. were considered essential part of the 
downstream process. Its purification also included typical biochemical operation such as 
high resolution stages (e.g. ion-exchange chromatography). The performance 
characteristics of the unit operation blocks were drawn fiom laboratory and pilot plant 
data. BioProcess SimulatorTL< was also used to calculate process economics. A total 
investment of $3 1.1 S8J8 1 was estimated for this process. 
BioProcess Simulatorm has recentiy (March, 1997) evolved into a new product called 
Batch Plus. Feedback fiom customers such as Novartis Phannaceuticais Corp. (E. 
Process Data 
Chernical and Biochemical Constituents 
Feed Stream Composition and Flows 
Equipment Specincations 
Constrahts 
Input via Interactive menus 
Bioprocess Simulator 
forms and graphics 
, 




















Cash Flow Profiles 
Return on Investment 
Figure 13: Architecture and flow of information in bioprocess simalPtor (Evans, 
1988) 
Hanover, NQ, Eli Lilly & Co. (Indianapolis, IN), Genentech (S. San Francisco, CA) and 
Merck (Whitehouse Station, NJ) fueled evolution of BioProcess Sirdatorm 
(Zimmermann, 1997). Batch Plus takes the user stepwise from laboratory scale to pilot 
stage to full-scale commercial production. It cm be w d  for a wide variety of unit 
operations and genenites cost analysis for each phase of scale-up. An integrated element 
of Batch Plus' cost evaluation is environmental impact assessrnent It provides 
calculations of projected atrnospheric emissions, as well as the contents of solid and 
liquid waste streams (Zimmermann, 1997). Batch Plus is geared to large phannaceutical 
companies with complex recipes. 
The adaptation of an existing flowsheeting program (e.g. Aspen Plus) to develop a 
biochemicai process simulator (such as Aspen Biokocess SimulatorN) has k e n  
criticized by some as being inefficient (Gritsis and Titchener-Hooker, 1989). According 
to Gntsis and Titchener-Hooker (1989), the simulator may still preserve certain 
attributes originating from its chernical engineering parenthood which make it either 
dificdt to use or inappropriate in some biochemid processing tasks. 
With this opinion in rnind, a research group at the University College London (UCL) 
used research information and &ta to develop models that describe individual 
biochemicd engineering unit operations and processes (Gritsis and Titchener-Hooker, 
1989). These were solved using numencal techniques and simulation tools capable of 
carrying out dynamic simulation, such as SPEED UP. Models for precipitation, 
centrifugation and ultrafiltration were developed and were used to simulate a separation 
train consisting of these t h e  consecutive unit operatiom. They also optimized the 
performance of the ultrafiltration unit. 
Later, they extended their models to simulate the purification of alcohol dehydrogenase 
(ADH) (Zhou et al., 1997; Lu et al., 1994). Two new unit operation models for fermenter 
and hornogenizer were included in this simulation. They used g-PROMS, a new equation 
oriented general modeling and simulation package for combined discrete and continuous 
process, to simulate the primary separation stages. 
A pilot d e  venfication of the simulated results was carried out by Clarkson et al. 
(1994). It was found that interaction between the unit operations renilted in poor level of 
agreement for some streams. The models were improved to account for these interactions 
(e-g. particle breakage during centrifugation that reduces the efficiency of precipitation 
step). This group however, has not yet reported development of any mode1 for high- 
resolution steps (Le. chromatography), which have becorne an essential part of down 
stream processing of high value products. Their activity also seems to be confined to 
academic studies. 
Bioko Designer@ appears to be the second commercial bioprocess sirnulator to follow 
Aspen BioProcess Simulatorm. Its development was initiateci at the Biotechnology 
Process Enginee~g Center (BPEC) of MIT and it was later comrnercialized by 
Intelligen Inc. It is claimed to be an attempt in integration of various activities of process 
design such as process synthesis, analysis and evaluation into a coherent package 
(Petrides, 1994). This package uses algorithmic knowledge mainly in the form of short 
cut models for material and energy balances for the unit operatiom. It is also capable of 
carrying out equipment sizhg and costing. Al1 the unit operation models in BioPro are 
algebraic when specified for steady state (Aelion and Petrides, 1994). Dynarnic models 
are also available for batch or semibatch operation (Petrides, 1994). It perfoxms process 
scheduling to handle the effect of batch and semi-continuous operation on the estimation 
of material balance and sizing of equipment. The program estimates the cycle times of 
the various process steps given the starting t h e  of each unit operation and generates a 
Gaan chart that graphicaily depicts the operation and turnaround h e s  of each unit 
operation BioRo DesignedB has been used at New Jersey Institutte of Technology as a 
teachhg tool for process design. Senior undergraduate and graduate students used 
BioPro to build biochemical processes, consider structural alternatives, perform 
sensitivity analysis on process parameters and conditions and enalyze and evaluate 
severai integrated processes for citric acid, sodium nitriloacetate etc. They aiso examined 
economic and environmental impacts of process modifications. The accuracy of the 
economic report was within f 25%. The feedback of the midents on using BioPro 
Designer@ was positive (AeIion and Petrides, 1994). B i o h  DesignedB has also been 
used for simulation and economic evaluation of biosynthetic human insulin production 
(Petrides et al., 1995; Petrides et al., 1996). Ernst et al. (1997) used SuperPm Designe-, 
which is a combination of BioPro Designer@ and EnWoRo Designer@ both fiom 
Intelligen Inc., for analysis and cost estimation of production of heparinase I expressed 
in E. coli. 
Biotechnology Design Simulator (BDS) from Life Sciences International (LSI, 
Philadelphia) is another batch-oriented product (Zimmermann, 1997). It can be used for 
scheduling of batch operations and resource utilimtion as a function of t h e  (Petrides et 
al., 1996). BDS can integrate behaviors of vendor equipment models, such as specific 
chromatography column, into a given simulation. This is a feanire which most of the 
other packages Iack (Zimmermann, 1997). BDS cm also integrate human decision- 
making guidelines into simulations, such as how shift changes affect technicians and 
managers. It considers environmental factors nich as VOC emissions. 
A novel bioprocess simulator called SIMBIOS is currentiy under development (Simon 
et al., 1994). It is being developed as a joint collaboration between Systems engineering 
Department of Research Inst i~e of Chernical Engineering H.A.S., in Hungary and the 
Chernid Engineering Department of Graz University of Technology in Ausiria. There 
are two levels of caiculation in this system: a) linearized models of unit operations for 
fast estimation of mass balances and b) in-depth calculation by rigorous, non-linear 
models. The nrst level of calculation is completed with a correction step. If the results 
are out of confidence limits then correction is carried out by rigorous models. When 
developed, the simulator will aiso perfonn sensitivity of output variables with respect to 
input values. 
Besides the integrated process simulators described above, there are several simulating 
tools available that simulate the fermentation process only. CAMBIO is nich a software 
for dynamic modeling and simulation of biochernical processes (Fana and Cheruy, 
1993). CAMBIO works by first developing a hct ional  diagnun of the reactions 
involved using a set of design symbols and mnemonic icons. From the fiinctional 
diagram, a dynamic material balance equation of the process is generated automatically 
by taking advantage of the knowledge in the diagram. These equations are m e r  
modified by user supplied reaction rate expressions. The dynamic behavior of the 
process is immediately visualized by interfacing automatically with specialized software. 
Fana and Cheruy (1993) reports modeling of an anaerobic digestion process using 
CAMBIO. 
Another bio-simulator cailed BIOSIM has k e n  developed for simulation of biological 
fermenter and ce11 culture reactors (Cadman and Davison, 1989). The simulator consists 
of a model library, a model builder, a dynamic simulator and a data comparator. These 
are integrated to a single menu-driven system that works in PC. The introductory menu 
allows the w r  to review the available models, modify them or to develop a new model. 
Provided the required parameters, initiai conditions and time of simulation, the simulator 
autornatically determines and varies the integration tirne step in order to meet relative 
error criteria. A model parameter estimatot is currently under development for BIOSIM. 
It has been used to model production of a-amylase h m  BaciZZw arnyZo2iquefacie11~. 
1.3. Scope and Objective 
The overall objective of this research was to explore the possibility of designing large 
scaie integrated bioprocesses using available biosimulation packages. Two bioprocess 
simulators were selected for this study: 
i) BioRocess SimulatorM (BPS) nom Aspen Technology and 
ii) Superpro Designer@ h m  Intelligen Inc. 
Production of tissue plasminogen activator (t-PA) fiom Chinese Hamster Ovary (CHO) 
cells was selected as a mode1 process for this study. t-PA is a high value product for 
human use; therefore, downstream processing is an important part of the overall process. 
Since process information is proprietary, five alternate flowsheets were developed for 
this process based on information fiom technicd literature, published laboratory sa le  
production and purification methods for t-PA combined with engineering judgment and 
experience with other recombinant products. The flowsheet based on conventional 
fermentation n o m  for mii111111aiian ce11 culture and standard purification methods for 
biophannaceuticals was designated as the base case flowsheet. The altemate flowsheets 
were variations of the base case and ciifferrd in the medium type and mode of operation 
of the bioreactor, unit operation in downstream processing and s a l e  up strategy. The 
first alternative to the base case was designed to evaluate the concept of two-stage ce11 
culture. Use of semm and semm fiee medium was considered in the growth and 
production bioreactor mpectively. For this flowsheet, the dthity chromatography 
columns of the base case were also replaced with ion exchange columns. The mode of 
operation of the biomictor was switched from batch to fed-batch for the second 
alternative while in the third alternative the stirred tank type bioreactor of the base case 
was substituted by an airlift bioreactor. Since ceU culture bioreactor cycles on last up to 
a week, in the fourth alternative, an economically sized single purification train was 
designed to process the product fiom multiple equal sized bioreactors instead of the 
single large bioreactor of the base case. For cornparison, the base case flowsheet was 
simulated using both simulators. Simulation of the other four flowsheets was carrieci out 
with BioProcess SimulatorT" only since it allows detailed analysis of the sirnulated 
process. 
Simulation of bioreactor is found to be as effective as the kinetic mode1 supplied. 
BioProcess Sirnulatorm allows addition of w r  supplied kinetic models so that the 
success of simulation of the bioreactor was a matter of finding appropriate kinetics, 
formuiated to account for the required details. Therefore, in this midy more emphasis 
was placed on the design of downstream processing as a part of the integral process. The 
high purity requirement of biotherapeutics signifies the importance of downstrearn 
processing for the t-PA production process. Process development with BioProcess 
Simulatorm was a trial and error approach. Repeated simulation runs were c d e d  out to 
design flowsheets that satisS, the predetermined values of purity, recovery and batch 
time. 
An advantage of using a process sirndator for process development is that it allows 
economic evaluation of the simulated process as a part of the package. Economics of the 
simulated flowsheets were evaluated by combining information fiom both, BioProcess 
Sirnulatorm and Superho Designd.  Economic performance was meanirrd in temis of 
Retum on Investment (ROI) and Gross Mar* (GM). 
Since the simulated flowsheets are based on information fiom literature, there were some 
parameters for which estimates could not be found. BioRocess Simulatorm was w d  to 
carry out sensitivity study of the simulated processes to uncertain parameters and 
variables to determine which of the unknown parameters are critical. This study also 
indicated the areas where research should be focused to improve process performance. 
The feature of BioProcess Simuiatorm that allows addition of user supplied kinetic 
models was utilized to compare some unstructured models for mammalian cells. The 
kinetic models were added as FORTRAN subroutines to the main bioreactor model. 
BioProcess Simulatorm generates concentration profiles for substrates and products 
according to the supplied kinetics to be used for time dependent specific gowth rate 
calculation. The model also allowed user defined variables and parameters to be varied 
to study the effect of these quantities. 
In summary, the specific goals of the research were: 
to critically evaluate the applicability of two commercially available bio-simulation 
packages for development of large %ale integrated bioprocesses. To date, evaluation of 
the bioprocess simulaton has k e n  reported by the developers only. This research will 
evaluate the simulators fiom a more independent user's perspective. 
to study some innovative concepts in bioprocess design such as two stage ce11 
culture, fed-batch operation and multiple bioreactor scale up for large scde process with 
the aid of the simulation packages and 
to examine the applicability of the simulator for ecowmic evaiuation and sensitivity 
d y s i s ,  that improves reliability of the results obtained. 
1.4. Contributions of the Reseatch 
The significant contributions of this research are: 
Identifïed the strengths and weaknesses of Aspen BioRocess Simulatorr" for 
bioprocess simulation. Although, BioRocess Simulatorm, equipped with rigomus 
unit operation models and model d y s i s  tools, appears to be a comprehensive 
flowsheeting package at a first glace, some of the unit operation models in the 
simulator were found not to function properly. 
Reported on first comparative study of BioRocess Simulatorn" and SuperPro 
Designer@ for bioprocess simulation at process level. 
Developed a comprehensive process and economic "investigative basis" for M e r  
research in bioprocess simulation study by othen. 
Developed a detailed process description including operating and design parameters 
of a propnetary process. This information was used in simulation, identification of 
criticd parameters and economic evaluation of the process. 
Dernonstrated the economic potential of novel process concepts. 
1.5. Organization of the Thesis 
The Introduction (Chapter One), that provides background for the research, is followed 
in Chapter Two by a Literature Review on the selected simulation packages (Aspen 
BioProcess SimuiatorTM and SuperPro Designer@) and the process (production of t-PA 
from CHO cells). Chapter Three describes the simulation methodology used with each 
Nnulator. The procedure adopted for economic evaluation, sensitivity d y s i s  and 
kinetic study are also discussed. The design basis for the simulated processes is 
presented in Section 3.5. A general process description for large-sale biopharmaceuticai 
production (Section 3.6) is included in this chapter whereas, a brief process specifïc 
description of each process flowsheet is presented in Chapter Four (Section 4.1 .2,4.2.2, 
4.3.2,4.42 and 4.5.2). 
Chapter Four is the main section of the thesis, which presents and discusses the 
simulation d t s  and results of the economic evaluation of each process. Each of the 
alternate processes is compared with the base case. A sensitivity study of process 
specific uncertain variables is presented at the end of each section to show how the 
process performance would change due to uncertainties arising h m  these sources. Al1 
the simulation results are further summarized at the end of this chapter for ease of 
comparison. 
Chapter Five addresses sensitivity study to parameters and variables common to al1 the 
processes. Chapter Six is an extension of application of BioProcess Simulatorn" to 
comparison of unstructured kinetic models. The conclusions and recornmendations for 
hiture work are presented in Chapter Seven. 
CHAPTER 2 
LITERATURE REVIEW 
2.1. THE SIMULATORS 
Aspen BioPmess Simulatorm (Aspen Technology hc., 1995) and SuperRo Design- 
(Intelligen Inc.. 1994) appear to be the mon popular commercial amulators for 
bioprocess so far. Table 2.1.1 s m s  the basic featuns of BioProcess SimulatorN 
and S u p e r h  Designer@. Both of these siripilators w m  used to sinnilate the base case of 
the t-PA production process. A detaiied cornparison of their perfommce at p m s s  lcvel 
has been carried out in section 4.1.3 and 4.1.5. The economic evaiwors of the simulators 
have btcn cornparcd m scaion 3.2. 
2 1.1. Aspen Blo Process SlmulatoP 
Aspen BioFYocess Smmktorm was deveioped by modification of its parent Asptn Plus. a 
thiid geaeration process sknulator for chernical process industries (Bhattacbarya and 
Motard, 1986). BioRoccss SÏmuIatorm. thcrcforc shares the weii-devebped Smuktion 
h t u r e s  of Aspen Plus, such as modtl analysis twls. Mode1 analysis tmls inchde pmcess 
optimkation. case mdy, data nt and scnsitniity study of the process parameters and 
variables to process @ormance (Aspen Technohgy Inc., 1995). The 'Design 
Sptcification' ftaturt a b w s  BioPmcess Sinnihtorm to design a unit operation block 
accordmg to the rcquired spccification. InitiaIy devcloped for steady state FSS. 
BioProcess Simulatorm has several batch unit operation blocks typical to bioprocessing. 
The ordinary differential equations describing the batch operation are solved using 
Gear's method (also known as Backward Différentiation Formula). Usea can manipulate 
the integration parameters such as integration step sue, magnitude of integration error 
etc. There are several convergence methods (e.g. Wegstein's, Secant, Broyden, SQP etc.) 
available for recycle streams. The convergence parameters are also adjustable. Aspen 
allows user specified convergence options, user selected tear strearns and calculation 
sequence for the convergence block. 
Besides these tailorable calculation methods, BioProcess Simulatorm has the capability 
of modifying the report options in several ways. BioProcess Simulatorm package allows 
customized reports to be printed out. In addition to block and strem reports, it can be 
specified to generate property report, utility report etc. Another important feature of 
BioProcess SimulatorN is the flowsheeting option. It ailows addition of &routines 
which are essential requirements for bioprocess simulation (Shanklin et al., 1999). 
BioProcess Simulatorz"< package uses an expert system to assist setting up the fiowsheet. 
The expert sy stem prevents over- and under-specification of the flowsheet (Grob, 1 993). 
Aspen is capable of handling process streams of any complexity, including solid flows 
and slurries. The built-in data banks contain over 1500 cornponents (Grob, 1993). It also 
allows the definition of new data structures to store and manipulate data on new and 
unusual species and streams (Bhattacharya and Motard, 1986). Using the provisions to 
store new property models, the requirements of biomass. nutrients, bioproducts and 
electrolytes typical of biochedcal processes can be incorporated. Aspen BioProcess 
Simuiatorm is equipped with costing and economic evaluation routines and data banks 
that d o w  process evaluation and technologicd assessrnent on a common basis. It 
generates economic report in tenns of capital cost, operating cost and profit, by 
calculating equipment, labour, material and utility c o n  
BioProcess SimulatorM has been used for process development by many pharmaceutical 
companies such as Novartis Pharmaceuticals Corp. (E. Hanover, NJ), Eli Lilly & Co. 
(Indianapolis, IN), Genentech (S. San Francisco, CA), Merck (Whitehouse Station, NJ) 
etc. 
SuperPro Designer@ on the other hand was developed specifically for bioprocesses with 
the ability to assess environmental impact. It consists of three main components: w r  
interface, synthetic component and analytical component. The synthetic component 
contains experiential knowledge mainly in the form of heuristics that result in the 
synthesis of a feasible flowsheet. The analytic component consists of algorithmic 
knowledge in the form of models for the unit operations that enable analysis and 
evaluation of the synthesized flowsheet. Its unit operation models allow simulation of 
integrated biochemicai, pharmaceutical, food, specialty chernical as well as waste 
recycling, treatment and disposal processes. Some new models for product formulation 
and packaging (e.g . extrusion, blow and injection molding, filling, labeling, boxing etc.), 
solids handling (e.g. silo, hopper etc.) and transportation have k e n  added to the latest 
version (v3.0) of SuperPro Design- (Petrides, 1 998). 
It carries out environmental impact assessrnent and VOC emission calculations as a part 
of the simulation. The unit operation block models are based on short-cut algebraic 
equations. It is, therefore, usefui when detailed information is not available for a process. 
These equations can be specified for steady state, batch and semibatch operation. Many 
of the unit operation models can be used either in design or in rating mode as required. 
Super Pro carries out matenal and energy balances for integrated flowsheets. It estimates 
equipment sizes and purchase costs. It is equipped with an economic evaluator capable 
of analyzing detailed economic report. SuperPro handles a mixecl mode of unit 
operations by scheduiing batch and semicontinuous processes. It has buüt-in library for 
process equipment, heatiriglcwling agents and construction material. It has built-in 
database for chemical components. A user expandable mixture database for buffers etc. 
has been added to version 3.0 of Superpro Designer@ (Petrides, 19%). It also allows 
addition of new components to io component database if required. Physical properties 
can be modified and economic data updated. 
SuperPro uses Weigstein's method of numencal convergence of materid and energy 
balances. It allows modification of convergence parameters such as maximum number of 
iterations, value for acceptable tolerance etc. (Intelligen inc., 1994). Like Aspen 
BioProcess SimulatorN7 it also allows scaling up or down of al1 input stream flows by a 
user-specified factor. 
The Pro Designers are intermediate level simulators, ideal for a "first crack" at a design 
and can operate with minimal data, using initiai default values (Zimmermann, 1997). 
They are limited to the Windows plaaorm. The user-friendly design shortens the 
learning time and allows designers to quickly exploit the software's fiinctions. 
Matenal balances in both SuperPro and Aspen BioProcess Simulatorm are estimated 
using the sequential rnodular approach (Petrides, 1994). The various unit operations in a 
flow sheet are sequenced according to their calculation order. Composition and flow rate 
of outlet streams are calculated given the inlet Stream and some specifïc engineering 
information for the units. 
SuperRo is used as a design tool by companies such as Smith Kiine Beecham, E. Merck 
(Gemany), Bristol-Myers Squibb, Eli Lilly, Rhone-Poulenc Rom, Geoyme, John 
Brown, Merck & Company, Novo Nordisk (Denmark), Pnzer and Fluor Daniel etc. 
(Inteiiigen Inc., 1 994). 
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2.2. THE PROCESS 
2.2.1. Process Selection 
Selection of a process for simulation was dictated by several criteria First of dl, it was 
decided to simulate an integrated process rather than separate units since study of an 
intepted process allows for the exploration of the interactions among the unit operation 
blocks and to identify the effect of upstream sections on downstream processing. For the 
necessity of process validation, it was also decided that the selected process shouid be an 
existing and established one. Importance was given on processes that involves typical 
biochemical unit operation blocks such as membrane separation and chromatography. 
The economic importance of the process was another cnteria Since a major advantage of 
process simulation is to reduce the process development cost, processes that involve a 
huge sum of money for development were searched for. 
Recombinant protein therapeutics have enormous economic potential (Figure 2.1.1) 
(Dunnill, 1987). Genetic engineering has been successful in producing large quantities of 
pharmaceuticals (e.g. human growth hormone, alpha-interferon, t-PA, insulin etc.) that 
were otherwise scarce. It has increased productivity, almost in a dnunatic fashion of 
many pharrnacologically active products and made them available cornmercially. 
Approximately 22% of the $9 biliion domestic sales of prescription dmgs in US in 1984 
came fiom products for which genetics and fermentation biotechnology played a 
significant role (Elander, 1989). It is reported that, in 1995, the annual sales of 
diagnostics and therapeutics resulted in over $5 billion dollars (Cooney, 1995). Leading 
biotech drugs broke over $1 billion in annual sales in 1997 (Business Cover Story 
Biophannaceuticals, 1998). Although the se lhg  pnce of these products is high, the costs 
of commerciai recombinant DNA work are &O considerably higher. Schering Plough 
invested $6 million in a pilot scale bioprocessing and purification facility, Genentech 
raised $32 million for cIinical test and development of t-PA, Eli Lilly invested $60 
million in facilities to produce human insulin, to mention a few (Elander, 1989). This 
represents an area where the benefits of process simulation cm be fully utilized. 
Production of recombinant therapeutics by genetic engineering is also complicated by 
the fact that recombinant cells are very difficult to work with because of theY hgility 
and genetic instability. Moreover, the very high purity requirement of the product makes 
downstream processing a very significant part of the overall process. 
Interferon 
\ Human factor VI11 
Tissue plasminogen activator 
Human growth hormone 
\ . Renin 
Benyl peniciliin ' \ Cheese 
10 
world production (todyear) 
Figure 2.2.1 : World Roduction Ievels and prices of the products of fermentation 
@unniil, 1987) 
ln light of the above reasons, produaion of t-PA fkom recombinant CHO cells was 
selected to be a suitable process. Production of t-PA represents by far the largest scale 
production of a recombinant protein in animal cells. Tissue Plasminogen activators are a 
group of proteolytic enzyme that fin& application in the treatment of cardiovascular and 
cerebrovascular obstructions (i.e. heart attack and stroke). The fact that, in the western 
world, these represent a major cause of death in men and women o v a  the age of 40, 
underlines the importance of this cellular product. Dining the last two decades, serious 
efforts were made to charactenze and produce this enyme in large scale. It finaiiy 
became cornmercially available when Genentech developed and obtained FDA approval 
for its large scale production in 1987 (Lubiniecki et al., 1989). The cell line has been 
patented while the production method has not been made public. Genentech produces t- 
PA at a purity of greater than 99.999%. Worldwide annual sales of t-PA resulted in 526 1 
million in 1997 (Business Cover Story Biopharmaceuticals, 1998). The current selling 
pnce of a gram of t-PA is about $16,000 (Cooney, 1999). 
2.22, Literafure Review on Selected Process 
282.281. INTRODUCTION 
2.2.2.l.(a). Function of t-PA 
Thrombosis is the blockage of blood circulation by deposited fibrin clot or thrombus and 
this is a major cause of death in the western world. Plasminogen activators are 
thrombolytic agents. These are a group of proteolytic enzymes that act on plasminogen 
and convert it to plasmin Pl& is a powerfûi fibrinolytic agent, which is capable of 
initiahg f ib~olyt ic  process to breakdown fibrin (Figure 2.22). 
There are two recog-d classes of human PlamÜnogen anivators, tissue type (t-PA) 
and urokiaase type (u-PA). Differences in biological and immunological properties 
between these two types have been observeci. There is fortuitous planninogen activator 
of bacterial origin - seeptokinase. Streptokinase is an extracellular protein released fiom 
various strains of Sîreptococci. Streptokinase acts by fonning a complex with 
plasminogen first in order to activate it. 
Plasminogen Activator 
1 coagulation -w fibrin ,-b fibrin degradation products 
(insoluble) (soluble) 
Figure 2.2.2: Fibrinolysis 
Cornmercially available Urokinase was fht isolated fiom human urine. During the rnid- 
to-late-19703, development was underway to produce Urokinase fiom normal human 
cell cultures. However, the combination of low product yields and high medium costs 
impeded the commercialization of this process. During the early 1980's it was reported 
that a related enzyme, tissue plasminogen activator (t-PA), offers potentiai clinical 
advantage over Urokinase (Bliem, 1988). 
t-PA is very specific in its action. It binds relatively strongly to fibrin clots prefantially 
activating plasminogen entrapped in blood clots. ït does not aiter the circulating 
plasminogen and other blood clotthg factors. u-PA on the other han& is relatively non- 
specific and activates both circulating and fibrin bound plasminogen. This indiscriminate 
activation leads to serious risk of hernorrhage. With S t r e p t o b e  antigenic reactions are 
common in addition to increased danger of hemorrhage (Butler, 1987). In view of these 
facts, t-PA is regarded as  more effective and safer thrombolytic agent compareci to 
others. The recent activities are devoted to develop second generation t-PA which are 
even more efféctive and longer lashg (Section 22.2.5). 
Plasminogen activaton are very widespread in the body. They occur in most body fluids 
(e.g. blood, lymph, urine, tears, saliva etc.) and in a wide variety of nimon and tissues. 
2.2.2.1.@). Structure of t-PA 
t-PA is a serine protease with a molecular weight of approximately 70,000 Da. It is a 
glycoprotein containing 7% sugar and has an isoelectric point of 7.5. 
It is composed of a single polypeptide chah containing 527 amino acids. It is 
synthesized within the cell as a polypeptide chah and released as a single chah enzyme. 
Upon limited proteolytic action by plasmin in the extracellular medium, the molede  is 
cleaved and converted to a two-chah activator linked by an inter-chain di-sulphide bond. 
The t-PA molecule is composed of a number of discrete regions (Figure 2.2.3). A h g e r  
domain near the N-terminus, an epidermal growth factor (EGF) domain that is cornmon 
to several suine proteases, a di-dfide looped kringle-bgle structure similar to 
constructs found in plasminogen and urokinase and a carboxy-terminal serine protease 
domain. 
There are four glycosylation sites in t-PA molecule at positions 1 18, 186, 21 8 and 448 
(Griffith and Electricwala, 1987). The site at 21 8 never appears to be glycosylated 
(Datar et al., 1993). The middle site (186) is not glycosylated most of the t h e .  Thus, 
depending on the nurnber of carbohydrate groups t-PA can be divided into two types: 
Type 1 (those containhg three carbohydrate groups) and type II (with two carbohydrate 
groups). 
2.2.2.2. Production of t-PA 
The potential therapeutic application of t-PA as fibrinolytic dmgs for the treatment of 
cardiovascular obstructions (Le. heart attack), cerebrovascular obstructions (Le. stroke) 
and pulmonary thrombotic obstructions motivated the efforts for its large scaie 
production. Clinical study at the beginning was limited by its insufficient supply. Its 
clinical use requiml a specific and efficient production method to give highly purined 
protein in high yield. Early attempts to produce large amount of t-PA firom animal cells 
were uasuccessfûi (Table 2.2.1). Production of t-PA fkom Bowes melanoma cell h e  in 
relatively large amount enabled its clinical trials. Current production methods using 
recombinant technology r d t s  in high level of t-PA production. 
The t-PA gene has been expressed in dserent systems such as  marnmalian cells, 
bacterial, yeast and insect cells. Except mammalian cells, all the other hosts were fomd 
to be unsuitable because t-PA was produceci intraceiiularly and it was either 
hyperglycosylated or hypoglycosylated. The level of production was also low in most 
cases (Lemontt et al.. 1985; Sarmientos et al., 1989; Upshall et al., 1987; Oka et al., 
1990; Schleuning, 1987). 
The current commercial method of tPA production uses mammalian cells as h o b  It has 
been shown that t-PA essentially identical to nannal t-PA can be produced in 
recombinant animal cells. A variety of animal ce11 lines have been reported to be 
successful for cloning and expression of t-PA. These include rat myeloma, mouse Cl27 
fibroblasts, CHO cells and human melanoma cells (Lubiniecki et al.. 1989). Available 
data suggest that CHO cells are generally better in ternis of productivity tban moa other 
host ce11 lines studied (Table 2.2.2) although direct cornparisons are difficult to make. 
While of comparable productivity to CHO cells, Cl27 cells are anchorage dependent. 
Scale up of Cl27 cells rnight, therefore prove more difficult than for CHO cells. Ali 
recombinant systems reported were fond substantiaily more productive than non- 
recombinant systems such as Bowes melanoma (Table 2.2.1). 
Table 2.2.1 : Comparative yields of t-PA melanoma, epithelial and recombinant DNA 
ce11 lines expressing melanoma t-PA (Grifiths and Electrîcwala, 1987) 
Ce11 line 
Bowes melanoma 
r Bowes melanoma 
Epithelial celi ( GPK) 
GPK ( + azacytidine ) 
GPK ( + concanavalin A) 
r CHO 



















Most of the expression vectoa used for t-PA production employed strong constitutive 
promoten and enhancm such as virus-derived or immunoglobulin regdatory elements 
to drive t-PA expression. Gene amplification technique was used to maximize the 
expression. Amplification by methotrexate (MTX) to inmase yield of t-PA was fint 
achieved by Genentech (Levinson et al., 1984) and has since been used in various 
constructs. However, the presence of M?X d t s  in some less desirable consequences 
in addition to the increased production level. Several researchers have observed 
prolonged doubling time of the cells and in some cases, increased ce11 fragility with less 
efficient ce11 growth in stimd bioreactoa. 
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non-recombinant cells s h o w  for cornparison 
For the recombinant ce11 lines, it still remains to be established whether the stimulants 
used to increase productivity of animai ce11 culture can further increase the yield of tPA 
nom these cells (Electricwala, 1987). Chen et ai. (1998) observeci that hyperosmolality 
leads to an increase in t-PA production by a CHO ce11 line. The specific rate of rt-PA 
production was found to incnase with medium osmolality in the range of 330 to 450 
mosrn, reaching approximately 1.6 times that obtained at physiological osmolality. 
Along with DNASE, production of t-PA represents the largest scaie production of 
recombinant proteins in animal cells (Cooney, 1999). Genentech, who pioneered 
production of t-PA in MTX (methotrexate)-amplified CHO cells, have retained CHO 
suspension culture as the commercial production rnethod. Two production plants using 
this technology at 10,000 litre fermentation scale have been built at Genentech in the 
USA and at Boehringer Ingleheim in Gennany (Lubiniecki et al., 1989). No major 
problems were encountered in scale-up of the system and the two plants were 
comrnissioned in 1987. Since then, quantitatively stable production of qualitatively 
consistent tPA has apparently been achieved. 
Since the market for t-PA looks impressive, research in this area is literaily clogged with 
cornpetiton (Klausner, 1986). Several companies have evaluated high cell density 
bioreactors, which avoid the use of excessively large bioreactors* as an alternative 
approach to producing the biomass requkd for t-PA production at this scale. In these 
bioreactors, ceii densities exceeding 10' per ml have been achieved instead of the few 
miilion per ml obtainable in classicai suspension culture* An example is the 24 litre scale 
fluidized bed reactor for t-PA production developed by Verax Corporation. Recombinant 
CHO cells were entrapped in a collagen-based matrix in a reactor. The reactor was 
continuously perfûsed with a serum fiee medium at a feed rate of 330 litres per day. A 
steady state t-PA level of 65 pglml was obtaiwd, corresponding to a daily output of 21.4 
g of t-PA. This level of production was maintained stable for at least 10 days (Tung et 
al., 1988). Similar quantities of t-PA have been obtained in other high-density 
mammalian celi culture systems based on perfwd hollow fibre reacton (Tyo et al., 
1988) and on pemised cerarnic ma& (Berg and Bodeker, 1988). Choi et al. (1995) used 
a depth filter perfusion system for continuous production of t-PA fiom recombinant 
CHO cells. The system was equipped with a 40 pm polypropylene depth filter for ce11 
immobilization. Final cell density with oxygen control was 1 .8x107 cells/ml of the total 
working volume and maximum t-PA productivity was 2.63 m w d a y .  Stable operation 
was possible for more than 20 days. 
The dificuities of process control and reproducibility in high density culture systems 
caused by non-homogeneous condition in the reactor led to a compromise where cells in 
fiee suspension were maintained in a pemised reactor. Production of a t-PA like 
thrornbolytic fiom CHO cells in a continuous perfusion bioreactor has been reported 
(Kallstrom et al., 1991). Cntical nutrients were added and waste products were removed 
by the continuous perfusion Stream. The ce11 density in the continuously perfused culture 
increased fiom 2X106 cells/ml in batch culture to 10X106 celldml by altering the 
medium flowrates. Optimal production occurred at ce11 density of approximately 5X106 
cells/ml. Production potentid was found to be determined by the availability of nutrients 
and energy rather than inhibitor dilution. Volumetric productivity of the t-PA variant, 
compared to a batch culture, increased 15 to Il-fol& using hi& perfûsion rates (4 
reactor volumelday). 
Microcarrier culture of CHO ceIl for tPA production has also been extemively studied. 
Semi-continuous culture of CHO celis on microcamers of gelatin and dextran has been 
evaluated (Nilsson et al., 1988). Signifïcantly higher specifîc and total production rates 
were observed on gelatin m i c r o c ~ e r s  compared to dextran. Addition of 6- 
aminohexanoic acid to the medium was found to improve the specific production rate in 
both cases. Effect of medium components on the productivity of tPA by fibroblast ceils 
on microcamer has been studied (Talcagi et d., 1994~). The same group developed an 
algorithm for on-line detemination of optimum the for switching fiom growth phase to 
production phase of tPA producing fibroblast cells on microCamer. The optimum 
switching time was detemined to be the time at which the tPA production activity of the 
cells in the growth culture became highest. The tPA production activity was found to be 
a function of ce11 concentration and oxygen consumption rate (Takagi and Ueda, 1994b). 
They also studied an oxygen supply stmtegy for microcarrier culture of the sarne ce11 line 
for t-PA production. An air spray system was used to maintain high oxygen transfer rate 
while the carriers were suspended by addition of soluble starch to the medium 
accompanied by slow agitation (Takagi et ai., 1994a). Celltech developed a microcarrier 
process at 40 L scale for tPA production fiorn mouse Cl27 cells. tPA concentration in 
this perfusion reactor rose as high as 55 rn@ (Rhodes and Birch, 1 988). This seems to 
be the largest m i c r o c ~ e r  culture for tPA production reported so far. 
A negative feedback system was observed by some during the synthesis of t-PA in cell 
culture. When the extnicellularly released t-PA level reached a certain concentration in 
the medium, the rate of cellular synthesis was f o n d  to decrease. This method of 
synthetic regulation, which is very unusual for an extracellularly released product, 
suggests that some of the t-PA may re-enter the cells, which was confirmed by various 
observations (Kadouri and Bohak, 1983). t-PA concentrations around 50 m g L  were 
found to be toxic to cells. In monolayer cultures, cells were found to detach h m  
substrate as these levels were approached ( K a h a n  et al., 1985). For maximum 
productivity, the concentration of extracellular t-PA must be kept low to minimize the 
negative feedback of its biosynthesis. This could be done by either using a high ratio of 
medium volume to cell nurnber or perfûsing the system continuously. A more 
econornical alternative would be to recycle the medium through a column capable of in- 
h e  extraction of t-PA (Kadouri and Bohak, 1983). 
2.2.2.3. Purification of t-PA 
2.2.23.(a). Animal Ceil Culture 
Information is not available on the large scale purification method of P A  that uses 
recombinant cells for its production. In laboratory, t-PA has been isolated fkom many 
organs and cells. This section considers the purification scheme used in laboratory scde 
purification of PA. 
Many of the methods used for purification of t-PA are lengthy and employed very hanh 
conditions. Chaotropic solutions of potassium thiocyanate or buffets of low pH have 
been used in some cases. These methods resulted in the recovery of a few rnilligrams of 
enyme from several kilogram of starting material. Table 2.2.3 (Griffiths and 
Electricwala, 1987) lists several purification methods used to recover t-PA fiom different 
sources together with their molecular weight and specific activity. The specific activities 
listed in this table are as quoted in the literature. They are expressed in different units 
and when expressed in the same units (against a reference International standard of 
human urokinase) they show wide variation with respect to different sources. The 
molecular weight of purified plasminogen activaton also varies considerably ranging 
fiom 35,000 to 85,000 Da. Such differences might have been caused by the diverse range 
of species, tissues and ce11 lines that have ken  used as a source of t-PA. This may also 
be a remlt of limited proteolysis of the native protein. This table considered only those 
methods were the enzyrne was characterized and purified to homogeneity. 
It is obsened from the table that the major step in the purification scheme in al1 the cases 
(except the first one) is chromatographic separation. The methods diEer in the different 
type of chromatographic material used e.g. metal chelate, Condi, n-Butyl agarose, Octyl 
Sepharose, H y droxyapatite, lectin or lysindarginine etc. (Table 2.2.3 and Table 23.4). 
Some methods used an extraction, precipîtation or a fractionation step before 
chromatography. The nnal step in ali the cases is gel filtration. t-PA produced fkom 
human embryonic lung cells (HEL cells) has been shown to be purifïed by a two step 
method (Brouty-Boye et al., 1984) involving chromatography on fibrin/Celite to 
remove the non-fibrin binding proteh such as urokinase-like plasminogen activator 
followed by gel filtration to elimlnate protein contaminants of high molecular weight. 
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octy 1-sepharose chrom. 
sephadex G-75 gel filtration 
sephadex G-150 gel filtration 
acetate buffer extraction 
( m 4 ) *  SO, precipitation 
zinc-chelate agarose chrorn. 
n-butyl agarose chrom. 
con-A agarose chrom. 
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lysinefibrin agarose chrom. 
(NH&SO, fkactionation 
adsorption on fibrin 
sephacryl S-300 chrom. 
arginine-sepharose chrom. 
sephacryl S-200 chrom. 
zinc chelate agarose chrom. 
con-A agarose chrom. 
sephadex G-150 gel filtration 
W4),SO4 precipitation 
f i -gel  blue chrom. 
p-amino beIlzaaminidine 
sepharose chrom. 
zinc chelate agarose chrom. 
con-A agarose chrom. 
sepharose G- 1 50 gel 
filtration 
fibrin celite affhity chrom. 




sephadex G-150 gel filtration 
f i b ~  celite affinity chrom. 
paminobenzaamhidine 
sepharose chrom. 
dtrogel ACA 22 gel 




human melanoma ce11 
(Einarsson et al., 1985) 
filtration 
MC chelate agarose chrom. 6,000 & i 2,500 
IU/mg 
200,000 IU/mg 
human melanoma ce11 
(Kniithof et al., 1985) 
con-A agarose chrom. 
ultmgel ACA 44 gel 
filtration 
immunosorbent chrom. 
arginine sepharose chrom. 
sephadex G-150 gel filtration 
SP sephadex chrom. 
sephadex G-100 gel filtration 
80- 1 00,000 
IU/mg 
Purification of t-PA from Bowes melanoma ce11 line, that secretes elevated amounts of t- 
PA compared to other cells, usually involves affinity chromatography and a gel filtration 
step. One preparation used irnmunoadsorption on antibodies as a major step in 
purification (Wallen et al., 1982). With the availability of monoclonal antibodies to 
melanoma t-PA , immunoafinity chromatography has k e n  used in another case as a 
single step purification method (Reagan et al., 1985). This was the only method among 
those tested that was able to separate tPA from uPA completefy (Schaumam et al., 
1990). tPA has also been purified using its afEnity for more or less specific s e ~ e  
protease inhibitors. Thus pbermmidine Sepharose has also k e n  used to bind tPA 
(Harakas et al., 1988). 
It is worth pointing out that al1 of these purification methods were carried out in 
laboratory scale. Many laboratory scale purification methods are not tndy scaleable to 
manufacniring levels and should be avoided. Methods involving ammonium sulfate 
precipitation at an early, large volume stage, preparative reveme phase HPLC or 
preparative electrophoresis are inappropriate for large scale (Tolbert, 1988). 
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S p  Sephadex 
Function 
binds al1 plasminogen activator 
separates u-PA and t-PA fiaction 
biospecificity for t-PA 
positive charge 
serine protease inhibitor 
removes non-fibrin binding protein 
monoclonal antibody to t-PA 
antibody to t-PA 
Purification on the laboratory scale tends to be based on analytical techniques, using 
expensive and sophisticated methods (Electricwala, 1987). Highly purified tPA has been 
obtained by these methods without much importance king paid to the overail recovery. 
On the laboratory scale, the objective is to achieve high yield but the main emphasis is 
on punty. Whereas on the industrial scaie, high yield reproducibility together with the 
maintenance of high purity are desirable. Thus, on the large scale, the factors governing 
the purification scheme are somewhat different, Some of the major ciifferences between 
analytical and large scaie purification methods have k e n  presented in Table 2.2.5. 
Techniques such as ultrafiltration, ion exchange chromatography, immunoaff?nity or 
other types of aflhity chromatography and gel filtration have been successNly used in 
large scaie purification. Scaie up of cbmatographic methods can often present a 
problem. 
Table 2.2.5: Differences between Anaiytical and Large Scale purification (Electricwala, 
Large - Scale 
large 
fast for high 
throughput 
important 
high yield required 
limited acceptance 
1987) 
In a laboratory scale, d l  flow rate is maintained tbrough chromatographie columns to 
achieve high resolution in contrast to fast flow rates on large scale, which are necessary 
to handle the large throughput Higher flow rates are handled on an industrial sa le  by 
using larger diameter columns or stacked columns. Similarly laboratory scale gradient 
elution is replaced by step elution on the indumiai scale because gradient elution is 
difficult to perform reproducibly. 
Sample Size 
Chromatography flow rate 
T h e  required 
Yield 
Use of expensive technique (s) 
The tirne required for purification is not important on the laboratory scale. But on the 
industrial scale it affects the con of the final product and, if the enzyme is unstable, the 
yield diminishes with the .  The t h e  required by gel nitration is dramatically reduced by 
using 'fast flow' matrices such as Sephacryl on the industriai scale. 
Analytical 
mal1 
slow for high resolution 
not important 
poor to high acceptable 
acceptable to achieve 
P ~ V  
2223.(b). Recombinant Ce& 
t-PA is produced as soluble, mature protein in animal cells. In an appropriately selected 
medium, purification fiom animal cells presents no particdar problem. The purification 
procedure developed (Rijken and Collen, 1981) for cultured human melanoma cell line 
has been adopted by others to purify recombinant t-PA produced in E. coli. yeast, and 
mammalian cells (Heinrikson and Tomasselli, 1991). This method employs three column 
chromatographie steps. The orst two steps are affinty chrornatography on zinc chelate 
agarose and concanavalin A respectively. The third step is a gel filtration on Sephadex 
G- 150. Zinc chelate chromatography is preferred over ultrafiltration and precipitation 
for initial enrichment of the conditioned medium because it resuIts in minimal loss of 
enzyme activity. 
2.2.2.4. Anamcal Methods 
t-PA'S cornplex physicochemical properties, higher molecular mass and variation in 
glycosylation pattern increases the possibility of the formation of undesirable product 
variants that can serve as a major irnpurity in the final product. It is probable that a 
highly purified preparation of t-PA will contain a large number of variants becaw of its 
inherent heterogeneity (e.g. the carbohydrate side chains) or because of degradative 
reactions such as deamidation. The two 'natural' variants of t-PA are type 1 and type II 
glycosy lated foms (Section 2.2.2.1). In addition, t-PA can exist in a two-c hain form as a 
result of proteolytic cleavage. The relative arnount of these variants in a product depends 
on the culture conditions and the recovery processes. 
The variation in glycosylation redts in charge heterogeneity. Therefore, isoelectric 
focusing (IEF) gel electrophoresis c m  be used to differentiate between the variants. Gel 
penneation chromatography (GPC) can be used to determine the amount of 2thain form 
in a given t-PA preparation. IEF can also be wd to examine many degradative 
reactions. Degradation f o m  redting fiom aggregation c m  be analyzed with size 
exclusion chromatography (Anicetti, 1989). Other analytical techniques used for the 
detection of con tamimmts in t-PA are presented in Table 2.2.6. 
Table 2.2.6: Impurities and contaminants of concem and anaiytical techniques fiequently 
employed for their detection in the QC of biotechnology-derived therapeutic proteins 
(Garg, 1991) 
impurities or Contaminan% 
Proteinaceous contaminants ( e-g. host 
ce11 proteins, other protein impwities) 
Endotoxin 
DNA 
Proteolytic degradation products 






Limulus arnoebocyte lysate . . 
Isoelectric focusing 
Analfical technique 
SDS-PAGE electrophoresis, HPLC, 
immunoassays ( ELISA etc.) 
Rabbit pyrogen test, LALO 
DNA dot-blot hybridization 
IEF", SDS-PAGE. HPLC, N- and C- 
terminus anaiysis 
Tryptic mapping, arnino acid analysis 
IEF 
Stedity testing 
Viral Susceptibility test 
2 1 CFR method ( Code of Federal 
Regdations) 
21 CFR610.11 
2.2.2.5. Recent Trends 
Clinical experience with t-PA has k e n  that the early claims of efficacy of t-PA were 
over emphanzed in tems of the potential clinical usefiilness of t-PA. The effectiveness 
of three thrombolytics- recombinant t-PA, microbial streptokinase (SI() and anisoylated 
plasminogen activator-streptokinase complex (APSAC) were compared in the third 
International Study of M i t  Swival (ISIS-3). Reports showed that the mortality for 
patients receiving t-PA was 10.3 percent, compared with 10.5 percent for APSAC and 
10.6 percent for SK (Bluestone, 1992). The report also revealed that 3 out of 1,000 
patients receiving SK SUffered stroke, compared to six receiving APSAC and seven 
receiving t-PA (Bluestone, 1992). However, fewer reports of allergy, hypotension and 
bleeding complexities were associated with the use of t-PA. 
Thereforr, researchers are looking for an improved t-PA, the so-called second-generation 
t-PA. The aim is to develop rival substances, t-PA mutants to improve the activity of t- 
PA and examine how adjuncts could increase t-PA's eficacy. 
Three approaches are king considered for the development of a second-generation t-PA: 
1) protein engineering, 2) modification of the ceil line and 3) synergism strategies. 
222.5.(a). Protein engineering 
Protein engineering appears to be the most elegant way of creating a second-generation, 
improved t-PA. The objective is to modify the different domains of the t-PA molecule to 
obtain an improved product (Table 2.2.7). The finger, knngle and the epidennal growth 
factor regions are drawing the greatest attention. Modified t-PA without the kringle 
structure has been found to be much more stable in vitro, in the presence of inhibitors 
(Klausner, 1986). This fmding shows the possibility of increasing the half-life of t-PA 
and thereby improving its therapeutic effectiveness. The finger domain looks like the 
fibrin-binding site of the t-PA molecule. investigators are looking for methods for 
exposing the fibrin-binding sites more and engineering additional fibrin-binding sites 
into the molecule. Emphasis is placed on decreasing the size of the molecule by 
elirninating inactive parts and reducing the required dosage. Since the interactions 
beo~een the different regions of the t-PA molecules are not yet clearly understood and 
changing one region of t-PA can have profound effect on the activity of another, only 
painstaking research will provide evidence on these novel pouibilities achievable by 
protein engineering. 
Several second-generation t-PA have already been developed. Reteplase has ody two of 
the five protein domains, the kringle-2 and protease domain. The alterations have 
increased the balf-life of the protein in human plasma from 3-6 minutes to 16-18 
minutes. The absence of F domain has made reteplase more effective in disnipting dots 
but it has also increased the posibility of unwanted bleeding (Davidson, 1997). In 
another second-generation t-PA, N P 4  developed by Genetics Institute (Frarningham, 
MA) and undergoing clinical trials by Bristol-Myers Squibb (BMS, New York), the F 
and E domains have been mnoved and amino acids in the molecule have been changed 
at t h e  different sites (Davidson, 1997). 
Table 2.2.7: û v e ~ e w  of approaches to development of second-generation t-PA 
Glycosylation 
site (s) 
t -PA domains 
deleted 
(CamHnght, 1992) 
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Perhaps the most important parameter for t-PA modification is the ce11 line. A new celi 
line has been used to prepare a kidney plasminogen activator @-PA), which seems to be 






cuculates as an inactive zymogen. It becornes active only when it cornes into contact 
with bound plasmin at the site of a blood clot and breaks down the dot (Klausner, 1986). 
Various companies have reportedy achieved high production of t-PA using new types of 
ce11 line such as transforrned myeloma cells. The role of glycosylation in t-PA activity is 
going to be explored in detail to enable investigatoa design an improved t-PA molecule. 
Enhancement of t-PA activity by application of giycoprotein remodeling technology will 
be considered. The possibility of pmducing a longer-acting t-PA molecule by its 
modification with polyethylene glycol (PEG) will be examineci. 
2.22Se(c). Synergism Strategies 
Iastead of trying to improve the t-PA molecule itself, a nurnber of commercial concems 
are working on products that couid be complementary to t-PA. Secretion of a 
recombinant hybrid plasminogen activator (t-PAfu-PA) by mouse myeloma cells has 
been reported (Pierard et al., 1989). 10 mg of t-PA with 3 mg of k-PA has been reported 
to be used successfully for heart attack patients. Synergism has reduced the normal 
dosage of pure t-PA fiom 60 -100 mg to a hction of it. hother set of molecules that 
could be synergistic with t-PA are protein S and protein C. Protein S is a cofactor to the 
anticoagulant protein C. Rotein S localizes protein C's activity to where it is needed and 
these two have k e n  found in vitro to accelerate the action of t-PA. Researchers are also 
looking at monoclonal antibodies to increase t-PA'S performance by steering it by the 
antibody to the vicinity of blood clots. They are also looking at genetically retngineered 
antibodies to engineer the thrombolytic agent into the antibody or to create an antibody 
with dual specificity, both to the clot and the thrombolytic agent 
Nitromed (Boston, MA) has developed a nitrosylated t-PA variant by combining the 
fibrinolytic activity of t-PA with the antiplatelet effkct of nitric oxide (Davidson, 1997). 
222.6. Concluding Remarks 
tPA has played a significant role in the establishment of cultured recombinant animal 
cells as a practical and proven technology for drug manufacture. Development of its 
production process has involved study of a large number of species, celi lines, and 
stimulants. To increase the production level, various expression system and promoters 
have been evaluated for recombinant t-PA. The recent trend of research in this field is 




The input files containing the process information supplied to the simulator to simuiate 
the base case flowsheet described in Chapter 4 have been compiled in Appendix A. The 
corresponding output file showing the results of the simulation run can be found in 
Appendk B. In the simulations carried out, variables and parameters supplied and 
obtained as resdts, were cross checked with literaîure values where available, to ensure 
that they do not represent physicaily unredistic situations. The information that served 
as guidelines for the choice of these quantities have been discussed under 'Process 
Description' in section 3.6. 
3. î. 1. Aspen Bio Process Simulator 
The following information is required to simulate any process with Aspen: 
components present in the process, 
properties of the components, 
flowsheet of the process, 
stream composition and flowrate and 
specincations for the unit operation blocks. 
BioProcess SimulatorZH can be used through a graphitai user interface (GUI) called the 
Model Manager. With Model Manager, the required information is supplied to the 
simulator by filling out forms or menus. Model Manager &omis degree of fieedom 
calculation so that none of the blocks are over- or under-specified. mer successful 
completion of the prompted f o m ,  the user is asked to submit the input file to the 
simulation engine. A simulation nui with BioProcess Simulatorm typically creates 24 
files, four of which are important to the end user (*.input, *.report, *.history and 
*.backup, where * represents a wildcard of the file name). The input infornation 
supplied to mode1 manager is summarized in the *.input file. The results are stored in the 
*.report file and the erron and warnings generated after the simulation are saved in the 
*.history file. The simulation nui is saved as a *.backup file for firture use. BioProcess 
Simulatorm can also be used on Unix platform. With Unix pladorm, the input 
information are written d o m  as an *.input file instead of filling out forms. 
COMPONENTS: The components present in the entire flowsheet, either as reactants or 
products, has to be defined in the simulation. Biohcess Simulatorm allows three types 
of component - conventional, non-conventional and biocomponent. Conventionai 
components are molecular components nich as solvents, solutes and gases. Examples of 
conventionai components are water, oxygen., lactic acid, elhanol, ammonia etc. Non- 
conventional components are heterogeneous soli& nich as cells, celi debris and complex 
media components such as senun. In most cases, properties are not avdable for non- 
conventionai component in the Aspen Biohcess Simulatorm data bank. 
Biocomponents are large biological molecules. This is a special type of conventional 
component that w s  property models better suited for proteins and polysaccharides. An 
example is t-PA. 
A total of thîrteen components (glucose, glutamine, Hams F-12 medium, t-PA, BSA, 
CHO celis, oxygen, nitrogen, CO, elution bufférs 12 and 3, equiliiration and wash 
buffers) were specified for most of the simulations reported in chapter 4. Glucose and 
glutamine contained in Ham's F-12 medium were specified as separate components. 
Glucose and glutamine free Ham's F-12 medium is essentially inorganic salt, of which 
87% is NaCl and 9.3% is NaHCO, (Butler, 1987). Therefore, Ham's F-12 medium was 
specified as NaCI. The other conventional components specified are water, the eluants 
and wash buffers for the chromatographie columns, oxygen, nitrogen and carbon 
dioxide. The buffkrs were specified as solutions containing different concentrations of 
mainly HCI, NaCl and m 4 H S 0 4  as desaibed in literature. t-PA and BSA were specified 
as biocomponent (i.e. protein). CHO ce11 was defined as non-conventional component. 
PROPERTIES: BioProcess SimulatorTH has built-in library of models for property 
estimation of conventional components. Properties of bovine senun albumin (BSA) are 
available in the databank. Properties of components declared as biocomponents (i.e. FBS 
and t-PA) were defaulted to those of BSA. BioProcess SimulatorTM calculates only two 
properties for non-conventional components - density and enthalpy. The user can supply 
other properties if required. The biodensity model BIODEN and bioenthalpy model 
BIOMTH were specified for the calculation of density and enthalpy of the cells. The 
BIODEN mode1 calculated density as a second order polynomial of temperature (p = a + 
bT + CT'). For CHO cells the density was set equal to that of water (a =lg/cm3, b and c = 
O). Enthalpy of non-conventiod components is calculated h m  heat of fomtion 
(AHOJ and a temperaturedependent heat capacity. The heat of formation is calculated 
fiom a hypothetical total combustion reaction (Biomatend + Oxygen = Carbon Dioxide 
+ Water + Nitrogen). Calcdation of heat of combustion is based on 106 kcal of energy 
released per mole of oxygen consumed (Bailey and OLlis, 1986). Since heat capacity of 
solids is relatively temperature independent, the heat capacity was set equal to 1 cdg-K 
(Aspen Plus, 1995). 
For t-PA and GIutamine, additional property data specifying molecdar weights were 
supplied. 
FLOWSHEET: The simulator has to be supplied with information on flowsheet 
comectivity. All the unit operation blocks present in the flowsheet and their input and 
output streams were specified in this step and the simulator (model manager) generated a 
process flow diagram fkom the information supplied. Five different flowsheets were 
simdated for the t-PA process. These flowsheets differed in the fermentation media 
used, type and mode of operation of the bioreactor and the scale-up stnitegy. Details of 
the simulated flowsheets are pmented in Chapter Four. 
STREAMS: The compositions and flowrates of al1 feed streams entering the process 
must be specified. The feed streams identified for the t-PA production process, are the 
batch charge and the air-CO, mixture to the bioreactor and the wash, equilibration and 
regeneration bufTer streams to the chromatography colurnns. The batch bioreactor model 
BFERM, requim one batch charge and at least one or more continuous feeds. A flowrate 
for the batch charge has to be defmed since Aspen is designed as a steady state 
simulator. This flowrate, however, does not affect the flowrate of the product strearns 
fiom the bioreactor. The media contains 90% Ham's F-12 medium, 10% Foetal Bovine 
S e m  (FBS) and 4 mM Glutamine. The molar concentration of FBS was caiculated to 
be 0.0015 moYL, assurning a density equal to water and molecdar weight of 66,000 
(that of BSA). Water was defined as the solvent for the batch charge meam. 
Concentration of glucose in the batch charge was specified as 10 mmoyL and glutamine 
as 5.12 mmoYL (4 mmoK fke glutamine plus 1.123 mmoYL from Ham's F-12 
medium). 
For this aerobic fermentation, sterile air was provided to the bioreactors at an average 
rate of 0.08 WM by an axial compressor thxough an air fiiter. This stream was specified 
to contain 5% CO,. The specified fiowrate is adjusted by the mode1 to maintain the 
specined &a and an air flowrate profile is generated in the report me. The equilibration 
b a e r  wd Ui labonitory with Lysine Sepharose 4B, is 0.02 M phosphate, 0.15 M 
sodium chlonde and 0.01% Tween 80 (Dodd et al., 1986). For washing, a mixture of 
0.02 M Tris, 0.5 M sodium chloride, 0.5 M L-arginine and 0.01% Tween 80 was 
employed. For ion exchange, the equilibration buffer was 0.1 M sodium acetate, 0.25 M 
sodium chlonde, 0.05% sodium nitrite and 0.01% Tween 80. This buffer was also used 
to wash the column (Knrithof et al, 1985). The flowrate of the buffers were specified 
such that the superficial velocities were within the range reported in the literatm 
(Section 3.6). 
UNIT OPERATION BLOCKS: The input information requind to simulate the 
different unit operation blocks is different. n ie  typical values for operating variables and 
parameters for each of the blocks were obtained fiom the literatue and supplied to the 
simulator. Detailed description of the process can be found in Section 3.6. 
Bioreactor: The model equations for bioreactor (BFERM) in Aspen BioProcess 
Simulatorm simulate fermentation of rnicroorganisms in stirred tank reactor in batch, 
fed-batch and continuous mode of operation. To apply the model equations to 
mammalian ce11 cultures, the unit for ce11 concentration had to be manipulated. In 
BioProcess Simulatorm the available unit for ce11 concentration is mass concentration 
(e.g. mg& g/L etc.). For m d i a n  cells it is customary to express ce11 concentration 
in tenns of no. of celf /mi. Therefore, the ce11 concentration was convexted to mass 
concentration for simulation by assuming that the weight of 3.8X109 ceils is quai to one 
gram dry weight (Zeng and Deckwer, 1995). 
The required input information to simulate the bioreactor are inoculum concentration and 
volume, volume charge, mbstnite and biomass ID, heat transfer parameters, growth and 
product formation kinetics, k,a and power correlations. There are some optional input 
requirements (temperaîure, pressure, down-time etc.) which could be supplied by the 
user if the default values set by the simulator are not acceptable. m e r  optional inputs 
are required to avail the optional fean~es (to plot the time profiles, to handle the-  
varying feed streams* to control a variable by manipulating an inlet stream etc.) of the 
model. 
The report file of BFERM generates resdt on m a s  and energy balance, dynamic 
composition in the fermenter, ce11 viability profile, substnite utilbation and biomass 
formation rates, flowrates in vent and heat duty profile. Out of these, the dynamic 
composition of the different components is of major importance. 
The model also carries out viability calculations provided a constant deathrate, aithough, 
in most practical situations deathrate is not a constant. For viability caiculations the cells 
have to be supplied with a BIOSTATE attribute meaning that its state can change with 
time and passage fiom one unit operation to the other. 
BFERM model has built-in comlations for the calculation of a) gas-liquid mass -fer 
coefficient, b) agitation power input, c) unaerated power and d) viscosity. It aiso contains 
built-in biomass growth reaction rate equations. In addition it allows users to constnict 
their own comlation or add a new comlation as a subroutine. Instead of product and 
biomass yields, kinetics in the form of subroutines are aiso accepted for growth and 
product formation. The input variables in the user kinetics are the concentration of the 
different components, mass fiaction of the different elements, temperature* pressure and 
total volume. The subroutine also allows user defined variables so that variables other 
than the ones supplied by the main program can be incorporated into the kinetic 
expression. 
Membrane Separaton: BioProcess Simulatorm uses the MEMBRANE and 
BMEMBRANE models to simulate continuous and batch or fed-batch operation of 
microfiltration and ultrafiltration units. The M E M B W  model caiculates the 
compositions and fiowrates of both permeate and retentate stream exiting the continuous 
filtration unit. A nxycle stream, an associated pump and a process stream cooler are 
inte@ parts of the model. BMEMBRANE calculates the composition and fiow rates of 
tirne-averaged penneate Stream for batch operation of the same units. It calculates 
retentate composition as a function of time and also calculates concentration, recovery 
and pumping work This model can simulate several diffemit membrane operations such 
as  concentration, continuous diafiltration and discontinuous diafiltration. Both the 
models have built-in flux models and models for caiculating physicd properties such as 
viscosity and difhivity. It also accepts user supplied flux models. 
Microfdtration: The inputs required to simulate the microfiltration unit are the feed, 
retentate and permeate pressure, recycle ratio or cross flow velocity, membrane geometry 
(type, ana, length and diameter of the fibers etc.) and flux model with parametea. For 
the resistance in series model, the flux parameters are membrane resistance and gel 
resistance as a fiinction of transmembrane pressure, Reynolds nurnber and key 
component concentration (Rg = Rg, (bp)' @elb (CJC ). 
The model also calculates extent of protein denaturation if the fraction of protein 
denatured is provided. 
Duhg the simulation of the microfiltration, a balance had to be made between the 
concentration factor (feed/retentate ratio) and the recovery of t-PA. A low concentration 
factor reduced the amount of fluid (pemeate) to be treated by the expensive aff?nity 
chromatography columns downstream but on the other hand lowered recovery of t-PA in 
permeate. 
UltrafS1tration: The purpose of the ultrafiltration unit in the flowsheet simulateci was to 
reduce the amount of fluid going to the next down strwun unit In con- to 
microfiltration, retentate is the Stream of interest in ultraf2tration where t-PA is 
concentrated by removal of water. 
BioProcess SimulatorTn simulates ultrafiltration using the same model (MEMBRANE) 
as for microfiltration. t-PA was defined as the key component for this unit, In the 
absence of cells, a slightly higher value for the trammembrane pressure could be used in 
this unit. Since there are no non-conventionai components (i.e. cells or ce11 debris) 
present in the feed streams, the input streams to this unit were spedied as conventional. 
Chromatography: BioProcess Simulatornn has a general model for simulating affulity, 
ion exchange, reverse phase and hy drophobic interaction c hromatography . The mode1 
applies to adsorption, wash and elution stages of operation. The model is based on the 
rate theory of mass transfer and accounts for film and pore diffunonal mass transfer 
resistances for each solute of interest. It assumcs equiiibrium exists at each point dong 
the length of the chromatography column (A- Technology, 1995). 
There are some variations in the input requkments for these düferent types of 
chromatography. The main information required to simulate an affinity column with 
BioProcess Simulatorm are column length, diameter, particle diameter, ve loci~  and end 
points of loading, washing and elution stages, elution profile, solute properties such as 
molecular weight, adsorbent capacity and adsorption isotherm constants etc. 
The rnodel calculates concentrations of products and contamirtants for the eluate 
throughout each stage of operation. The stages are teRninated by user supplied cnteria 
based on product or con taminant concentrations. The mode1 reports the number of 
columns required to the nearest integer number and the effective column usage. It also 
reports the recovery and purity of the components of interest The model uses extended 
Langmuir isotherm to calculate binding equilibrium for multi-component systems and 
also aliows the user to specify an adsorption isotherm. It dows  the user to either use the 
bdt-in correlation or spec* methods for estimating the m a s  transfer coefficients. 
The affinity adsorbent (ligand) recornrnended by Phannacia (Catalogue 1990/91) for 
serine protease such as t-PA is lysine sepharose. The loading, washing and elution 
velocities are found to Vary over wide range in literature. The initial guesses were 
updated by looking at the response (t-PA concentration at column outlet) and pressure 
&op across the colurnn. The fiaction of eluate to be collected as product was also 
determined from the elution profile. 
Gel Filtration: The model for gel-filtration reports the composition of the eluate as a 
function of elution volume. It estimates pressure &op across the bed and can plot 
concentration profiles to generate chromatograms. The model uses stenc-volume theory 
to estirnate the elution volume for each component. It uses the plate model theory to 
calculate the extent of peak spreading. The input information required for simulation of 
gel filtration with BioProcess SimulatorTM are column dimensions, gel panuneters, 
operating conditions (sample volume, flow rate etc.) and molecuiar weight of solutes for 
the caiculation of elution volume. BioProcess Simulatorm has a built-in data bank that 
contains parameters for thirteen gels. There are also provisions to enter parameters for 
user-defmed gels. 
Since debugging of the cornplete process becomes complicated and cumbersome, the 
individual unit operation blocks were simuiated fïrst. When there were no syntax error, 
convergence problem or simulation difficulty with the separate blocks, they were put 
together to generate the complete flowsheet. However, for some cases (e.g. diafiltration) 
the errors causing the simulation problem were not easily identifiable and therefore 
could not be rernedied. 
The synthesis (seleetion of number and size) of the final flowsheet was a trial and error 
process, since it was found that the performance of the membrane separation and 
chromatography blocks were interrelated The opemting variables were varied within 
limits to synthesize a fiowsheet that meets the pre-specified overail recovery within the 
batch tirne outluied in the design basis (Section 3.5). 
BioProcess Simulatorm time averages the output of the batch blocks to combine the 
batch operation with the continuous mode. The average performance is then used to treat 
the batch operation as a "pseudo continuous" unit operation. 
3.1.2. Supeffm Designer@ 
The basic approach to simulation with SuperPro Designer@ (SPD) is the same as 
descnbed for Aspen BioProcess Simulatorm. 
Components: The components present in the flowsheet are introduced with SuperPm 
Designd. Components can either be selected, if present, from the built-in data bank or 
defined as a new component for the specific design case. The new component can be 
added to the component databank to be available for another design case. For the 
simulated process t-PA, biomass (CHO cell), glutamine and ammonium bicarbonate 
(elution buffer) were added as user supplied components. 
Properties: Each component in the data bank has two types of properties associated with 
it - Basic cornponent properties (e.g. molecular weight, particle size, density, heat 
capacity, cntical temperature and pressure etc.) and environmental component properties 
(e.g. COD, BOD, TS, TOC, diffusivity in air and water etc.). The built-in property 
databank contains default p r o m e s  for the components present. These propeaies can be 
modined or updated. Each component property is employed in certain uuit operation 
models. For the new components defined for the design case, formula and molecular 
weights were mpplied to SuperPro Designea. Particle size was suppiied for CHO cell. 
Flowsheet and Streams: The flowsheet is created by selecting the different unit 
operations and connecting the inpurloutput streams. Editing of the flowsheet thus 
generated, is very simple. Superho Designer@ specifies the flowrate and composition of 
the feed strearns in the dialog box accompanying each stream in the flowsheet. 
Unit Operation Block: Information was supplied for the different unit operation blocks 
in the flowsheet. 
Fermenter: This model simulates a stirred fermenter using a simple stoichiometric 
reactor model. The main reaction data required are reaction stoichiometric coefficients 
and extent of reaction. Other required information are liquid to total height and height to 
diameter ratio, agitation rate, fermentation temperature and heat traasfer agent. In rating 
mode, liquid volume and number of units need to be specified. The output data are 
height, diameter, total volume of the fermenter, power, heating or cooling and residence 
t h e  if used in rating mode. 
Membrane Filters: Identical modelling equations are used to simulate microfilter and 
ultrafilter by SuperPro. The model simulates the performance of a semicontinuous unit. 
The required input data are the rejection coefficient, average filtrate flux, maximum 
particle concentration in retentate, denaturation percentage, temperature, heat tramfer 
agent etc. For microfilter, membrane pore size and for ultrafilter molecular weight cut- 
off must be provided. Operation in rating mode also requires specification on membrane 
area and n u m k  of rimts. The output generated is powcr, heating or cooling, 
concentration factor and membrane area. 
Chromatographie Columns: SuperPro uses identical modelling equations for a f 5 n . i ~  
chromatography and ion exchange. The only Herence is in the default values of some 
variables (e.g. min unit cost). The model cm be w d  either to calculate the cycle time 
by specifying the hear velocities for loading, elution and washing-regeneration or vice 
versa. The required input for the model are resin binding capacity, binding percentage 
and recovery yield for each component, total eluant required, amount of buffers required 
for different stages etc. Simulation in rathg mode would also reqWre specification on 
column length, diameter and number of unit. The main objective of this chromatographic 
column model is to estimate the number and six of columns requkd to carry out the 
desired purification, most parameters affecthg purification and overall matenal balances 
king specified by the user. 
Gel Filtration: The model for gel filtration is very similar to the model of the 
chromatographic column in SuperPro Designea. This model requires specification on 
recovery yield of each component and sample volume as a percentage of column 
volume. The output generated is the same as for the previous model. 
Scheduling information was supplied for the different steps of the process using the 
Gantt Chart menu. M e r  niccessful completion of the simulation, the options under the 
task menu was used to generate the stream report (*.SR). If information on raw material, 
revenue and waste strearns are supplied, the other options under the task menu can be 
used, which are: perfom economic calculation, generate economic evaluation report 
(*.EER), itemized cost report (*.ICR), environmentai impact report (*.EIR) and input 
data report (* .DR). 
Input information required to carry out sirdation with Aspen BioRocess SidatorTM 
and SuperRo Designer@ are diffkrent because they use ciiffirent unit operation models 
(rigorous and short cut models). Most of the information required by BioRocess 
Simulatorfhd were available in the literanire or couid be estimated fiom the built-in 
correlations. On the other han& in Superh, some of the information required by some 
of the unit operation blocks c m  ody be obtained fiom experiments. For example, 
simulation of the chromatographic colurnn required the knowledge of binding percentage 
and recovery of each component. For these situations9 resuits h m  BioProcess 
Simuiatorm simulations were used as input to SuperPro. 
The purity requirement of therapeutic phannaceuticals Lice t-PA is very stringent. In 
general, the final product should be fke of infectious agents and meet the limits 
specified for other contarninants such as DNA, ceii and media proteins, endotoxin etc. 
(Anicetti, et al., 1989). In this simulation, it was not possible to follow the removai of 
DNA and endotoxin. Instead, clearance of ody  foreign proteins was investigated. 
Among these contaminating proteins, the clearance of bovine s e m  albumin (BSA) was 
considered to be critical, since t-PA and BSA have very close molecular weights (about 
68,000 and 65,000 rcspectively). Validated processes have shown that a combination of 
two chrornatographic steps normally results in the desired reduced level of retrovirus and 
DNA (Brady et al., 1990). Therefore, two chrornatographic steps were included in the 
flowsheet and it was assumed that the desired level of removal of these contaminants is 
achieved by the processes. 
For caiculation of t-PA purity nom simulation, it was noted that, the basic d e s  for 
presewing significance States for addition and subtraction, a figure in a sum or difference 
is signincant only if al1 figures in the same position relative to the decimai point in the 
numbers being added or subtracted are significant. For multiplication and division, the 
number of significant figures in a product or quotient is the sarne as in the one of the 
quantities being muitiplied or divided which has the fewest (Reilly, 1992). Therefore, 
statistifally, to calculate a puriîy of up to six significant figures (99.9999%). al1 the 
inputs to the simulator should have been specified up to the same extent. In reaiity, none 
of the inputs (e.g. flowrate, composition etc.) can be detennined to such accuracy. 
However, processes, based on flowsheets similar to the ones simulateci, are found to be 
capable of producing t-PA of the required purity (Cooney, 1999). Therefore, this issue 
was not considered critical in this research. 
Economic evaiuation provides an idea of the total cost involved in a process. It can 
i d e n e  the economicaily inefficient steps of a process so that attention c m  be fofused to 
improvdoptimize those steps. Econornic evaluation is also necessary to compare process 
alternatives. It helps to eliminate alternatives with weak economic potential before too 
much research effort has k e n  invested. Process alternatives have been compamd on 
econornic basis for severai biochemicals nich as penicillin, ethanol, reducing sugars, 
single ce11 protein etc. (Evans, 1988; Maiorella et al., 1984). Among recombinant 
products, Datar et al. (1993) compared the economics of t-PA production in CHO cells 
and E. coli. They also carried out econornic evaluation of production of human insulin in 
recombinant E. coli. Short cut material balance estimates were used in both the cases to 
size the equipment. 
Economic evaluations are subject to assumptions regarding the process. Previously 
different conclusions were reported as to the economic viability of the processes because 
of the diversity of the basic assumptions made in the studies (Bhattacharya and Motard, 
1986). For example, Datar and Rosen (1990) and Petrides et al. (1995) both carried out 
economic evaluation for intracellular biosynthetic human insulin (BHI) production in E. 
coli by the proinsulin method. Datar and Rosen (1990) based their equipment sizing on 
step yield and mass balance whereas the latter case was based on simulation with BioPro 
Designem. The only difference between the flowsheets considered wexe the three 
additional chromatographie steps included by Petrides et al. (1995) for their plant 
designed for 1500 kg of BHI per year compaied to the 1000 kg plant of Datar and Rosen 
(1990). However, the conclusions reached by the two groups were completely different. 
The purchased equipment cost estimated by Petrides et al. (1995) was 4.4 times that 
reported by the other group. Breakdown of the annual operating cost showed that for the 
first case (Datar and Rosen, 1990) labor was the dominant contributor (23.37%) and 
contribution by raw materials and utilities were 18.91% and 13.95% respectively. In 
contrast, for the latter case (Petrides et al., 1995) the major contributor (48.2%) was 
DFC-dependent items (depreciation, maintenance material, insurance, local taxes and 
factory expense). Combined raw material and consumables accoimted for 37.9% while 
5% contribution was made by labordependent items and only 0.3% by utilities. A 
higher degree of uniformity can be expected by carrying out economic evaluation with a 
process simuiator. 
ASPEN PLUS was used for economic evaluation of peniciilin production (Evans, 1988). 
Economics of producing porcine growth hormone in recombinant E. coli was 
investigated by Petrides et al. (1 989) using BioProcess Simulator'H. Emst et al. (1 997) 
used SuperPro Designer@ for economic evaiuation of a process for production of 
recombinant heparinase 1 expressed in E. c d .  
Aspen BioProcess Simulatorm and SuperPro Designer@ are both equipped with 
econornic evaluators. Both of these simulators follow the same basic approach for 
economic evaluation and contain modifiable cost factors and correlations and provide 
default estimations. However, the economic evaluator of Aspen BioProcess SimulatorZH. 
which has k e n  derived from the chemical process simulator Aspen Plus, is more geared 
towards chemical processes. Its calculation mode is ngorous and rrquires a lot of data 
from real projects to make appropnate use of the available options. SuperPro Des ignd  
on the other hand, has an economic evaluator that is specifically developed for 
bioprocesses. It is simple and easy to use. For preliminary screening of these conceptual 
flowsheets and in the absence of detailed information, econornic evaluation with 
SuperPro was thought to be nifncient in this case. 
Economic evaiuation consisteci of three stages - capital coa estimation, operathg cost 
estimation and profitability analysis. 
Capital Cost Estimation: The number and size of equipment for caiculation of 
purchased equipment cost were obtained firom simulation by BioRocess SimulatorTM. 
SuperPm Designe* was used in rating mode so that the size and number of the different 
equipment obtained h m  the two simulators were the same. Estimation of equipment 
purchase cost was obtained fiom SuperPro Design&. SuperRo generates an equipment 
list dong with the size and number of each item as a part of economic evaluation. Then 
it uses the built-in power law model (CKo = [Q/Qor) to calculate the purchase cost of 
the equipment (Ca.  For example, the following power law is used to calculate the 
purchase coa of fermenter by Superho: 
SuperPm Designd also accepts user supplied updated cost or cost model for purchase 
cost estimation. A 20% allowance (Petrides et al., 1989) was made in the purchased 
equipment cos  to account for unlisted equipment such as heat exchanger, pump, storage 
tank etc. The total ((&) and fked capitai (C,) was then estimated by multiplying the 
purchase equipment coa fiom SuperPro Designer@ by appropnate cost factors. The cost 
factors u x d  are 4.6 for fixed capital investment (Cm) and 5.5 for total capital investment 
(Cd .  These estimates are of 'bbudget authorization" grade only and reflect the 
expenence in the engineering and construction of similar projects (Datar et al., 1993). 
Modifiable built-in cost factors in SuperPro Designer0 could have also been used to 
estimate the capital cost by combining Direct Fixed Capital (DFC) and working capital. 
DFC is estimated fiom its different components (piping, instrumentation, innilation, 
electrical facilities, buildings, yard improvement, awiliary facilities, engineering, 
construction, contractor's fee and contingency) whereas, esthate of working capital 
fiom SuperPm Designe- covers cost for 30 days of labor, raw material, utilities and 
waste treatment. However, since the economics of the simulated processes were 
evaluated for cornparison purposes only, the "budget authorization" eshates were 
considered sufficient. 
In BioProcess Simulatorn", equipment is divided into five major equipment types for 
COS estimation. These equipment types are: heat transfer equipment, vessels and tanks, 
pumps and cornpressors, towers and user models. The user has to speci@ the sizing and 
costing data. Several equipment types are then combined to represent a common set of 
equipment, such as a distillation column consisting of a tower, heat exchanger, pump etc. 
This method is inconvenient for estimation of pmhase price of typical biochemical unit 
operation blocks (e.g. bioreactor, membrane separators, chromatography column etc.) 
and therefore estimates fiom SuperPro Designer@ were used. 
Opershg Cost Estimation: Operating costs were estimated by combining information 
from both the simulators. Estirnates on amount of raw materials, process chemicals and 
other consunables required by the process were obtained fiom simulation with 
BioProcess Simulator? The amount of raw materials, particularly the buffers required 
for the chromatography columns, was convenient to calculate from the results reported 
by BioProcess Simulatorm since it generates elution profiles. SuperPro Designer@ 
requires specification on the amount of buffers required as a multiple of the column 
volume and in literature, these amounts are found to Vary over a wide range (Clonis, 
1990) (Section 3.6.5). The number of labor hours on the other hand, was obtained fkom 
SuperPro Designea. BioProcess SimulatorN aiso estimates base labor hours, however, 
since the models in SuperPro Designem are particularly suitable for bioprocesses, these 
estimates were considered to be more diable. This estimate included labor for 
warehousing (2000 hdbatch), packaging (2000 hrlbatch) quality control (1000 hrhatch) 
and othea (2000 hrhatch). The unit labor rate considered was $18/hour and the prices of 
the media and buffers as follows @star et al., 1993): 
serum fiee medium $2S/L 
10% semm containing medium $ t 8/L 
diafiltration stream $5/L 
elution buffér for aî3kit.y chrom. $1 O/L 
quilibration buffer $SM. 
elution buffer for gel chrom. $28.75/L 
wash buffer for gel chromatography $5.5/L 
The replacement frequency and unit cost for the chromatographie media and membranes 
were considered as following (SuperPm Designer@, 1996): 
I .Affinity Chromatography : replacement fkquency 200 cycles 
unit cost of resin $2000/L 
III.Ge1 Chromatography: 
replacement frequency 200 cycles 
unit cost of resin !§400/L 
replacement frequency 300 cycles 
unit cost of resin $2OO/L 
1V.Membrane Separation: replacement frequency 2000 oper. hour 
membrane unit cos  $200/m2 
Realizing the variability in these pnces, sensitivity studies were carried out to the overali 
economics of the process to labor (Section 4.3.7), semm fiee medium price (Section 
4.1.6). 10% semm containhg medium price (Section 4.2.6), price of diafiltration stream 
(Section 4.2.6) and replacement fiequencies (Section 4.1.6). 
The total operating cost was calculated by d g  up the components, estimates of 
which were obtained by applying cos  factors. Modifiable cost factors are available in the 
built-in evaluator of SuperPro Designe* for several cost components of operating cost 
such as f i g e  benefits, supervision, operating supplies. laboratory expense. insurance, 
local taxes, factory expense and administration overhead. Datar et ai. (1990) used cos 
factors to evaluate the economics of human growth hormone production h m  
recombinant E. cdi. These cost factors were fouod to be more appropriate for calculation 
of capital investment and operating cost of recombinant protein production in absence of 
detailed information and were adapted h m .  A FORTRAN program was written for this 
purpose. The cost factors used cm be found in Appendix C. 
Profitability Analysis: The econornics of the flowsheet was evduated in terms of 
Retum on Investment (ROI) defineci as the ratio of (net profit afkr tax + depreciation) to 
total capital investment and Gnws Margin (GM) defined as the ratio of pretax profit to 
annual product sales. Other measures such as Unit Production Cost (UPC) defined as the 
ratio of total expense to annual production and Cost of Sales (COS) defmed as the ratio 
of (dkct cost + indirect cost + depreciation) to revenue have also k e n  used by some 
authors (Datar et al., 1993). 
The econornic evaluatoa of Superpro Designer@ and BioProcess Simulatorm also 
generates cash flow analysis tables which contain the net cash flow for each year of the 
expeaed life time of the projet taking into account loan payments for DFC, working 
capital, up front royalties and up fiont R & D, if any. Cash flow aaaiysis tables were not 
considered for the sake of simplicity. 
The economics of the process under study (t-PA fiom CHO cells) is expected to differ 
fiom bulk biochernical production processes due to several rwwns. Research and 
development costs for this process should be significantly higher because of the 
inclusion of clinical trials and goverment approvd costs, which are generally very high. 
The next important item is utility. Phamürceutical plants require special kinds of process 
utilities such as water for injection, pharmaceutical water, clean stem, different classes 
of air (class 10,000 air for purification suites, class 1000 and class 100 air for fiil and 
finish areas) etc. in addition to plant utilities. Cost for these process utilities will be 
sigdicantly higher than the plant utilities normally required. Also the requirement to 
maintain d e t y  measures to prevent release of the recombinant cells to the environment 
has to be considered. For plants producing pharmaceuticals fiom recombinant animal 
cells, a containment level of at les t  GLSP (Good Large Scale Practice) is recommended 
(Miller and Bergmann, 1993). The maintenance of this safety level will add to the waste 
treatrnent cost substantiaily. Al1 these costs which can Vary over a wide range depending 
on the process and thereby incorporate uncertainty in the estimated economics will be 
investigated in Chapter Five. 
3.3. SENSlTlVlN STUDY 
The 'smsitivity study' feature of BioProcess Simulatorm was used to cany out 
sensitivity to uncertain parameters and variables. There are three steps in the 
development of a sensitivity block. First of dl, the dependent variables to be studied 
have to be defined. There is a built-in exhaustive list of variables in Mode1 Manager, 
fiom which the user can choose the variables of interest. The next aep is to declare the 
variables to be tabulated for each independent variable. The fuial step is to defme the 
independent variables and to specify the interval over which sensitivity study is to be 
carried out. The user also has to specify the number of points to be shidied within the 
interval or the increment for each step. Sensitivity study appears as a separate block in 
the input file (Appendix F). 
3.4. STUDY OF KINETICS 
To study the unstnictured kinetic models for mammalian cells, each model was -en 
down as a FORTRAN subroutine. The subroutines were added to the main fermenter 
model. The parameters of the model couid be varied using a sensitivity block. For most 
cases, the variation of the parameters over a reasonable intervai changed the performance 
of the bioreactor so significantly that simulation did not converge. The effect of specinc 
growth rate was studied by simply replacing the expression in the subroutine with a new 
expression. 
3.5. DESIGN BASlS 
The calculation of the design basis for the process to be simulated is s h o w  in Table 
3.5.1. The process is based on 2.8 million annual cases of heart attack and stroke 
worldwide. Treatability with t-PA depends on the patients' age and the tirne elapsed 
since omet of the heart attack. Typically about 40% or only 1.1 million cases are found 
to be treatable by t-PA. The process is designed for 10% market penetration. A complete 
dosage of 100 mg, therefore, requires the production of 1 1,000 gram of purified t-PA per 
year. For an assumed recovery of 40% and product titer of 33.5 mg t-PAL (Datar et al.. 
1993), 820,000L plant capacity is estimated. In laboratory, t-PA concentrations of higher 
than 33.5 mg/L have been observed. However, amplification with MTX in higher 
producers resulted in increased doubling time and also in some cases, increased fragility 
(Cartwright and Crespo, 1991). t-PA concentrations around 50 mg/L were also found to 
be toxic to cells. In monolayer cultures, cells were found to detach from substrate as 
these levels were approached (Kaufinan et al., 1985). Since these changes will prevent 
efficient ce11 growth in stirred bioreactors, higher t-PA concentrations were not assumed 
for the design basis. However, in reality, the product titer may improve with time 
without toxicity to the cells (Cooney, 1999). 
A 20% margin was dlocated for unforeseen events such as product contamination etc. 
This is a rather conservative margin since contamination loss of even 5% is considereà 
reasonable (Nelson, 1988). The bioreactor volume thus calculated was found to be 
30,000L for 35 batches requiring 10 days each. Since a single 30000 L bioreactor for 
CHO cell cultivation is impracticable with the current state of technology, the total 
bioreactor volume was divided into five equal sized bioreactoa. The use of multiple 
bioreactors also provides a buffer against doreseen losses due to contamination, 
equipment breakdown and other problems (Section 4.5.1). One of these five bioreactoa 
with the associated dowmtream units was simulated for the base case (Section 4.1), two 
stage cell culture (Section 4.2) and the airlift bioreactor based flowsheets (Section 4.4). 
nie  bioreactor volume was recalculated for the fed-batch cases (Section 4.3) and for the 
single vernis multiple bioreactor study (Section 4.5) it was M e r  divided into six 1000 
L bioreactors. 
Table 3 S. 1 : Design Basis (Datar, R.V., 1993, Chisti, Y ., 1993) 
Worldwide cases 2.8 rnilliodyear 
Treatable cases (40%) 1.1 rnillionfyear 
Market penetration (1 0%) 1 10,000 1 year 
Arnount of t-PA per dose 100 mg 
Production of purified t-PA 1 1,000 g/year 
Recovery Yield 40 % 
Product titer before purification 33.5 mg/L 
Plant capacity 820,000 Llyear 
Over design for Contingency 20% 
Plant capacity 1 025,000 L 
Time to complete one batch 10 days 
No. of Batches per year 35 
Batch Volume 30,000 L 
Fermenter Liquid Volume 5 X 6000 L 
Total volume 5 X 8500 L 
3.6. DEVELOPMENT OF GENERAL PROCESS DESCRIPTION 
Commercial production of t-PA under the name ~ctivase. (common name Aiteplase) 
began in Novenber, 1987, by Genentech, Inc., San Francisco, CA t-PA is produced in 
CHO ceils. The master working cell bank is tested for stability and the absence of 
exogenous bacteria, mycoplasma, h g i  and virai agents associated with mammaiian ceU 
culture. Molecular identity test for t-PA includes tryptic mapping, specifïc activity and 
protein content d y s i s .  The nnal product is tested for appeanuice, sterility, safety, 
pyrogenicity, identity, purity, potency, pH, formulation chemicals content, moisntre and 
fil1 volume (Sofer and Nystrom, 1 99 1). 
A typicai biotherapeutic production plant involves several sections in the dowmtrearn 
processing unit (Figure 3.6.1). A unit by unit process description has been developed for 
the complete process of t-PA production based on information fiom litmature. The 
fiowsheet for this process is based on the one outlined by Datar et ai. (1993). The 
flowsheet consists of fermentation followed by microfiltration for ce11 separation and 
ultrafiltration for broth volume reduction. The permeated broth is then passed through 
two sets of affinity chromatography and ultrafiltration units. The fmal step is a gel 
filtration. Scale up of inoculum with seed fermenters has been omitted fiom the 
flowsheet since this operation is similar to the operation of the production bioreactor. 
For t-PA, the gel filtered product is stenle filtered and then lyophilized. Validation steps 
for this process include demonstrating removal of foreign proteins and ce11 culture 
additives as well as inactivation and removal of mode1 retroviral particles (Sofer and 
Nystrom, 1 99 1 ). 
Following is a general process description developed for the process simulated. 
3.6.1. Bioreactor: 
The fim step in the design of a fermentation process is to decide on the type of the 
bioreactor. Commerciaiiy available bioreactors range fiom simple stirred tank to 
cornplicated membrane perfusion systems. The various designs have all proven 
successful, to a greater or lesser extent, in culturing mlrmmalian cells. Table 3.6.1 
compares the different bioreactor systems in ternis of operability, ease of d e - u p  and 
productivity (Kearns, 1990). 
The simple operation and ease of scale-up of stirred tank and airlift bioreactors give them 
preference over other systems for large-sale operation. Stirred tank reactors are the most 
dominant type of ce11 culture bioreactors in industry today (Smith, 1994). This is mainly 
due to the experience and knowledge gained in this area from the traditional 
fermentation industry. Many large-scale mammaîian ce11 cultures use stirred tank 
reactors since they are perceived as king diable and well understood. The largest 
reported ce11 culture processes in stirred suspension are operated in Japan at 20,000 L 
scde for tobacco cells (Arathoon and Birch, 1986). Wellcorne Biotechnology Ltd. 
produces interferon fiom Namalwa cells at 8000 L scale in a magnetically driven stirred 
tank reactor (Phillips et al., 1985; Pullen et al., 1985). Similar technology is used to 
produce Foot and mouth Disease vaccines fiom baby hamster kidney cells at 3000 
scale by Weilcome (Pullen et al., 1985). 
Table 3.6.1 : Cornparison of Bioreactor S ystems (Kearns, 1 990) 
Productivity 
Stirred Tank Reactor 
Airlift Reactor 
Hollow Fiber Reactor 
Ceramic Matrix 
(Opticell, Charles River) 
Glass Bead Reactor 
Fluidized Bed Reactor 
(ver=) 
Membroferm 
( S b )  
Stirred TanklAirlift Reactor 
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Figure 3.6.1 : Generalized flowsheet for d o m  proceshg steps applied 
to recombinant protein from animal ceiis 
However, a major drawback of S h e d  tank reactors in case of mammalian ce11 culture is 
that they oflen produce high shear, which is detrimental for these fragile cells. AIso 
maintenance of sterile conditions in the bioreactor is a problem because of leakage 
through the moving parts. 
Airiift bioreactors, on the other hand, produce a gentle, low shear environment suitable 
for tissue culture and genetically engineered microorganism (Chisti, 1989). Airlift 
design is simple since it removes the need for motoa and agitators associated with 
agitated reactors. In addition, hydrodynamic and mass-transfer characteristics of the 
airlifi reactor are predictable with increase in scale (Arathoon and Birch, 1986). There 
are several examples too of its use in large-scale culture of mammalian cells. The largest 
airlift reactor (1000 L) is used by Celltech for production of monoclonal &body fiom 
hybndoma Celltech has also designed a 10,000 L airlift reactor for the sarne purpose 
(Birch et al., 1987). 
The choice between these two types of reactors is dictated by the ce11 line. The 
characteristics of ce11 line that are of concem are ce11 biology, genetic stability, growth 
pattern, growth kinetics, oxygen requirements, shear sensitivity and nutrient requirement 
(Nelson, 1988). It is found that CHO cells tend to form aggregates in suspension in 
conventionai medium (Boraston et al., 1992). This is in con- to hybridoma, which 
occur naturaily as anchorage independent cells (lymphocyte part) and can be grown in 
airlift reactors. Our experience with CHO cells revealed that these aggregates can be 
broken d o m  by stirring the suspension at low rprn (below 200 rpm). At this low speed 
of stirring no observable ce11 damage occurred to CHO celis (Dutton, 1998). For 
cornparison, a rotational speed of 150 rpm (impelier tip speed of 0.35 mls) was found to 
have no detrimental effect on hybridoma c e k  (Chisti, 1993). Instead, cells could be 
more prone to damage in the air-bubble-rich enviromnent in airlift reactors due to bubble 
break up (Handa et al., 1987). The largest commemial producer of t-PA, Genentech, uses 
suspension culture of CHO cells in stimd tank reactoa. Therefore, stirred tank appears 
to be a better option than airliît for this particular ce11 line. 
Next, a choice had to be made regarding the fermentation mode - suspension or 
microcarrier culture. Since CHO cells could be both anchorage dependent and 
independent (Boraston et al., 1992), both kind of culture is possible with this ce11 Iine. 
Al1 of the large-scale ce11 culture process mentioned uses suspension technology. The 
commercial process for t-PA also uses suspension culture (Lubiniecki et ai., 1989). 
Examples of large-scale micro carrier culture are lacking, one of the difficult aspects in 
scale up being the transfer of cells fiom one culture to the next (Arathoon and Birch, 
1986). The largest scale of micro carrier culture seems to be the production of viruses at 
1000 L (Reuveny, 1990). So suspension culture appears to be the preferred mode of 
fermentation in this case. Experience with CHO cells show that they fom aggregates in 
suspension of senun containing medium. These aggregates can be broken down by 
stimng at 150 rpm (Dutton, 1998) or even by adjusting the amino acid and inorganic salt 
content of the medium so that they cm grow as single-ce11 suspension (Boraston et ai., 
1992). Therefore, the production of t-PA in stirred tank reactor in suspension culture 
seems feasible. 
The upstream section of the bioreactor consists of medium preparation and inoculation. 
Currently there are two approaches to media preparation: one is to prepare stock 
solutions of component mixtures of the defined basal medium. The basal medium is 
essentidy a mixture of carbohydrate, amino acids, salts, vitamhs and various other 
biochernicals. The carbohydrate w d  is unially glucose. Substitution of glucose with 
galactose, hctose, maltose and starch in the medium has been studied but no advantage 
was observed (Macmillan et al., 1987). Similarly the amino acid commody employed in 
the media preparation is glutamine although some investigators have reported thet 
asparagine and glycyl-dutamine, with a much longer haKiSe, could also serve the same 
purpose for CHO ceiis (Dyring et al., 1994; Kurano et ai., 1990; Holmlund et al., 1992). 
At the time of use the final medium is then prepared fiom fiozen stock solutions. The 
second, more common approach is to prepare a batch of medium ready to use from 
powder, which is fiequently purchased fiom medium manufactureers. These powder 
mUaures are then dissolved in appropriate amount of USPMrFI grade water and other 
supplements are added to this solution to complete the medium. Subsequently, the 
medium is filtex sterilized, and may be then quarantined at 40" C for a period of up to 
three weeks, depending upon the holding capacity of the plant (Bliem, 1988). 
The ce11 culture production process begins with the preparation of a seed stock culture 
nom the working ce11 bank. For inoculum preparation, a production plant may have a 
battexy of bioreacton of progressively increasing volume comected in series. Each of 
these bioreactors provides inoculum for the next larger reactor in the train by aseptic 
transfer of the inoculum cultue. It is di&cult to generalize about scakup rates since it 
depends on the type of culture, its growth rate, its viability and whether the cells will be 
suspended or grown on microcarrien (Beck et al., 1987). For the 1000 L airlift 
bioreactor used by Celltech for MAb production, the inoculurn culture was grown in 
roller botties (ca. 1 litre) and then transferred aspetically to a 10 L inoculum bioreactor. 
When ce11 density reached a level of 106/ml, the contents were transferred to a 100 L 
bioreactor. This in him, provided inoculum for the sterile, medium-filled 1000 L 
bioreactor (Birch et al., 1987). The inoculum usually constitutes between 5925% of the 
working volume of the bioreactor (Chisti, 1992). Amplification of an ampoule of cells 
(about 10' cells) to the level required for seeding a bioreactor (-5x1 O' to 10" cells) takes 
several weeks (Bliem, 1988). M e r  completion of the fermentation proces the separated 
celis are sent to a kill tank for total inactivation. 
The oxygen demand of animal ceils is low in cornparison to mimbial cells. The oxygen 
uptake rate of mammalian ceil lines has k e n  shown to be in the range of (2-10) X 1012 
g/ceiLh and the meamred oxygm demand, (0-045-0.47) mm01 oxygedliter-hou at 106 
cellshl (Fleischaker and Sinskey, 1981). Oxygenation or aeration in stirred-tank 
bioreactors can be achieved by three methods, individually or in combination: membrane 
aeration, surface aeration or direct sparge aeration. The available surface area per unit 
volume limits the use of d a c e  aeration to unsparged stirred-tank bioreactors of 
between 10 L and 100 L depending on the culture's oxygen uptake rate and deasity. For 
membrane aeration, silicon tubing is generally used because of its high oxygen 
penneability and autoclavability. However, when scaling up to very large volumes, the 
amount of silicon tubing required for efficient oxygen transfer increases proportionately 
and may becorne limiting (Nelson, 1988). Air sparging, although it causes ce11 damage 
or foarning, and sometimes both, is the most direct method for supplemental oxygenation 
and is used in most large bioreactors. However, there is an upper l h i t  on the partial 
pressure of dissolved oxygen due to toxicity to mammdian cells (Young and Dean, 
1987) and the recommended air flow (containing 5% CO3 rate to stirred reacton for ce11 
culture is Iess than 0.1 WM (Arathoon and Birch, 1986). The inlet air and also the 
exhaust gases fiom bioreactors are filter sterilized. Either absolute (such as 0.1 to 0.4 p 
hydrophobic filters) or depth filters are employed (Chisti and Moo-Young, 1991). OAen 
wo filter cartridges in series are used at both locations. The first filter serves as a 
prefilter and protects the fmal filter. Bioreactors are typically maintained at 2 to 10 psi 
above atmosphenc pressure (Beck et ai., 1987). The dissolved oxygen concentration 
maintained in the labonitory scale bioreactors (2 litres) for CHO ce11 culture is found to 
be between 40% and 60% (Hansen and Emborg, 1994; Kurano et al., 1990, Lakhotia et 
al., 1992) and the fermentation temperature is 37" C (Dyring et al., 1994; Kurano et al., 
1990; Nilsson et al., 1988). 
The literature is replete with correlations for oxygen mass-traosfer &a) coefficients 
fiom the scale-up of microbial fermentation. These correlations for kLa use the gassed 
volumetic power input and the superficial gas velocity as parameters. These comlations 
are based on a well-dispened gas phase and the high power input that are typical of 
mimbial systems. Such comlations are not appropriate for mammalian celi culture 
systems because of the extremely low agitation and aeration rates that are required 
because of the shear sensitivity of these cells (Nelson, 1988). Thexfore, the basic 
approach to kLa calculation was adopted to get an estimate of the oxygen mass-=fer 
coefficient for the simulated bioreactor (Appendk D). The calculateci value of kLa was 
found to be about 6 lï'. 
The possible limiting factors in the scaling up of ce11 culture bioreactors include physical 
parameters such as oxygen tension or turbulence, biological parameters such as substrate 
utilization or strain stability and biochemical parameten such as product half-life in the 
ce11 culture environment. A technique that underlines most of the cment scale-up 
strategies ernployed in microbial and lately in animal and plant technology is the 
dimensional anaiysis. Dimensional analysis in ce11 culture maidy concerns the use of the 
dimensionless power number. The power number describes the dynamic mixing forces 
of liquid agitation using impellers (Bliem and Katinger, 1988). Where oxygen trader is 
not a limitation* scaling up is achieved by rnaintaining a similar fluid turnover, that is 
impeller pumping rate per unit bioreactor volume, at the two scales (Chisti, 1993). 
The aspect ratio for stirred tank bioreactors are usually maintained around 1 for better 
bulk mixing. The impeller diameter to bioreactor diameter ratio is kept around 0.3 
(Chisti and Moo-Young, 1991). Agitation through mechanical seals is considered risky 
and hence magnetically coupled agitators are used in large-sde stirred tank bioreactors 
(Phillips et ai., 1985; Chisti, 1993). Topdnve systems are preferred by some because the 
mechanical seals are out of the liquid, preventing them fiom damaging cells or 
contributhg toxic trace contaminmts. On the other hand, bottom-drive systems are 
favored by others because of both, the large size of the agitator motors and agitator shatts 
that are necessary in topdrive systems (Nelson, 1988). Baffles are d e l y  eliminated 
fiom mammalian ce11 culture The power input per volume for ceil culture processes lies 
in the region of 0.005-0.1 W/kg in coneast to microbial processes which usuaiiy lie in 
the region of 1-5 W k g  (Bliem and Katinger, 1988). Operathg speeds for ceil culture 
agitators are normally kept below 100 rpm (Beck et al., 1987). Scaled up agitation and 
power input requirement for ce11 culture bioreactors can be calculated by maintaining 
similar fluid turnover, that is similar impeller pumping rate per unit bioreactor volume at 
the two scales (Chisti, 1993). This approach resuited in an agitation rate of 77 rpm and 
power input of 13 w/m3 for the pmcess to be simulated (Appendix D). Scaled up 
agitation and power input requirement can also be calculated by maintabhg a constant 
Kolmogorov length scale (Nelson, 1988). For an impeller diameter of 0.6 m this 
approach resulted in an agitation rate of 0.57 s" (obtained by trial and error approach) 
(Appendix D). The resulting power input was found to be too mal1 (1.15 w/m3) and 
below the range (0.005-0.1 W k g )  reported by Bliem and ffitinger (1 988). 
Many impeller types have been proposed for mammalian cells, however, there is no 
single best recommendation for the impeller of choice. Marine type propellen have 
worked well under specific practical conditions up to severai thousand litres. Another 
type that has been found satisfactory in tissue culture vessels up to 500 L is the Elephant 
Ear Impeller (Charles and Wilson, 1994). Besides these other types of impellers such as 
sail-type agitator (Tolbert and Feder, 1983). paddle and coiled stirrer vibromker ( L p  
and Acton, 1975; Hu and Dodge, 1985), ''scuii" type agitator (Hu and Dodge, 1985) etc. 
have also been applied for ce11 culture. 
A paaially structureci kinetic mode1 developed for hybridoma (Phillips, 1991) and 
adapted for CHO cells @utton, 1998) was used for the simulated bioreactoa Growth 
and product formation kinetics were supplied as user dehed subroutines. The batch time 
was assumed to be 200 hours. The parameters for this mode1 were obtained fiam 
experiments carried out with CHO ceff s @utton, 1998). Howwer, with the specifk cell 
line used in the experiments, the maximum t-PA titre was fouod to be ody about 10.5 
mg& which is much lower than that considered in the design basis (33.5 mgL) and 
reported for a different cell line @star et al., 1993). The bioreactor, therefore, was 
simulated independently of the downstream uni& and the product titre in the stream 
entering the first block of the dowmtmam train was assumed to be the same as 
considered in the design basis. The kinetic equations for this model can be found in 
Appendix G. Several other unstmctured kinetic model h m  literature for hybridoma and 
CHO cells have k e n  investigated in Chapter Six. 
3.6.2. Cooling Down o f  Broth: 
The ce11 culture broth has to be cooled d o m  to 4" C to prevent denaturation of the 
product and minimize the possibility of contamination. This cooling d o m  is usually 
carried out in the bioreactor by circulating coolant through the jacket (Charles and 
Wilson, 1994). 
3.63. Primary Separation 
Unit operations recomrnended for primary separation are centrifugation and 
rnicrofihration. 
Microfiltration has several advantages over other methods of harvesting. In con- to 
centrifugation, where supernatant can be heavily contaminated with colloids and smdl 
particles, microfiltration completely removes suspended solids and produces a M y  
clarified product Stream (Antoniou et al., 1990). It allows operation in closed system 
without generating aerosols, which is an essential feature for processing genetically 
engineered microorganisms and ceils. In closed systems it results in high yields (>95%)). 
Although centrifugation offers hi& processing speed and cm be scaled up, it subjects 
the cells to high shear environment, which can be avoided by using microfiltration. 
These systems generdy have greater than 99.9% retention of cells (Zahka and Leahy, 
1985). A 15-fold concentration of rnammaiian cells was anained by van Reis et al. 
(1 99 1) during cross-flow filtration in industrial scale at an average yield of >99%. 
3.6.4. Initial Enrichment 
Ultrafîltration, precipitation and adsorption are among the methods recommended for 
initial enrichment Precipitation although widely applicable, is a relatively slow method 
with poor yield It is difncult to carry out at large scde and is inefficient in diiute protein 
solutions. The requirement to add a precipitant and its subsequent rernoval is also 
disadvantageous fiom both process design as well as economic standpoint (Cartwright, 
1 994). 
Adsorption, which is a simple technique for large s a l e  separation, has the disadvantage 
that new process parameters has to be developed for each individual product and again 
the cornponent adsorbed has to be subsequently recovered fiom the solid phase. 
Ultrafiltration is almost universally employed for initial e~chrnent  because of its rapid 
throughput and versatility (Cartwright, 1994). Ultra and Microfiltration for primary 
separation and initial enrichment can be carried out by one of three types of membrane 
system - hollow fiber, plate and frame or spiral cartridge. Hollow fiber and plate and 
h e  membranes are more easily cleaned than spiral cartridges (Scott et ai., 1987). 
Hollow fibers have the highest surface area to voiume ratio among filtration modules. 
The low pressure drops and fîow rate make this type of membranes most economical in 
terms of energy consumption. However, the small diameter fibers are susceptible to 
plugging and the purchase and replacement cost of these type of membrane is very high 
(Cheryan, 1986). The only report on indutrial scale harvest of t-PA using microfiltration 
used hollow fiber type of membrane (Reis, 1991). 
Gentle process conditions are recommended for initial harvest of product so that the cells 
are subjected to only rnild forces (Rudolph and MacDonald, 1994). This is to prevent the 
cells fiom lysing, which can r d t  in increased level of contaminating proteins and 
nucleic acids. Most of the data for simuiation were chosen to maintain conditions similar 
to those maintained by Reis et al. (1991). To keep the trammembrane pressure amund 5 
kPa (0.05 atm) and axial pressure drop around 25 kPa, the putnp pressure was cafculated 
to be 1.25 atm and penneate and retentate pressures 1.08 and 1 atm respectively. This 
results in a tnuimiembrane pressure of 0.045 atm (0.67 psi). This is within the range of 
transmembrane pressure ( 4  psi) recommended by Rudolph and MacDonald (1994) 
aithough transmembrane pressures up to 2 psi have been applied for harvesting animal 
cells in pilot scale (-1 m2) (Maiorella et al., 1990). The flux observed at 4*C with ce11 
harvesting is between 30 to 60 L/m2-h and at 30°C is between 60 to 120 Um2-h. A much 
higher haasmembrane pressure (20 to 40 psi) is employed for concentration of protein 
resulting in pemeate flw between 10 to 100 Wm2-h at 4OC (Rudolph and MacDonald, 
1994). For recombinant human growth hormone, transmembme pressure up to 0.65 atm 
has been used (Maa and Hsu, 1995). The maximum solids concentration that can be 
handied by the ce11 harvesting filter is 10' celldml and 10 gR. or 20% for clarification 
and concentration of proteins. Length and diameter of the fibres were chosen to be 0.435 
m and 6X104 m respectively. The system described by Reis (1991) used 180 m2 of 
membrane area at a feed rate of 3.3X104 L/h. The pemeate flux was 50 Um2-h. A 
membrane pore size of 0.2 p was used by Reis (1991) for microfiltration of CHO cells. 
This pore size appears satisfactory because although mammalian cells have an 
approximate size of 15 - 20 pm (Scharer, 1996), ce11 debris as mal1 as 0.4 pm could be 
present (Bowen, 1993). 
The resistance in senes flux mode1 was chosen for the system. Membrane resistance and 
paraxneters for calculation of gel resistance were obtained fiom severai sources (Tamer, 
1995, Lee, 1989, Wood, 1988). In the calculation of gel resistance (Rg = Rg, (Ap)' (Re)b 
(CJC ), the exponent on pressure (a) was set to 0.13 instead of 0.7 as reported for pressure 
in kPa, to take into account the different unit of pressure (N/m2) for this particular block 
in BioProcess Simulatorm. The exponents b and c were set to -0.7 and 0.2 as obtained 
fiom literature. All of the above works carrieci out to obtain the exponents for gel 
resistance calculation used E. coli. The only report (Reis et al., 1991) on filtration of t- 
PA containing broth does wt mention the calculation of resistauce. The data pmented 
was used to get an estimate of the total mistance, which tumed out to be 6.6X10" mal. 
The total resistance for the simuiated filtration blocks, calcdated by combining 
contributions from membrane and gel resistance, were found to be similar in magnitude. 
The observed range of Reynolds Number for hollow fiber membranes is between 500 to 
3000 (Cheqan, 1986). The critical average wall shear rate, above which cell damage is 
observed, was found to be about 3000 s-' for crossflow microfiltration of animal cells 
(Maiorella, 1 990). 
Tangential flow ultrafiltration was found to result in at least ten-fold reduction in volume 
within an hour of harvesting the bioreactor with Wtually quantitative recovery of a 
monoclonal antibody (Birch et al., 1987). While Hanhbarger et al. (1 995) reported that 
volume reductions of 50: t are common for protein purification using ultrafiltration. 
It is observed that protein is not denatured by shear force during microfiltration except in 
gas-liquid interface at elevated temperature (around 40" C) and high pH >8 (Rudolph and 
MacDonald, 1994). Since the temperature of the downstream train is assumed to be 4" C, 
the percentage of protein denatured is expected to be very low for the simulated 
processes. 
Membrane filters are sanitized by treatment with hypochiorite (bleach) or sodium 
hydroxide solutions (Inampudi et al., 1995). Membranes shouid be cleaned immediately 
following use. Protein residue on membranes should not be allowed to corne in contact 
with air since removal of dried protein is very difficult (Wheelwright, 199 1). Membranes 
are kept wet with water or buffer to prevent precipitation of protein. Residual proteins 
are removed by washing with sodium hydroxide and in severe cases with protein 
digestive enzyme. For ki lhg vegetative bacteria Berglof et al. (1 988) recommends 0.1M 
NaOH for an hour of contact time. 
3.6.5. Main Purification 
Chromatographie steps are the ones recommended for main purification of recombinant 
protein nom animal cells. Among these, afkity chromatography has the advantage of 
king very bio-specific. 
Aninity Chromatography: 
The fim step in the design of an affinity chromatography process is the choice of Hity 
ligand and support matrix. Table 2.4.6 lists some of the a&nity ligands used for 
Iaboratory scaie purification of t-PA. A catalogue fiom Pharmacia (Pharmacia LKB 
Biotechnology) was consulted to choose a ligand and a matrix that will result in high 
capacity for t-PA. The catalogue lists Lysine Sepharose 4B and Arginine Sepharose 4B 
as suitable adsorbents for affinity purification of t-PA. It also lists a capacity of >0.6 mg 
plasminogedml gel for Lysine Sepharose 4B. For plasminogen activator its capacity was 
assumed to be 0.5 mglm1 gel (Scharer, 1996). 
Next, an equilibrium relationship in the form of an isotherm needs to be established for t- 
PA Lysine sepharose system. There is no information in the literature about the type of 
equilibrium relationship that exists between t-PA and any ligand. According to Arnold et 
al. (1985), many afinity systems show a hyperbolic Langmuir type equilibrium relation. 
Hedman et al. (1987) also found that for several combinations of stationary phase and 
proteins, Langmuir isotherm is a suitable equation to describe experimental equiiibrium 
meanirements. Langmuir isotherm is also found to be most cornmonly used in the midy 
of both biospecific zûlhity chromatographic processes (Anspach et ai., 1989; Arve and 
Liapis, 1987; Chase, 1984) and ion exchange chromatography (Cowan et al., 1989; 
Gosling et al., 1989). So, it was asmmed that the equilibrium relationship in this case 
can be described by Langmuir type isotherm. There are only few papers that have 
considered the adsorption isothem constants of proteins on Ligands. The Langmuir 
adsorption isotherm constant reported for a monoclonal antihdy on Sepharose 4B is 162 
XI d cm3/g (Arnold et al., 1985). A value of 120 XI 0' cm3/g was assumed for adsorption 
isothenn constant in the simulation, 
Moa of the chromatographic methods described in the literature are laboratory scale. 
DBerences between analytical and large-scale purification methods have been shown in 
Table 2.4.7. Sofer and Nystrom (1989) outlined the procedure for scaiing up of 
Iaboratory scale chromatogxaphic techniques. Experimentally determined optimum 
column length, linear flowrate and sample concentration are kept the uune in the sale 
up of chrornatographic columns. The diameter, volumetric flowrate and sample loading 
are increased in the larger scale. In large columns, the weight of the adsorbent material 
can cause distortion of the packing in the middle. Therefore, the column height is 
restricted to a maximum of 50 cm when scaling up (Scopes, 1994). The height to 
diameter ratio is smaller than 2 and sometimes below 1 .O (Yamamoto et al., 1988), so 
that the throughput can be maxirnized without redting in excessive pressure &op. The 
recommended ratio of diameter to height for adsorption chromatography colurnns for 
process-scde work is approximately 2 to 4 (Bonne jea and Terras, 1994). In simulation, 
the dimension of the column (diameter = 40 cm and height = 80 cm) was selected such 
that D/L is 2. The column height was restncted to below 50 cm. 
For column chromatography, it is a established practice to use relatively large diameter 
particles (approximately 100 prn) in the fïrst column in order to achieve a high 
volumetric throughput at a moderate column inlet pressure. Smalier particles have 
preferentially k e n  used for the nnal polishing purincation steps (Hedman et al., 1991). 
The range of particle diameter defined by Pharmacia for chromatogniphic appiication 
varies between 45 and 160 p. Particle sizes usually used in column chromatography 
are larger than 40 pn (Chisti and Moo-Young, 1990). A particle diameter of 100 pm 
was used in the simulation. 
Step elution is recommended in scaied-up chromatographic processes instead of 
continuous concentration gradient to simplify operation (Bomejea, 1994). There is no 
guideline as to the magnitude of velocity to be used for loading the column. Modem 
process-scde gels can withstand high linear flow velocities of seved hundred and even 
a thousand centimeters per hour (Bomerjea, 1994). However, the kinetics of the 
adsorption and desorption of the product to the gel may limit the actual flow rate to a 
much lower figure, at least for the binding and elution steps. Higher flow rates can be 
used during the washing, regeneration and reequilibration steps to decrease the overall 
cycle time. The loading velocity reported in the literature is found to Vary between 6 to 
270 cm/h 1 to 5 times the column volume of wash fluid and 4 to 12 t h e s  column 
volume of elution fiuid have been reported to be used in analyticd scaie 
chromatographic processes (Clonis, 1990). The different equilibration and elution 
buffers used in laboratory scaie affinity chromatography of t-PA are KSCN, ammonium 
bicarbonate, guanidinium hydrochloride, sodium chloride, phospahte b a e r  etc. 
In simulation, a conservative value of 40% of the total capacity was asnuned for loading 
of the chromatography column in the loading stage. On preparative scale, column 
loading of 85% of total capacity has k e n  used for purification of monoclonal antibody 
with Protein A Sepharose (Birch et ai., 1987). This single step affinity purification 
resulted in high purîty (>95%) and very high yield (>90%). The recovery of bioiogicai 
activity in chromatographic columns varies fiom process to process. Typical figures for 
recovery are around 80 to 85% (Johansson et al., 1986). 
Even high resolution chromatography can not achieve the required punty for 
phamraceutical applications in a single operation and several chromatographic steps in 
succession are umally required for most processes (Bonnerjea and Terras, 1994). 
Chromatography systems are not considered tme closed systems with respect to aseptic 
processing. The primary concern in regeneration and steniization of chromatography 
columns are buildup of protein, DNA and endotoxins. There are various agents for 
microbial inactivation such as phosphoric acià, ethanol, hibitane digluconate associated 
with b e q l  alcohol, ethylene oxide, formaidehyde, hypochlorites and hydrogen peroxide 
(Bengio et al., 1995). The choice of the right agent is dependent on both, the source of 
suspected contamination and the chernical resistance of the packing. Sodium hydroxide 
is the most widely used agent in industrial chromatography processing for the clean-in- 
place of media and equipment. However, when spodated f o m  of microorganism are 
suspected sodium hydroxide is not suffcient for total inactivation and peracetic acid can 
totally inactivate such spores in minutes (Bengio et al., 1995). 
3.6.6. Final Purification 
This step consists of size exclusion or gel filtration chromatography for removal of 
aggregates and remaining impurities. 
Gel Filtration: 
The final step in the down swam processing of t-PA is gel filtration. It is often used as a 
final stage in many purification schemes to remove trace arnounts of impurities and self- 
aggregates of the product. Gel filtration, however, is a low-capacity technique and not 
well niited to industrial scale use (Bonnerjea and Terras, 1994). For gel filtration, 
remlution is a fùnction of column lm@, ratio of sarnple volume to column volume, 
linear flow velocity and sampie concentration. Many matrices for gel filtration are weak 
and compressible when packed in large columns. Column lengths of approximately 1 
meter are feasible on process scale with &id gels (Bomerjea and Terras, 1994). This 
restricts the diameter to about 20 cm. For wide-diameter gel filtration columns 
(diameternength = 3.0) required to obtain high throughput, columns comected in series 
or stacked columns can be used. For simulation of gel filtration, a 147 L column with a 
height to diameter ratio of 1.5 wes assumeci. 
The ratio of sample volume to column volume is usually between 1 to 5% for gel 
filtration columns (Wheelwright, 1991). For irnpurities of largely differing molecuiar 
weights, the sarnple volume can be increased up to 10% of the column volume 
(Bomerjea and Terras, 1994). A sample volume, 5% of the column volume was assumed 
for simulation. The protein concentration that can be handled by gel filtration lies 
between 10 to 50 g/L (Bomejea and Terras, 1994). 
Flow velocity for gel-filtration is usually an order of magnitude lower than the flow 
velocities characteristic of adsorption chrornatography. The recommended flow velocity 
is within 3-30 cmlh (Bonnerjea and Temis, 1994). According to Wheelwright (1 99 l), the 
optimal flowrate for maximum resolution is approximately 2 ml/cm2-h. Sofer (1986) 
maintained a velocity of 13 cm/h for large-scaie gel filtration of insuiin in a 96 L 
column. The flo w rate for this simulation is assumed to be 16 c d .  
The gel filtration media used for laboratory scale purification of t-PA are Sephadex G- 
100, G-150 and G-200, with Sephadex G-150 king the most popular. The usefbl 
molecular weight hctionation range of Sephadex G-150 for globular proteins is 5x10' 
to 1 .Sx105 (Pharmacia LKB Biotechnology). Fast flow matrices such as Sephacryl S-200, 
which is also fairly rigid, may be a good choice for large scale application of gel 
filtraiion (Glick, 1997). The elution buffers used in laboratory scale gel fltration of t-PA 
are ammonium bicarbonate, sodium acetate, phosphate buffer etc. 
CHAPTER 4 
SIMULATION OF PROCESSES 
4.1. Simulation of Base Case with BPS and SuperPro Designera 
The base case fbwshect was developed using the typkal conditions f o d  in the 
laboratory scaie production and purification of t-PA and pubiished in the bxattpe. Both 
Aspcn BioProcess SmnilatorTY (BPS) and SupaRo Designe* w a e  used to simur;uc this 
Qowsheet. A description of the 5wsheet follows. 
4.1.2. PROCESS DESCRIPTION 
The downsucam proctsrs of the base case flowsbtct consist of two aîttrnatt steps 
of ui-n and afnnity cbromatography, foIbwed by a fiaal step of gel 
chmatography @gure 4.1.1). The rtquired proctss information and opaatiag 
conditions, requind as input for simulaha w a c  gMhend h m  Iiteraturt* The kinetics 
for the biorcactor was dtveloptd in our labomory. The shdatsd biortactor is a stEred 
tank type with the CHO ctlls grown m suspension culturr. This is the modt ofopaation 
92 
adopted by Genentech for large-sale production of t-PA (Cartwright et al., 1992). The 
bioreactor of this flowsheet uses senun fke medium. The s e m  fke medium used in our 
laboratory consists of HB-CHO basal mixture and a proprietary mpplement (unmucor 
Canada Inc.). The actual composition of the serurn fiee medium is not known except that 
it contains 320 mgL of total protein. The bioreactor is inocuiated with LOO0 L of 
inocdum having a concentration of 2x1 @ cells/ml. Liquid is assumed to occupy 80% of 
the bioreactor volume. The ratio of liquid height to total diarneter (LAI) is assumed to be 
1.5 and the impeller diarneter di, to tank diameter d,/D = 0.3 (Chisti, 1993). The contents 
of the bioreactor are aerated with 0.02 VVM stenle air. 
Permeate and retentate pressws for the membrane filtration units were chosen to yield a 
transmembrane pressure of 4 psi, as recommended by Rudolph and MacDonald (1 994) 
and Maiorella et al. (1991) for hawesting animal cells. Resistance in series model was 
chosen as the flux model for the system. Membrane resistance and gel resistance 
parameters were obtained fiom several sources (Tamer, 1995; Lee, 1989; Wood, 1988). 
The affinity ligand recommended for purification of t-PA is Lysine Sepharose, which has 
a capacity of >0.6 mg plasminogen per ml gel (Pharrnacia LKB Biotechnology). It is 
widely used in laboratory scale purification of t-PA because of its biospecificity (Clonis, 
1990). A Langmuir type equilibrium relationship was assumed for the system since thîs 
relationship has been found satisfactory for many ligand-protein combinations (Arnold et 
al., 1985). The Langmuir adsorption isothenn consuint was assumed to be 120X103 
cm3/g. This value seems reasonable when compared to the reported value of 162x10' 
cm3/g for anti-benzenearsonate monoclonal antibody on Sepharose 4B (Arnold et ai., 
1985). Simulation was carried out for a 200 L column having a height to diameter ratio of 
0.5 and a superficial loading velocity of about 40 cm/h. 
Sephadex G-100, G-150 and G-200 are the gel nitration media used in the laboratory 
scale pudication for t-PA, with Sephadex G-150 king most popular. Gel filtration was 
sirnulated in a 147 L column with a length to diameter ratio of 1 S. The sample volume 
was taken as 5% of column volume as recommended (Wheelwright, 1991) and the flow 
velocity was 16 cm/h. 
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Figure 4.1.1 : Base case flowsheet for t-PA production 
The process is designed to produce 11,000 g of purified t-PA per year (Section 3.9, 
which is the same considered by Datar et al., (1993), so that the economics of the 
simulated flowsheets could be compared to their reported values. To meet this production 
level, five 6000 L bioreactors are required. One of these five bioreactors with its 
associated dowmtream processing units was simulated. 
4.13. SIMULATION AND RESULTS 
For simulation purposes, the concentration of BSA-like protein in the serum free medium 
was considered equal to that of senun containhg medium. The total protein concentration 
of semm is about 100 mg/d  (Macmillan et al., 1987). 60% o f  these protein were 
considered to be BSA-like (Scharer, 1996) and then a sensitivity study (Section 4.1.6) 
was carried out to see how lower concentration of BSA in the senun fkee medium affects 
the process. Required process information about flowsheet and streams, composition of 
each Stream, properties and values of operating variables and parameters of the different 
unit operation blocks, were supplied through input files. 
Summary of the simulation results is presented in Table 4.1.1 (BPS simulation) and 4.1.2 
(SuperPro Simulation). Detailed results can be found in Appendix B. The base case 
requires five sets of equipment (Table 3.5.1) to meet the total production of 30,000 L. 
The overall recoveries of the flowsheet are 45.7% according to BPS and 45.97% 
according to SuperPro Designea. These are well above the recovery yield (40%) 
assurned in the design basis. The batch time (21 8 hours or about 9.08 days) is also within 
the time (10 days) assumed. This allows for a turnaround time of about 17 hours for the 
bioreactors. A new feature of version 4.0 (to be released in early 1999) of SuperPro 
Designer@ (Intelligen Inc., 1994) would caiculate t h e  taken for unit procedures taking 
place in the bioreactor such as charging of medium, sterilization, clean-in-place etc. This 
will allow an accurate calculation of tuniaround tirne for the bioreactors. Tumaround 
times of 8 hours have been found satisfactory for recombinant bactena at 23,000 L scale 
(Charles and Wilson, 1994). 
Table 4.1.1 : Simulation resuits for base case flowsheet with BPS 









































The change in volume of the broth as it moves through the processing train is shown in 
Figure 4.1.2. Broth volume increases after each chromatographic step and therefore an 
ultrafiltration step is required to reduce the volume so that the throughput to the next 
column is not too large. In the membrane separation units, lower retentate volume is 
obtained at the expense of recovery in the block. The ultrafiltration units were simuiated 
such that the reduction in broth volume does not cause the retentate to become too 
concentmted in t-PA. There is an upper level set within the mode1 in BPS. Operation at a 
concentration factor resulting in t-PA concentration higher than this generates a warning 
in the report and history file. No such feature was observed with SuperPro Designea. In 
the chromatography columns, compromise had to be made between recovery and degree 
of purification. A more narrowly cut fraction resuited in a higher degree of purification at 
the expense of reduced recovery. 
biorr;ictor micro filter ultrafilter aff. chrom. ultrafilter afE chrom. ultrafilter gci chrom. 
Figure 4.1.2.: Broth volume at d i f f i t  points of purification 
As a supporthg feature of BPS, among other variables, it calculates the pressure drop in 
the chromatographic columns and generates a warning when the specifïed process 
conditions cause any column to openite at subatmosphenc pressure. This situation was 
observed in the gel filtration column with the fîrst simulation run and the pressure was 
f k d  nibsequently. 
A cornparison of the results obtained with the two simulators shows that almost identical 
figures are obtained by feeding the information h m  BPS to SuperPro Designer@ for 
simulating the process. However, there are some limitations of SuperPro Designer@ that 
were encountered while using the simulator for this particular proceu. The "Fermentor" 
mode1 that simulates stirred tank bioreactor in SuperPro Designer@ was not used in the 
simulation because the mode1 requires stoichiometric coefficients, which are not constant 
quantities for this process. BPS, in contxast, generates time profiles for al1 the reactants 
and products in the bioreactor according to the kinetics provided. For the chromatogxaphy 
columns, the recoveries reported by BPS were used directly as input to SuperPro 
Designea. This resulted in exactly the same recovery in these columns. However, for the 
membrane separation units, the rejection coefficients specified for the BPS models had to 
be modified because their definition is different for the two simulators. In BPS rejection 
coefficient (&) is used to calculate the solute concentrations in the permeate (Cp) relative 
to bulk retentate concentration (C,) and is defined as: 
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whereas, in SuperPro Designer@ it is used to estimate the hction of a component (FJ 
remaining in the retentate as follows (McGregor, 1986) : 
where CF is concentration factor defined as the ratio of volumetric flowrate of the feed to 
that of the concentrate. The rejection coefficient was further adjusted to maintain al1 the 
variables, which are common to the models in both the simulators, at the same values so 
that the two simulators could be compared. When used in rating mode, the membrane 
separation mode1 in SuperPro Designer@ requins specification on rejection coefficient 
(&), average filtrate flux, maximum concentration of the key component in retentate and 
membrane area among other variables. The shulator in this mode adjusts the 
concentration factor, which in tum detemines the retentate volume, to calculate the 
fractions of components remaining in retentate (Fi) and to meet the specification on the 
maximum concentration of the key component in the retentate. A readjustrnent of the 
rejection coefficient causes the simdator to readjust the CF calculated such that the above 
requirements are satisfied. The rejection coefficient was adjusted until a CF close to the 
one reported by BPS was obtained. Tables 4.1.3 and 4.1.4 show the rejection coefficients 
used and the maximum t-PA concentration reported for the membrane separation units in 
the simulated process for the two simulators. 
From Table 4.1.1 it is also found that BPS estimates that this flowsheet is capable of 
produchg t-PA of required purity (99.9998%)). With the cumnt version of SuperPm 
Designer@ (v 2.0) it was not possible to obtain t-PA purity up to four decimal points at 
Table 4.1.3: Rejection coefficients (RJ used for simulating the membrane separation units 















the scale used. SuperPro Designer@ reports mult up to five dechal points and do not 
have an engineering format for reporting numbers. With the sa le  used, a 99.9999% 
purity of t-PA with respect to BSA would mean that the concentration of BSA is below 
104 uni& of concentration. A problem was dso encountmd while supplying 
specification for the chromatography columns due to the same reason. Simulation of the 
affinity chromatography columns with SuperPro Designe* requires the binding 
percentage and yield of each protein. This information was obtained from BPS. The yield 
of BSA in the first column was found to be about 2x10~.  However, the mode1 for 
chromatography columns in SuperPro Designer@ only accepts yields as a percentage of 
up to two decimal points. In the absence of engineering format it was not possible to 
reproduce yield of BSA with SuperPro Designer@ at th is  scale. However, since it was 
possible to almost exactly reproduce the recovery and yield of t-PA, one can expect that a 
simulation with scaled up numbers would show that the required purity of t-PA is also 
met with SuperPro Designer@ simulation. 
4.1.4. ECONOMIC EVALUATION 
Table 4.1.4: Maximum t-PA concentration in retentate reported for the membrane 
separation unîts by the simulaton 
Economic evaluation was carrïed out by combining idonnation fiom both the simulators. 
Estimation of purchased equipment cost and operathg labor was obtained fiom SuperPro 
Designd. Size and number of the equipment were obtained fiom both BPS and 
SuperPro Designer@ (Section 3.2). SupaPro Designer@ was used in rating mode so that 
the site and number of the different equipment obtained nom the two simulators were the 
same. Datar and Rosen (1990), while evaluating economics of a process producing 













appropriate for caiculation of capital investment and operating cost of recombinant 
protein production process and were adapted hm.  A FORTRAN program was written for 
this purpose. The cost factors used can be found in Appendix C. 
The economics of the flowsheet was evaluated in ternis of R e m  on Investment (ROI) 
and Gross Margin (GM). The results were compared with those of Datar et al. (1993), 
who carried out a comparative study of t-PA production in animal ce11 and bacterial 
fermentation. The reported economics is for a process producing t-PA fiom CHO cells 
using the sarne purification scheme as the base case but separate bioreactoa for growth 
and production using serum containing medium in both. An alternate flowsheet that uses 
two stage ceIl culture as outlined by Datar et al. (1993), is simulated and compared in the 
next section (Section 4.2). The equipment in their flowsheet were sized based on 
production demand, aep yields and mass balances. The batch time was assumeci to be 5-7 
days. In their calculation, the selling price of t-PA was taken to be S22,000/g and the 
production rate, 1 1,000 gfyear so that revenue (R) is 242 X 1 O6 dollars. These same 
figures are used for economic evaluation of the base case so that the WQ processes can be 
compared. A more redistic selling price of t-PA would be about $l6,OOO/g (Cooney, 
1999). Table 4.1 .S shows the caiculation of the economic parameters for the two cases. 
The ROI for the base case is about 11% lower than the one considered by Datar et al. 
(1993). However, their calculations are based on 47% overall recovery whereas the 
simulated process is based on 40%. The estimated equipment purchase cost for the base 
case is 28% higher. Datar et al. (1993) do not mention the size and number of any 
equipment in their flowsheet except for the bioreactor (7000 L). The purchased 
equipment costs in their case are 1993 prices calculated fiom grass-roots and in some 
cases obtained fiom vendon and updated in-houe files. The prices obtained fiom 
SuperPm are 1994 prices. 
Table 4.1.5: Comparative economic d y s i s  (in millions of dollars) 
A breakdown of the equipment purchase cost (Figure 4.1.3) for the base case shows that 
bioreactoa account for about 14% of the total coa and among the downstream units, gel 
filtration columns (27%) are the major conmbutoa followed by the chrornatographic 
columns (25%). In contrast, Datar et al. (1993) reported that, for their flowsheet, 
bioreactors account for 54% of the C, whereas recovery equipment contributes only 
24%. ïhis discrepancy is most Iikely due to the higher overall recovery (47%) assumed 
for their flowsheet, which reduced the size of the recovery units. The large bioreactor 
volume (42,000 L) used by their two-step culture process could have also partiy 
coneibuted to this incongmity. It was not possible to compare the number and size of the 
recovery uni6 in these flowsheets. 
Purchased Equipment Cost, C,, 
Fixed Capital, C, = (4.6XCd 
Total Capital, C, = (5.5XCA 
Revenue, R 
Annual Operating Cost, AOC 
Gross Profit, GP = (R-AOC) 
Net Profit, NP (40% tax) 
Net Cash Flow, (NP + Dep.) 
Retum on Investment, ROI 
Gross Margin, GM = (GPR) 
Of the annual operathg cost (AOC), process chemicais and media was found to account 
for 42% and labor, about 5.2% of the total coa (Figure 4.1.4). At an estimated pnce of 
$25/L, cost of semm fiee medium accounts for about 62% of the total process chemicals 
and media cost It is clear that the profitability of this flowsheet is very sensitive to this 
pnce. Process chemicals and media coa is a d l y  found to be Iowa for the base case. 
Datar et al. (1993) considered the use of serum containing medium in  the^ bioreactors 
























aux. eqp. 14% 
Figure 4.1.3: Breakdown of equipment purchase 










Figure 4.1.4: Breakdown of annual operating cost 
their material price, which for the base case is found to be 62%. Their flowsheet, 
therefon, was found to be very sensitive to senun pnce and a sensitivity study for that 
case showed that, a 70% increase in the serurn pnce would bring about 35% reduction in 
the ROI of the process. The estirnated Iabor costs are found to be close and are higher for 
the other flowsheet probably because of the larger nurnber of bioreactoa (Figure 4.1.4). 
The combined contribution of tax/insurance and plant overhead in the case of Datar et al. 
(1993) is found to be $4.68 million which is close to the number ($4.5 million) obtained 
for the base case. Estimation of contributions h m  utilities, waste treatment and 
patenthoyalties using cost factors (Datar and Rosen, 1990) yielded srnaller nurnbers. 
Contribution fiom other sources combined came to $22.22 million for the base case and 
$36.27 million for the other flowsheet. 
4.1.5. COMPARISON OF BPS AND SUPER PRO DESIGNER 
The short-cut unit operation models of SuperPro make simulation of bioprocess simple 
and easy. However, for some models the required input information was not easily 
available. For exarnple, to simulate a bioreactor with SuperPro, the extent of reaction 
m u t  be known. This is a quantity not common in the jargon of biotechnology. Instead, 
BatchPro Designer (uitelligen, Inc., 1997), another tool from lntelligen Inc., appean to be 
more suitable for bioprocess simulation, especially the bioreactor, since it is equipped 
with ngorous and versatile reaction modules. 
Most unit operation models in SuperPro are very simplistic. The majority of the unit 
operation rnodels use a constant linear multiplier to convert a component inlet-stream to 
the outiet Stream composition. Therefore, reaction yields and separation rates are rarely a 
fiinction of process Stream properties or operating conditions (Shanklin, 1999). This 
straightforwafd approach in modelling taken by SuperPr0 &ts in l o s  of its analyticai 
ability. For example, the micronlter mode1 in SuperPm requins the specification of 
permeate flux directiy rather than calculating the flux fiom specified resistance, pressure 
drop and fiuid viscosity as is done by Aspen BPS. With an appropriate model, this 
hdamental approach adopted by BPS allows the user to explore the effect of change in 
transmembrane pressure or increased resistance due to fouling. It is aiso not possible to 
access the built-in unit operation models of SuperPro DesignedB to modify or improve 
them, a feature identified as one of the unique requirements of a bioprocess simulator 
(Shanklin, 1 999). 
The output generated by SuperPro is not very informative. Superpro cannot generate 
graphical outputs and therefore, unlike BPS, it is not possible to follow the changes in the 
variables of the process with this simulator. 
The simplicity of simulation with SuperPro with small amounts of process information 
venus the analytical ability of BPS suggests that these two sirnulators should be used 
simultaneously. Since simulation of most of the units is simpler with SuperPro, it can be 
used initially to screen process alternatives in a short tirne and with minimal effort. Once 
a process has been chosen, it can be analyzed using the more complex approach of BPS 
to find the optimum operating conditions and predict the changes that might result fiom 
changing parameters of the process. 
'contains thermodynamic and other properties, information for economic evaluation, 
scheduling data besides components, flowsheet connectivity and block specifications 
bcontains only the name of the components, databmks to be wd, flowsheet connectivity 
and unit operation block specifications 
Table 4.1.6: Cornparison of SuperPro and BPS at process level 
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development of Batch Plus (Zimmermann, 1997) by Aspm Techuology. Development of 
Batch Plus was based on feedback from pharmaceuticai companies using BPS. On the 
other hand, efforts continue to improve and add new features to SuperPm Designea. 
Handling of visual objects and interfacing with other applications are much easier with 
later versions of the software. New features have b e n  added to enhance presentation of 
the flowsheet and formatting of the stream reports. New unit operation models (e.g. 
custom mixer, splitter, batch evaporator, extractor, inclined plate clarifier etc.) have been 
included and updating of the economic models (e.g. equipment cost data, estimation of 
labor requirement etc.) have been carried out (Intelligen Inc., 1996; Intelligen Inc., 199%). 
Modifications of the existing models of SuperPro Designer@ (e.g. fermentors, 
chromatography columns, filtea etc.) are going on and some new variables (e.g. aeration 
rate in the bioreactor model) have k e n  added to the existing models. 
Some of the funve modifications in Superho are going to deal with the very practical 
aspects of bioprocessing. Handling of unit procedure is going to be implemented in 
version 4.0 of the software! to be released in 1999 (Petrides, 1998). This will enable 
calculation of time for bioreactor operations such as charging of medium, sterilization, 
clean-in-place etc. Some bioprocess specific operations such as a Centritech centrifuge 
for modeling removal of mammalian cells under gentle conditions, will be added and 
more refined scheduling of batch operation down to task-level activities are going to be 
included (Intelligen Inc., 1997). A new class of stream to represent flow of discrete 
entities, such as bottles, boxes etc. has already been added to the later versions and unit 
operations for molding, filling, boxing etc. have been implemented to mode1 product 
formulation and packaging. To model the novel concept of multiple and overlapping 
batches (Section 4.9, provision has been made in version 3.0 to allow process steps to 
s k  equipment in batch recipes. Calculation of resources such as utilities, labor, raw 
materials etc., for multiple and overlapping batches to eliminate resource bottlenecks is 
going to be implemented. 
This section reports on sensitivity of the base proctss to process spca&f variables. A more 
general sensitivity sîudy for unit operation bbcks and tcoaomic pararœters and variables, 
applicabie to ail the shnhted processes, is presented in Chaptcr Fivt. Thc purpose of this 
secrion is both, to investigate how sny change in the particuiar variable would a&ct the 
p e s s  performance and also to md out by how mach the simulation rcsults an affectcd 
if the estimate used for the variabk is not concct. 
1. Price of Semm Free Medium 
The price of serum h e  d u m  is a variable that is expected to change due to the endltss 
effort to develop low cost senun fret mEdium Sensitivity study to saum âce medium 
price shows that 50% reduction in this pria will result m 12% iacfease in the ROI of the 
base process and 70% increase wili bring about 12.5% reduction (Figure 4.1.5). 
Thertforc, although the base process is sensitive to senun b medium prict, it is not as 
sensitive as the other fiowsheet (Datar et aL, 1993) is to serurn price (Previous Section). 
2. Percentage of BSA in Semm Free Medium 
In the base case simuiatioa, it was a s s d  that the concentration of BSA like protein in 
the serum fiee d u m  is equal to its concentnuion in serurn contaiaiag mdlw (Section 
4.1.3). Two simulation nuis were carried out to study the sensitMty of the base process to 
Iowa BSA liLt protein concentration in the d m  The main effect was o b s m d  in the 
pcrformanœ of the affinity chromatography colunins. Table 4.1.7 compares the ncovery 
and purity of t-PA m these colunnis as concentration of BSA like protein goes dom in the 
medium 
It appears h m  the tabk that a 50% reduction of BSA concentration in the medium 
would rcsult in significant improvemnt in nconry in the nrst afnnity ciaomatography 
column, A W e r  rcduction wouId inipmve purity but wouid not d t  in proportionate 
higher rccovexy. This provides a huge ka t ive  to use low protein medium and not jun 
serum k e  medium for t-PA production. With 30% BSA Kke protein in the medium, it 
appears that cornpletely pure t-PA can be obtained with a single chromatography column. 
However, BPS reports the purity in the chromatography columns up to thRe dechal 
places and therefore, a purity of 100% as reported by BPS only means that it exceeds 
99.999%. For t-PA the required purity is 99.9999%. Which means the process may still 
require another chromatography column. In Section 3.1.1 it was also mentioned that 
removal of idectious agents and other contaminants such as DNA, endotoxin etc. require 
a combination of two chromatography steps. Therefore, dthough the purity of t-PA with 
respect to BSA in a 30% BSA containhg medium reaches more than 99.999% with a 
single chromatography column, the requirement of another chromatography step from the 
process can not be eliminated. The regdatory authorities also require a combination of 
two different chromatography steps for these processes, so that the gel filtration column 
for the polishing step should also be present in this flowsheet (Cooney, 1999). 
Table 4.1.7: Cornparison of recovery and purity with changing BSA concentration 
The volume of product recovered from the chromatography column in both cases is 75 L 
per column. Therefore the sizes of the subsequent down Stream uni& wiU not be afTected 




3. Combination of Aninity Chromatography and Ion-Exchange 
Since ion-exchange resins are cheaper than affinity media (Sofer, 1986; Moo-Young and 
Chisti, 1990), it was M e r  investigated whether a combination of affinity and ion- 
exchange process rather than two aff?nity columns as considered for the base case, would 








was &ed out which revealed that such a combination would r d t  in 93.93% recovery 
and 99.9977% purity in the ion-exchange column. 
The elution peak from the ion-exchange column is skewed with a long tail. The p r o u  
Table 4.1.8: Simulation results with BPS for combined affinity and ion-exchange 
chromatography flowsheet 
recovery is achieved in 2 15L of volume, whereas, with an affinity column (base case) the 




















larger sizes of downstream units following the column. Altematively, using larger 




treated by the gel filtration column (Table 4.1 A.), which are much more expensive then 
the membrane separation units. The total batch time in this case therefore, would be 220.5 
































Purchased Equipment Cost, C, 
Fixed Capital, C, = (4.6XCp3 
Total Capital, Çc = (5.5XCd 
Revenue, R 
Annual Operathg Cost, AOC 
Gross Profit, GP = (R-AOC) 
Net Profit, NP (40% tax) 
Net Cash Flow, (NP + Dep.) 
Retum on investment, ROI 
Gross M a r k  GM = (GPR) 



























Table 4.1.9 presents the overall econornics for this process and compares it to the base 
case. As anticipated, combination of chromatography (affinity and ion exchange) process 
is found to be a very attractive alternative to the base case. The reduced equipment 
purchase cost results fiorn the use of fewer number of gel filtration (3 instead of 6) 
columns. Throughput to the gel filtration column could be reduced to a srnaller volume 
with this process at the cost of lower recovery since the recovery in the ion-exchange 
colurnn (93.9%) is higher than the m t y  column (90.7%) in the base case. Therefore, 
the overall recovery is still above than that requind (40%). The lower annual operating 
coa resulted mainly fiom the lower replacement cost of the ion exchange resin ($400/L) 
compared to aflinity chromatography media ($2000/L). However, the main concern with 
this flowsheet is whether a combination of an affinity chromatography column and an 
ion-exchange column followed by gel filtration, would be able to reduce the endotoxins, 
DNA and other contaminants to the desired level. This can only be investigated by 
experimental studies. 
4. Replacement Fnquency of Chromatographie Resin and Membrane 
Replacement of chromatographic resin and ultrafiltration and microfiltration membranes 
accounts for about 18% of the niw material cost for this process. Though this repments a 
small fraction of the overall cost, the figures used in its calculation varied widefy 
depending on the source. The lifetime for chromatographic mins (atnnty and ion 
exchange) suggested by Superho Designes, is 200 cycles, and for gel filtration media, 
is 300 cycles. For membrane separation units, the lifetime is assumed to be 2000 
operating hom. The replacement costs fkom this source are $2000/L for affinity 
chromatography, $400/L for ion exchange, $200/L for gel filtration and $200/m2 for 
membranes. The figures for these reporteci by Petrides et al. (1989) is slightiy diffemit 
They considered replacement fkquency of 400 cycles for ion exchange and gel filtration 
media and replacement cost of 16450/L for ion exchange, 6400L for gel filtration and 
$250/m2 for ultrafiltration membranes. 
in the base process, only 35 cycles are cattied out with the chromatographie columns per 
year. Therefore, with this process it rnay not be necessary to q l a c e  the resins every year. 
However, the lifetirne of the resins depends on the particuîar resin itself and it has also 
been noted that the position of the column in the purification sequence also influences the 
lifetime of the resin (Sofer and Nystrom, 1989). Since the sample contains more 
contarninants towards the beginning of the sequence, the fht separation medium used 
generally requires more fiequent replacement than the others. A single replacement of the 
resins was considered in the annual operating cost calculation. Similarly, for the 
membranes, single replacement was considered although the operating hour per year is 
much less than that recornmended for replacement. Therefore, a sensitivity study was 
can-ied out to determine by how much uncertainties involved in the caiculation fkom this 
source will effect the overail process performance. 
Figure 4.1.6 shows that, if replacement takes place once every 175 cycles (i. e. close to 
the recommended replacement fiequency), and the cost for the replacement is distributed 
equally over the whole period, the ROI will improve by 4% (case 2). If replacement cost 
is not distributed (case l), the ROI of the process for the year in which replacement does 
not take place will increase by 5%. 
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Figure 4.1.6: Sensitivity to Repiacement Frequeney 
4.2. Process Alternative: Two Stage CeIl Culture 
4.2.1. INTRODUCTION 
This alternative to the base case flowsheet uses the concept of two-stage ce11 culture. 
Separate bioreactoa are used for growth and production of the cells where the growth 
bioreactor is supplied with senun containing medium and the production bioreactor with 
senim fiee medium. S e m  contains some growth promoting substance, which are 
difficult to replicate in senim free medium. The main advantage of two-stage ce11 culture 
is the greatly simplified downstream processing in absence of background protein in the 
medium. Since downstream processing accounts for about 70 to 80% of the overall cost 
for high value products like t-PA, such a flowsheet seems worth investigating. 
4.2.2. PROCESS DESCRIPTION 
Although several investigators (Dutton, 1998; Lubiniecki et al., 1989) have reported that 
CHO cells tend to form aggregaies in suspension culture in medium containing serum, 
such medium has been w d  by several other investigators (Kunino et al., 1990; 
Leelavatcharamas et al., 1994; Hansen and Emborg, 1994; Lakhotia et al., 1992; e.g. 10% 
fetal calf serum, H O %  FCS, 3% fetal bovine serum etc.) for suspension culture of CHO 
ceIls in stirred bioreactors. A tangential-flow filtration system has been devised to 
produce t-PA by two-stage ce11 culture that reduces levels of semm coming from the seed 
train before inocdating the production vesse1 (Ogez and Builder, 1990). Datar et al. 
(1993) also carried out economic evaluation of a two-stage celi culture process, based on 
experimental observation, for production of t-PA nom CHO celi. 
In the altemate flowsheet, show in Figure 4.2.1 dong with the base case flowsheet, the 
growth bioreactor is supplied with medium containing 10% serum whereas the 
production bioreactor is charged with serurn fie+ medium. The concentration of BSA-like 
protein in the serum free medium is assumed to be 10% of that in the semm containing 
medium. Because of this low background protein concentration, the d o w n s t m  process 
of this flowsheet uses ion exchange chromatography for purification. Ion-exchange 
chromatography is assumed to be sunicient to reach the desired purity. In laboratory, it 
has ken  demonstrated that purification of t-PA h m  senun fiee medium using a single 
ion-exchange column followed by gel filtration resulted in a purification factor of 58 and 
an overail yield of 61% (Kniithof et al., 1985). 
With the two step ce11 culture flowsheet, broth fiom the growth bioreactor is reduced to 
about 50% of its original volume by microfiltration. Therefore, the number of production 
bioreactoa is half of that of growth bioreactors (Datar et al., 1993) and the number of 
associated downstream units is half of that requîred by the base process. Before 
introduction to the production bioreactor, the cells From the growth bioreactor are washed 
to remove the b d k  of the senun protellis. This ce11 washing is carried out in the 
microfilter. In laboratory, phosphate bufTered saline is w d  to wash cells grown in semm 
containing medium pnor to tramferring them to serum fiee medium (Knrithof et al., 
1985). 
Takagi and Ueda (1994) reported on on-line determination of optimum time for switching 
fiom growth phase to production phase for t-PA production for anchorage-dependent 
diploid fibtoblast cells of human embryo lung (HEL) Ui microcarrier culture. The 
optimum switching t h e  was detemineci to be the time at which the t-PA production 
activity of the cells in growth cuiture became highest. t-PA production activity of the 
ceUs was estimated by on-line regnssion d y s i s  using physiological data of the current 
state, including oxygen co~lsumption rate and ceii concentration, as weil as data b m  past 
batches. The optimum switching tirne was fomd to Vary with growth culture batches. 
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Simulation of this process requires information about process parameters and operating 
conditions. The simulated bioreactors are stirred tank type with the CHO cells grown in 
suspension culture. The batch charge to the growth bioreactor consists of 10% Fetal 
Bovine Serurn (FBS), 90% Ham's F-12 medium and 4rnM Glutamine. The bioreactor is 
inoculated with 1 O00 L of inoculum having a concentration of 2x1 Os ceils/d. Ham's F- 
12 medium is replaced with HB-CHO basai mixture and a propnetary supplement 
(Immucor Canada Inc-) in serum fiee medium for the production bioreactor. The contents 
of the bioreactor are aerated with 0-02 VVM sterile air. 
The operating variables and parameters for the different uni& of the d o m  stmm train are 
the same as for the base case (Section 4-12). The affinity chromatography columns of the 
base case are, however, substituted with ion-exchange chromatography columns in this 
flowsheet. The ion-exchange columns in the altemate flowsheet are simulated under 
similar conditions as for the affinity chromatography columns. The ion-exc hange resins 
used in the labonitory scale purification of t-PA are strong cations such as SP Sephadex 
C-50 and Mono S (Kruithof et ai., 1985, Prouty, 1993). The total ionic capacity of SP 
Sephadex C-50 is found to be between 2.0 - 2.6 rnmoVg (Pharmacia LKB 
Biotechnology). An estimated d a c e  area of 1 cm2/cm3 was w d  in the simulation. The 
operation was simulated at a pH of 4.5, close to the i s o e l h c  point of BSA (5.0) as 
descnbed in the laboratory scale purification methods. In laboratory, the ionmchange 
column is equilibrated with a mixture of 0.1M sodium acetate, 0.25M sodium chloride, 
0.01% Tween 80 and 0.05% Na% at pH 4.5. This same b a e r  is used to wash the 
column and t-PA is eluted by a sodium chloride gradient nom 0.25 to 1M in the same 
buffer (Kruithof et al., 1985). The other labonitory method uses two steps with ion 
exchange for purification of t-PA (Prouty, 1993). A shallow gradient of NaCl (0.1 to 
0.157 M) at pH 5 is used to elute the protein in 35 m M  acetic acid. 
For ion-exchange, column length has no major impact on resolution (Chisti and Moo- 
Young, 1990). Therefore, ion exchange columns tend to be short, up to lm in height 
Columns are scaled up in diameter to accommodate the quaatity of matrix needed for the 
separation, holding constant height. Cross-linking procedures have resulted in matrices 
for ion exchange with improved rigidity and flow characteristics Separation efficiency 
was not affected by increasing veiocity up to 280 cmk in a 150 L DEAE-Sepharose CL- 
6B Fast Flow column (Berglof and Cooney, 1989). The column was scaled up b m  
laboratory to large scale by maintahhg the same elution conditions since resolution was 
found to be largely dependent upon elution conditions. 
4.2.3. SIMULATION AND RESULTS 
Table 42.1 shows the Aspen BPS simulation results for this flowsheet. From the table it 
is found that this flowsheet is capable of producing t-PA of requiml purity (99.9998%). 
The overaii recovery of the flowsheet is 46.3%. This is weli above the recovery yield 
(40%) assumed in the design basis. The time required for completion of one batch for this 
flowsheet is 221 hours or about 9.2 days. This is also within the batch time (10 days) 
assumed in the basis. This flowsheet requires five sets of equipment for the fïrst two seps 
and then ody thm sets afterwards because of the assumption stated in the previous 
section. The cell concentration in the production bioreactor therefore, is twice the 
concentration in the growth bioreactor and the product concentration is also double. 
A ce11 wash stage, to remove senun from the broth of g~owth bioreactor, was attempted 
using the diafiltration option of the batch membrane separation model of BPS. However, 
the model with diafiltration never converged. The model performed without problem 
until the diafiltration step was reached and then stopped. The emr  message retrieved 
fiom the history file reported that the solver encounters divisions by zero with further 
calculation. Repeated trials with this model tumed out to be unsuccessful. Therefore, a 
reasonable volume was assumed for the diafiltration strearn to caiculate the raw material 
cost A sensitivity study to the diafiltration stream volume was also performed (Section 
4.2.6). 
Table 4.2.1 : Simulation results for alternate flowsheet 
1 BI OC^ I size 
' Microfilter 80 m2 1 - - - 
Production Bioreactor 5000 L 121 - 6.86 390.0 
Micro filter 70 m2 1 84.5 6.86 329.55 
Ultrafilter 50 m2 1 84.76 O 279.32 
I 
Ion-Exchange Chrom. 200 L X 2 5 83.45 99.93 233.0 
I 
Ultrafilter 15 m2 0.7 92.37 - 215.3 
Ion-Exchange Chrom. 113 L 4 87.16 99.999 187.66 
Ultrafilter S m2 0.4 96.26 - 180.65 
Gel Filtration 147LX5 6.9 99.997 99.9998 180.64 
The elution pronle of t-PA fiom the ion exchange column was different than the one 
observed fiom the aninity chromatography colurnn of the base case. The t-PA peak was 
found to have an elongated tail. This tailing codd have been a result of large particle 
diarneter, high flow rate and low molecular diffùsivity of the solute (Yamamoto, 1978, 
1979). Tailing of elution curve is also observed with ion exchange chromatography when 
increased sample concentration causes the column to operate in the nonlinear region of 
the isotherm (Kato et al., 1982). With the sample concentrations (0.3 g/L and 0.7 g/L in 
the first and second colurnn mpectively) handled in the ion exchange columns of this 
flowsheet, the second explanation seems improbable. Even then, simulations were c d e d  
out with lower t-PA concentration. Strangely enough, the peaks were found to have 
longer tails and lower heights at progressively Iowa concentrations and sharpening of the 
peak was observed at higher concentrations. For single component Laugmuir isotherms, 
tailing of the peak increases as the nonlinearity increases (Yamamoto et al., 1988; Lin et 
al., 1989). The second coefficient of the isotherm is a measure of nonlinearity, which in 
the BPS model is denoted by "kload". A sensitivity study of the ion exchange model, 
however, revealed that, the performance of the colurnn was insensitive to kload (Chapter 
Five). Simulations were also canied out with lower flow rate (haif of the design case flow 
rate). No improvement in the elution profile, however, was observed by changing this 
variable. 
A stmng self-sharpening effect is exhibited by the elution profile as mas tnuisfer 
coefficient becomes large (Lin et al. 1989). To increase the mass tramfer coefficient, 
simulations were camed out with smaller particle diameter (up to 60 pm of particle 
diameter). Although the reported mass m e r  coefficient increased, there was no change 
in the elution profile. To improve the molecular diffusivity, simulation was d e d  out 
with a lower molecular weight (up to one-tenth of the actuai molecular weight) of t-PA 
just for observation purposes. Again, the elution curve was d t e r e d .  These observations 
suggest that this phenornenon could be a result of limitation of the ion-exchange model in 
BPS. This may also resuit fiom the choice of parameters (e.g. capacity, adsorption 
isotherm constant etc.) for this model, for most of which no close esrimates were 
available nom literature. Sensitivity study to these parameters was carried out and the 
results are presented in Chapter Five. Solute capacity and charge were found to be 
critical parameters for this model. 
Because of this tailing elution curve, the volume of product h m  the ion exchange 
columns was much larger compared to the affinity columns (300 L compared to 67 L). 
This required larger membrane separation uni& following both the ion exchange columns. 
The volume of the second ion exchange column was also found to be bigger (1 13 L) 
compared to the second mîty chromatography colurnn (85 L). However, as discussed 
in the following sections, the contribution of membrane separation units to the total 
equipment purchased coa is not sigmficant and the ion exchange colurnns are also much 
cheaper than Sinity columns. Therefore, the economics of the process was not 
significantly afTected by the larger product volume fiom the columns. 
4.2.4. ECONOMIC EVALUATION 
The economics of this flowsheet was evaluated using the estimates of purchased 
equipment cost and operating labor fiom SuperPro Designer@ for calculation of total 
capital investment and annual operating cost. Cost factors (Datar and Rosen, 1990) used 
in this cdculation can be found in Appendix C. Table 4.2.2 s u m m h s  the economics of 
the simulated process. 
Breakdown of equipment cost (Figure 4.2.2) for uiis case shows that contribution fkom 
fermentation equipment accounts for about 30% of the total cost. This is due to the eight 
bioreactoa w d  for growth and production of the ceus. Ion-exchange chrornatography 
columns account for about 18% followed by membrane separation and gel fdtration 
columns, which contribute almost equaily (16% and 15% respeftively). A breakdown of 
the annual operating cost shows that contribution 6rom raw material (41%) dominates the 
total coa Of the raw material cost 84% cornes nom fermentation media for the eight 
bioreactoa (Figure 4.2.3). The gel filtration columns contribute by 7.4% whiie the ion- 
exchange columns accoimt for only 5.5% and the diafiltration stream, 2.3%. A sensitivity 
study was c d e d  out to diafiltration Stream since simdation of diafiltration did not 
converge (Section 4.2.6). 
Table 4.2.2: Economic analysis (in millions of dollars) 
Purchascd Equipment Cost, ( C d  
Fixed Capital Investment, C, = (4.6XCpd 
Total Capital Investment, C, = (5.5XCA 
Revenue, R 
Annual Operathg Cost, AOC 
Gross Profit, GP = (R-AOC) 
Net Profit, NP (40% tax) 
- I 
4.2.5. COMPARXSON WTH BASE CASE 







Net Cash Flow (NP + Dep.) 
ROI (Net Cash Flow/ c,) * 
Gross Margin, GM = (GP/R) 





on Investment (ROI) and Gross Margin (GM). The economics of the base case is 
recalculated assuming the selling price of t-PA to be $16,00O/g as suggested by Cooney 
(1999). Table 42.3 shows the calculation of the economic parameten for the flowsheets. 
As it appears fiom the table, the two-stage ce11 culture flowsheet has higher ROI and GM 
because of both lower total capital investment (which is a consequence of lower 
purchased equipment cost) and lower annual operating cost 
Table 4.2.3 : Comparative econornic analysis (in millions of dollars) 
Purchased Equipment Cost, (Cpd 
Fixed Capital Investment, C, = (4.6XCd 
Total Capital Investment, C, = (5.n<C& 
Revenue, R 
Annual Operating Cost, AOC 
G i o ~  Profit, GP = (R-AOC) 
Net Profit, NP (40% tax) 
Net Cash Flow (NP + Dep.) 
ROI (Net Cash Flow1 Ç,) 





























Figure 4.2.3: Breakdown of raw material cost 
The two stage ce11 culture flowsheet uses fewer (three) sets of equipment following ce11 
separation compared to the base case (five). This results in signifiant savings ($5.4 
million) in the equipment purchase cost and consequently Iowa capital investment for 
this flowsheet. The expensive affinity columns of the base case have been replaceci with 
cheaper ion-exchange columns in this flowsheet The purchase cost obtained from 
SuperPro for these columns are a h o a  the sarne, however, the replacement cost for the 
mins are quite different (â2000L vernis $400/L). Therefore, the contribution (20%) 
fiom afhity columns to raw material for base case is much higher compared to the 
contribution (5.5%) from ion-exchange columns. The contribution of media, on the other 
hand, increased fiom 62% for the base case to 84% for the two-stage ce11 culture 
flowsheet. 
For both the cases, raw material accounts for the major portion (about 40%) of o f a n n u a l  
operating cost for the processes. The operating coa for the two-stage ce11 culture 
tlowsheet is found to be lower which is mainly due to the use of lower priced s e m  
containing medium in the growth bioreactor and also replacement of affinity columns by 
the ion-exchangers. S e m  containing medium for the five growth bioreactors accounts 
for 59% of the media cost compared to 41% by the semm fie media for the three 
production bioreactors. 
Since senim p h  is a vafiable that can easily change, sensitMty of the hwsheet to serum 
prix  was stllàied to invtstigate by how much the proccss can bene& fbm a bwcr saum 
price. Figure 4.2.4 shows that a 5Wb dcacase in this pria wiil result in about 6% Uicrrase 
in the ROI of the proctss. Th~~tforc, the proctss is f&ly sensitive to saum @CC. 
2, DW~ltration Stream 
The dkfiitration stnam contributes very insi-tly (2.3%) to the total raw smterial 
prict of îhe proctss. However, since the simulation of the microfiltration mode1 with the 
diafiitration option'did not converge, a sensitivity snidy was carried out to detamine 
whether this would effect the process sipnincantiy. F i p  4.2.5 shows that even a dfold 
hcrcasc in the volm of the dMhttion smam win only bwer the ROI by 1.8%. 
Therefore, the e&t of this smam on the overall process economics seems very 
Lisignificant. However, a larger diafihafion vol- would a h  niean increased batch t h  
or incrcased mrnbrane ana for a fixed batch timt for the process. 
18 
Serum Price (%IL) 
Figure 4.2.4: Sensitivity to serum price 
-- -- 
5 10 20 
price ($IL) 
Figure 4.2.5: Sensitivity to prke of diafiltration 
stream 
4.3. Process Alternative: Fed-batch Mode of Operation 
43.1. INTRODUCTION 
Animal ce11 cultivation technology has faced some unresolved issues for the pst forty 
years, which include low product concentration, low viable ceil density, short production 
phase, toxic byproduct accumulation and depletion of essentiai nutrients. Metabolic waste 
products, lactate and ammonia, have signifiant effect on ce11 growth and metabolite 
production. Lactate is mainly produced fiom glucose metabolimi and ammonium is 
excreted when amino acids are metabolized by the cells. Accumulation of waste 
metabolites at a high rate can be avoided through controlled feeding of nutrients, glucose 
and glutamine. The control of nutrient level can be realized only by a continuous 
dynamic feeding using fed-batch mode of operation. A sound strategy for fed-batch 
culture must consider both, providing nifficient nutrients and minimizing the production 
of undesired metabolites and the increase of osmolality (Zhou et al., 1995). Experirnents 
have shown that fed-batch operation can result in up to 8-fold increase in product 
concentration compared with conventionai batch culture in the same bioreactor. This 
feeding strategy can also be w d  to feed specially formulated supplemental medium, 
which in one case nsulted in 17-fold increase in product concentration (Xie and Wang, 
1996). Fed-batch mode substantially increases the fînai product concentration while 
keeping the simplicity of operation and of quality control to comply with FDA 
regdations (Tremblay et al., 1992). Genetic drift and contamination problems are also 
minimi;i:ed since the culture lasts about twice as long as a reguiar batch culture (Tremblay 
et al., 1992). Although RIA  has not yet approved fed-batch operation for production of 
biological fiom animal cell culture, the high product concentration achievable with this 
mode of operation makes investigation of this process worthwhile for large-sde 
operation. 
4.3.2. PROCESS DESCRIPTION 
Process information for the bioreactor was obtained from Iiterature reporthg fed-batch 
operation mainly with hybridoma (Zhou et al., 1995; Kurokawa et al., 1994). Inoculum 
ce11 concentration in these experiments were varied between 12x10s to 4x10s cells/ml. 
Zhou et al. (1995) reported the production of IgG in mouse-mouse hybridoma by fed- 
batch culture. They used a continuous feed consisting of 15.5-fold salt fiee (without 
inorganic components) concentrated medium, 258.3 rnM glucose and 93 mM glutamine 
to maintain glucose concentration in the medium at about O.lSg/L. Glutamine 
concentration was not controlled. The maximum total and viable ce11 concentration 
reached were 1.3 6x 1 07 and 1 Z x  1 07 cells/mi respective1 y. Lactic acid production was 
significantly reduced. The antibody concentration reached was about 58 m a 7  which is 
7.25 times the concentration achieved by batch culture of the same ceil line. Over a 
period of 230 hour, 135 ml of the continuous feed was added to the original volume of 
500 mi. Both glucose and glutamine concentration were maintained at 1.1 mM (0.2 gL) 
and 0.685m.M (0.1 g/L) respectively by Kurokawa et al. (1994) in a fed-batch culture of 
hybridoma to obtain a monoclonal antibody concentration of 172 mgL. The 
concentration of glucose and glutamine in the feed were 55.55 mM (10 g/L) and 34.24 
mM (5 g/L) respectively. The füial ce11 concentration reached afler 120 hour was 4. lx 106 
cells/ml. 
The above observations were simulated for a stirred tank type bioreactor operated in fed- 
batch mode with the CHO ceils grown in suspension culture. Senmi fke medium was 
used in the bioreactors of this flowsheet. 
The downstream process considered was similar to the one used in the base case so that 
the flowsheets could be compared on the basis of mode of operation of bioreactor only. 
Details of the downstrearn units can be found under Section 4.1 2. Cell separation fiom 
broth was achieved by microfiltration, followed by two altemate steps of ultrafiltration 
and &ty chromatography for main purification. The fina step was polishing by gel 
filtration. 
4.3.3. SIMULATION AND RESULTS 
Two fed-batch processes demibed by Kurokawa et al. (1994) (case A) and Zhou et al. 
(1995) (case B) were simulated. For simulation purposes, two continuous feed streams 
were defined, one contains glucose and the other containhg glutamine only. The 
"Feedback ControP option of Aspen BioProcess Simulatom was used to control the 
concentration of glucose and glutamine in the bioreactor by manipulating the fiowrate of 
the continuous feed streams. 
In case A, both glucose and glutamine concentrations in the medium were controlled. The 
initial working volume of the bioreactor was specified to be 3000 L and the concentration 
of glucose and glutamine in the media to be 1.48 mM and 0.92 m M  respectively. For this 
case, the concentrations of these substrates in the continuous feed were 0.055 M and 
0.034 M and the set points were 1.1 1 mM (0.2 g/L) and 0.685 mM (0.1 fi) respectively. 
These are the same concentrations as maintained by Kurokawa et al. (1994) in their 
experirnent, where an adaptive coneol algorithm was w d  to control glucose and 
glutamine concentration. Kurokawa et al. (1994) did not compare the product 
concentration achieved by the fed-batch scheme to batch operation. Instead they 
demonstrated that simultaneous control of both glucose and glutamine concentrations is 
advantageous for production of phamiaceuticals by animal cell cul- and lower the 
substrate concentration level maintaineci higher the product concentration achieved. For 
simulation purposes it was assumed that the product concentration reached in this case 
was four times the concentration reached in the batch bioreactor. Aiso. the batch time for 
the bioreactor for simulation purposes was considered to be 200 hours instead of 120 
houn as reported. Since a d e r  batch time would d o w  more batches to be carried out 
annuaily, the process can be carrieci out in a smaller sized plant. This will resuit in higher 
ROI, thereby masking the efZect of higher product concentration on ROI alone (Section 
4.3.7). 
Only glucose concentration in the culture media was controlled in case B. The initial 
working volume of the bioreactor in this case was specified to be 2800 L and the 
concentration of glucose and glutamine in the media to be 1.39 mM and 0.3 mM 
respectively. For this case, the concentrations of these substrates in the continuous feed 
were 0.2583 M and 0.098 M and the desind level of glucose concentration in the media 
was 0.0833 mM (0.15 g/L). These are again the same concentrations as rnaintained by 
Zhou et al. (1995). In laboratory, flowrate adjustment for controlling glucose 
concentration was achieved in response to oxygen uptake rate (OUR), which is 
stoichiometrically related to rate of glucose consumption. For simulation purposes, a 
product concentration of eight times was considered and the batch t h e  was assumed to 
be 200 hours instead of 230 hours for reasons aheady explained. 
The simulation results obtained by Aspen BioProcess Sirnulatom for the fed-batch 
bioreactors show the final bioreactor volume and the amount of the continuous feed 
streams required. Aspen calculates the amount of the continuous streams as a multiple of 
the actual flowrate of the feed streams as defined in the input mes rather than generating 
a time profile for the flowrate of the continuous feed stream. However, if an optimum 
feed profile is known, it can be supplied to the simuiator using the optional "Feed- 
Profile" form s k e  BioRocess Sirnulatom accepts time varying feeà pronle in the form 
of the following polynomial: 
The batch time in the bioreactor can be divided iato several intexvals and the polynomial 
cm Vary from interval to intend. 
Table 4.3.1 shows the final bioreactor volumes and the actual amount of feed added as 
calculated by Aspen for the two bioreactors. 
Table 4.3.1 : Simulation resuits for the fed-batch bioreactors 
Simulation of the downstream eain was carried out by supplying the simulator with 
information pnsented under process description section. Concentration of t-PA in the 
broth fiom the bioreactor was specified as either four times (Case A) or eight times (Case 
B) the concentration from the batch biomctor (33.5 m f i )  (Section 3.5). For the 
downstream train, severai solutions (size and number of the units) can be obtained by 
changing the membrane ma, cycle time and pump capacity for the membrane separation 
units within prafacal lirnits. lheK changes result in different concentrations and volumes 
of product coming out from these units and going to the nem unit, which is the 
chromatography column. The volume and number of the columns change to handle the 
different throughputs and different concentrations, which cause the column to operate at a 
different point of the isothem. The interaction that was observed between these two units 




The design basis (Section 3.5) considered for the base case had to be modified for the 
fed-batch processes so as to obtain the same muai  production of t-PA. The bioreactor 
volume was ncalculated to take advantage of the higher product titre concentration, 
which also reduced the size of the downstream units. The new bioreactor volumes were 
based on 40% overall recovery. However, it was difficult to reproduce the desued overall 
recovery and therefore, different bioreactor volumes were also considered for case B. The 
interaction between ultrafiltration and chromatopphy columns dows for numemus 
alternate solutions. The development (Le. selection of ske for the unit operation blocks) 
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production of t-PA (13750 g/year with a 20% product margin) is met within the given 
tirne constraint (-1 0 days). 
Several alternate fiowsheets that use different size of the unit operation blocks were 
developed h m  simulation for case A and case B. Table 43.2 and Table 4.3.3 show 
r e d t  for two different flowsheets for Case A, which differ in the size of the unit 
operation blocks and recoveries therein. With the first flowsheet, an overail recovery of 
43.2% is obtained while with the second one the recovery is only 21.7%. Two sets of the 
equipment for process 1 and four sets of equipment for process 2 are required to meet the 
required production levei. For the equal sized bioreactors of the two processes, 
microfilters of different size (65x2 m2 and 60x4 m2 for process 1 and process 2 
respectively) were simulated for ce11 separation. Initial enrichment of the microfiltered 
broth was canied out with ulûafïlters of equal shed membrane (50 m2) with twice the 
number of units for process 2 compaml to process 1. These differences in the upstrram 
units reduced the retentate volume fiom about 740LX.2 and a t-PA concentration of 0.6 
g/L for process 1, to 296LX4 and t-PA concentration of 1.2 g/L for process 2. The r e d t  
was the greatly differing recovery (about 81% and 49%) of the more than 99.9% pure t- 
PA in the first affinity chromatography column. The concentration of t-PA in the feed to 
this column was found to be critical to its performance. 
Although, the total size of the fïrst three units for process 2 were found to be much larger 
than process 1, the total number of chromatography columns required by the two 
processes were not very different Process 1 required 20 columns, 186 L each to achieve 
this recovery compared to 16 columns of almost equal volume for process 2. The column 
in process 1 also took 50 minutes more to complete one cycle of operation thaa that for 
process 2. The produa volume fiom the columns were 272 L x 20 for process 1 and 100 
L x 16 for process 2. Reduction of the larger p d u c t  volume fiom the chromatography 
column of process 1 required a larger ultrafilter (60x2 m2 compared to 10x4 m2) and 
longer filtration time (0.95 hour c o m p d  to 0.75 hour). The size of the following unit 
130 
operation blocks were not very significautly different although larger number (or size) 
was required for al1 of these blocks for process 2. 







M F  II 
UF III 
GEL 
Size T i e  Rec. t-PA [t-PA] Broth 
(hl (%) (g) Pn Voiume (L) 












4250 L X 4  
60 mLX4 
50mLX4 
190L X 16 
10 mLX 4 
1 4 X X 8  
10 mLX 4 










































4250 X 4 
3161 X4 




30.77 X 4 
2 3 Z 8  
Table 4.3.4 summarizes the overail performance of the two processes for case A, 
developed by trial and e m r  approach with BioRocess Simulatorm. 
Table 4.3.4: Cornparison of simulateci altemate flowsheets for case A 
Bioreactor Volume 
Overall Recovery in each Bioreactor 




[t-PA] in Chromatography Column 
No. of Chromatography Columns 
Table 4.3.5: Simulation resuits for case B (8 x batch) process 1 
Process 1 











186 x 20 
Volume (L) 
3745 X 2 
494g 
1.2gfL 
190 x 16 
Size 
3745 X 2 
For case B, three different flowsheets were constructeci h m  simulation. Out of these, 
process 1 and process 2 meet the desired production level of t-PA, while process 3 
underproduces by 23%. The overaii recovery for proces 1 is 21 2%. Therefore, two sets 
of equipment are required by process 1 to meet the production level (Table 4.3.5). The 











uses much smalier bioreactor volume and membrane area compared to process 1 (Table 
4.3.6). However, to handle the large retentate volume dilute in t-PA, the process requires 
fifteen chromatography columas and aiso achieves high ncovery of t-PA in the coiumns. 
The different trials that were canied out with process 2 to meet the desired production 
level of t-PA are summarized in Table 4.3.7. The overall recovery of this process was 
found to be determined by the recovery in the first affinity column as observed for case 
A. The volume of retentate fkorn UF 1 was varied by varying either the membraue area or 
the operating time of this batch ultrafiltration block. The redsultinggiecovenes, of more 
than 99.99% pure t-PA, in the M F  II block were found to increase with decreasing t-PA 
concentration in the feed (i.e. the retentate) to the column. An additional chromatography 
column was required for every 80 L of retentate volume for 40% loading (design case) of 
the 200 L columns. 
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Process 3 uses haif the size of equipment as  process 2. It was trïed to maintain a high 


















However, the resulting ovedl recovery (55%) was not high enough to meet the desired 
production levei (Table 4.3.8). 
Table 4.3.7: Recovery and productivity versus t-PA concentration in the affinity column 
1 Retentate Volume [ [t-P A] 1 Recovery Productivity 1 
Block r- 
Table 4.3.8: Simulation redts for case B (8x batch) process 3 













4.3.4. INTERACTION BE-EN UNITS: 
Simulation revealed that interaction exists between the membrane separation units and 
the chromatography columns in the do~ll~fream train which limits the recovery of t-PA 
in the chromatography columns. 
For a fixed filtration time, the retentate volume depends on the membrane area of the 
ultrafiltration units. The retentate volume in tuni detennines the size and number of 
column of the chromatography units (Figure 4.3.1). As the membrane ana is increased, 
retentate volume goes d o m  and then fore, the number of chromatograp hy columns 
required is reduced. However, as retentate volume is decreased, the concentration of t-PA 
in the retentate increases. As the rate at which BSA permeates out fiom the filtration units 
is much higher than that of t-PA, increasing membrane area resuits in higher ratio of t-PA 
to BSA in the retentate. The resdt of this concentration overload (Ghodbane and 









Figure 4.3.1 : Interaction between ultrafiltration and chromatopraphy 
Figure 4.3.2 shows two elution profiles for t-PA and %SA h m  the columns at two 
Merent ratios of the proteins. For a ratio of 10 (Figure 4.32.(a)), the large t-PA peak 
interferes with BSA and since t-PA is required at very high purïty, the amount of t-PA 
represented by the area under this peak is wasted. Only the amount of t-PA under the m a  
of the second smailer peak is recovered. So, in this case the recovery of t-PA is low. For 
the other case (Figure 4.3.2.(b)), where this ratio is 0.1, a srna11 peak of t-PA is obtained, 
which represents almost pure t-PA and therefore, in this case recovery is very high. 
In simuiating the chromatography column with BioProcess Simulatorm, it was found that 
increase in t-PA concentration only increases the area under the interfering t-PA peak, 
while the other peak remains unchanged. Since, t-PA is required at very hi& punty, the t- 
PA associated with the fint peak is wasted. nienfore, aithough concentration of t-PA is 
increased by the fed-batch process, the recovery in the chromatographic columns does 
not increase. Ghodhe  and Guichon (1988) simulated a chromatographic column for a 
binary mixture. The product concentration was varied over a wide range in this 
simulation. In this case, the recovery was found to increase with increasing concentration, 
although the effect diminished with increasing sample size unless very high 
concentrations were reached (greater than dative concentration of 0.8). The purity of the 
product was 99%. However, in this case Langmuir isothenn constants assumed for the 
components were very close (2.38 and 2.56) unlike the case considered here. The 
presence of a split elution peak for t-PA and the increase in the area of the smaller 
interfering peak with higher concentration could be an artifact of the simulator. It is 
impossible to draw any conclusion fiom observations since the oniy works reported in 
literature for affinity chromatography are carrieci out for anaiyticai purpose using smali 
sample size and Iow concentrations. 
For the hypotheticai case shown in Figure 4.3 -3, the retentate volume was fixed at 100 L. 
Under this situation, although, Iower recovery is obtained at higher t-PA to BSA ratio, 
production of t-PA, which is the product of recovay and t-PA concentration, actuaiiy 
O 100 200 300 400 500 
Elution Volume (1) 
Figure 4.3.2.(a): Elution profile for t-PAIBSA = 10 
200 300 
Elution Volume (L) 
Figure 4.3.2.(b): Elution profile for t-PNBSA= 0.1 
increases up to a certain point. Thereafter, the production incrwws only marginaUy but 
recovery decreases very significantly. Under these conditions the optimum ratio, at which 
the column should be operated? lies around 0.2. At this point, recovery is about 50% and 
concentration of t-PA in retentate is about 1.2 gL. The production cuve was also found 
to reach a plateau in preparative liquid chromatography of a binary mixture with 
increasing sample size but not with incteasing concentration (Ghodbane and Guichon 
(1988)). This effect was not pronounced in the base case simulation where concentration 
of t-PA is much lower. This places a limitation on the operation of the ultrafiltration 
units. They can be operated up to a certain low concentration factor (feed 
volurnehetentate volume) and therefore, the retentate volume is still going to be large. 
This will necessitate a larger number of colurnns for purification as aiready observed in 
the previous section. 
O 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 
t-PAtFBS 
Figure 4.3.3: Productivity and recovery of QPA in 
affinity chromatography column 
4.3.5. ECONOMIC EVALUATION 
The economics of the fed-batch processes were evaluated by combining information nom 
the two simulators, BioRocess S imulatorm and SuperPro Designer@, for reasons 
explained in Section 3.2. Table 4.3.9 summarizes the economic performance of the 
processes for case A. 
Table 4.3.9: Summary of economic performance of fed-batch process (case A) 
1 case A 1 CPE 1 CTC 1 AOC 1 ROI 1 GM 1 
Breakdom of purchased equipment costs (Figure 4.3.4. (a, b)) for the processes of case 
A shows that for process 1, about 77% of the contribution cornes h m  downstrearn units 
compared to 70% for process 2. Out of this, chromatography columns account for about 
73% and 64% for the processes respectively. Therefore, although process 2 requires twice 
the bioreactor volume and much larger membrane ma, contribution from cos  of 
chrornatographic columns is still large and CpE of process 2 is only 10.4% higher than 
process 1. Retum on investment (ROI) for process 1 is aiso about 15% higher. 
Process 1 
Process 2 
The muai operating cost (AOC) for process 2 is 9.8% higher than process 1. For this 
cost (AOC) the greatest contribution comes nom raw material (around 43%). A fiuther 
breakdown of the raw material cost (Figure 4.3.5. (a, b)) shows that, for process 1, the 
media accounts for 30% compared to 70% for downstream units. For process 2, which 
uses four sets of equipment, the scenario is reversed and in this case media and other 
material for the two bioreactors account for 59% compared to 41% by downstream units. 
It is dso to be noted that, between these two processes, although process 2 has twice the 
bioreactor volume and membrane area, the numbers of chromatographic columas are 
very close. The contribution of the continuous feed is 1.4% and 3% for process 1 and 
process 2 respectively. Although this represents a very small percentage, a sensitivity 
















Figure 43.4.(a): Breakdown of equipment purchase 
cost for process 1 of case A fed-batch process 
Figure 43.4.m): Breakdown of equipment purchase 
cost for process 2 of case A fed-batch process 
Figure 4.3S.(a): Breakdown of raw materiai cost 
for process 1 of case A fed-batch process 
Figure 43J.(b): Breakdown of raw material cost 
for process 2 of case A fed-batch process 
Table 4.3.10: Cornparison of alternate flowsheet simulation for case B 
In case B, lowest purchased equipment cost is calculated for process 3, which requires 
lowest number of chromatography columns. Breakdown of CpE (Figure 4.3.6.(a, b)) for 
process 1 shows again that downstrrarn units are the significant contributoa to this cos. 
Affinity Chromatopphy columns account for 68% of the cost for process 2, which uses 
largest number of columns for the fm chromatographie step. Contribution from 
bioreactor is highest for process 1 (1 1.8% comped  to 4.2% and 7% for process 2 and 
process 3 respectively) which requires the largest combined bioreactor volume. For the 
other units the contributions are more or less congruent 
Bioreactor Volume 
Overall Recovery 
Downstream Processing T i e  
t-PA/batc h 
[t-PA] in Chrom. 
Rec. in AFF 1 
No. of Chrom. Col. 
Breakdown of mual operating c o s  (AOC) again reveals, that raw material is the largest 
(around 42%) contributor in this case. Contribution h m  labor is higher (around 7%) in 
this case than case A (about 5.5%). Since fed-batch processes 
Table 4.3.1 1 : Summary of economic performance of fed-batch process (Case B) 
Process 1 
3745 L x 2 
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Figure 4.3.6.(a): Breakdown of equlpment purchase 
cost for process 1 of case B fed-batch process 
4 LI- 
- - -  
Figure 43.6.(b): Breakdown of equlpment purchase 
cost for process2 of case B fed-batch process 
58% 
Figure 43.7.(a): Breakdown of raw material cost for 
process 1 of case B fed-batch process 
gei membrane 
13% 1% 
Figure 4.3.7.(b): Breakdown of raw material cost 
for process 2 of case B fed-batch process 
may involve more labor force for preparation of continuous feed, sterilization, and 
maintenance of ce11 culture for a time span that is roughly twice as long as batch culture 
(Tremblay et al., 1992), a sensitivity study was camed out on labor cost for these 
processes (Section 4.3.7). Combined contribution from sources such as operating 
supplies, plant overhead and administration (calculated as a bc t ion  of operating labor) 
and maintenauce supplies, tax and insurance (calcdated as a fiuiction of fued capital 
investment) and depreciation etc. is found to be of similar magnitude (around 12%) as 
raw material. In this calculation fixed contributions were assumed fiom utilities, waste 
treatment, research and development, distribution and patent (Datar and Rosen, 1990). 
Breakdown of raw material cost (Figure 4.3.7. (a,b)) show that media and inoculum 
accounts for 58% of the con for process 1 that uses largest combined bioreactor volume. 
Affinity chromatography column materials are the larges contributors for process 2 and 
3, accounting for about 45% of the total con. Contribution fiom continuous feed is 
around 1 % in al1 the cases. 
4.3.6. COMPARISON WTH BASE CASE 
Ln Table 4.3.12, the simulation resdts for the fed-batch cases are compared with the base 
case. The results for process 1 of both cases are shown since they have higher ROI than 
the other processes. It is noted from the table that switching nom batch to fed-batch mode 
of operation results in significant reduction in the sizes of the unit operation blocks, 
particularly for the fint three blocks (Le. bioreactor, microfilter and ultrafilter) becaw of 
the higher product concentration. However, the number and size of the affinity 
chromatography columns are very similar. 
The design basis (Section 3.5) considered for the base case had to be modified for the 
fed-batch processes so as to obtain the same annual production of t-PA. The biomictor 
volume was recaiculated to take advantage of the higher product titre concentration, 
whîch reduced the size of the downstream units (Table 4.3.13). The improvement in 
economics therefore renilted h m  a smailer plant size rather than higher revenue. 
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Table 4.3.13: Comparison of economic performance of batch and fed-batch processes 
S i z e  
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A cornparison of the pufchased equipment coa shows that the contri'bution of cost related 
to fermentation equipment goes down h m  14% to about 4% as the process switches 
h m  batch to fed-batch mode of operation. Cost related to gel chromatography columns 
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X 4  
also dtcruists because of the gnatïy nductd thoughput. In conwsr, cost associated with 
afnnity chromatography columns inczta~es h m  25% a> 57% for case A and tben to 6û% 
for case B. 
Cornparison of the mual operathg cost shows that raw material anci nrdia is the largest 
cost cumponent in al i  the cases with the contribution king about 43%. Contn%ution h m  
labar related itcms is found to bt higher for the ftd-batch processes (about 7% compareci 
to 5% for batch). 
A cornparison of raw matcrial con revtals that for the batch process, ftrmtntation media 
accounts for about 60% cumpared to WO for downsûtam units. In the case of fed-batch 
processes, the scenario is reversed. For these processes, media accounts for about 40% 
cornparcd to about 6096 for downstmm units. The significance of downstream units in 
&terminhg the overail cost of phamÿiautical tberapeutics is alxeady known (Cartwright, 
1994). By moving h m  batch to fed-batch mode of opaation the balance of cost 
contribution ktwccn frmitntation aad dowostrtam units stcrns to movc m e r  up 
towards the pinification units. 
I) Sensitivity to Continuous Feed Cost 
Although mntinuous fêeû cost represents a very smaii penxntage (around 1%) of total 
raw matcrial price, a sensitivity study was carried out. It is anticipated that, the cumnt 
efforts of formulating stoichiomtricaily balance& nutrient fortifid media QCie and 
Wang, 1994, Piou et. al, 1995) to achieve even higha product concentradon may result 
in severai fol& i n m e  in this pricc. 
As shown in Figure 4.3.8, a 10-fou increasc in the price of this s o r u ~  over the base pria 
of $lO.O/L, would only lowcr the ROI of the process by 3.5%. Thatforc, fcd-batch 
processes will remain an economically amactive alternative to batch opaation even if the 
price of the continuous feed increascs signincantly* 
Another uncertain quantity in the simulation of the fed-batch processes is the volume of 
the continuous feed added. The effect of increased cost of the stream wiil stilb be 
insignificant. However, the necessity of larger plant size to b d l e  the increased 
throughput will significantly lower ROI of the process. 
II) Sensitivity to Labor Cost 
Fed-batch processes in principle should involve more labor force than a batch process for 
preparation of continuous feed, its sterilhtion and maintenance of ce11 culture which 
lasts roughly twice as long as a regular batch culture (Txzmblay et al., 1992). In general, 
labor cost is found to be the largest coa component, accounting for more than 50%, for 
bioreactors (Wilkinson, 1987). For chmmatography columns, labor cost tends to run far 
ahead of supplies and amortized equipment (Wheelwright, 1987). Therefore, a sensitivity 
study was camed out to labor con for the fed-batch processes. In addition to cost for 
supemision (A), maintenance (B) and operating labor (C), this study included cost of 
other labor dependent items of annual operating cost such as operating supplies (10% of 
C), laboratory charges (25% of C), plant overhead (60% of (A+B+C)) and administration 
(25% of plant overhead) (Datar and Rosen, 1990). 
Although, labor cost accounts for about 5.5% and 7% of the annual operating cos  for 
case A and case B respectively of the fed-batch processes, it was found that a 50% 
increase in the labor cost will bring about 9% reduction in ROI of the process (Figure 
4.3.9). Therefore, increase in the base unit labor rate (S181hour) or the labor-hour may 
have significant efTiect on the economics of the process and the possibility of minimizing 
labor cost by automation of the process should be investigated. 
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Figure 4.3.8: Sensitivity to Cont Feed CosWolume 
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Figure 4.3.9: Sensitivity to Labor Cost 
III) Batcti Time 
Another variable that has signiticant e&ct on the ROI of thc proccss, is the batch tim. A 
break&wn 4.3.10) of the batch time for case A M-batch process shows that the 
opaation of tht bkmactor occupies 93% of the total timc rt~uirtd for the compktc 
batch. In this simulatinn, cqual batch tim (-9 days) was coilsidacd for the batch and 
fed-batch processes. Howtvfr, in gen#al fed-batch cuuiirts lasts roughly twice as bng 
as ~tgular  batch culnaes (Trcmblay et aL, 1992). For ftd-batch culnues itseif, 
achievemnt of higher product titre using féd-batch opaation may nquire longer culture 
tirne. For example, case A (4X) required 120 hours cornparrd to 230 hours for case B 
(8X) in the labotatory (expcrimtnts camcd out with ciiffatnt ce11 lines). 
The effect of shoner batch tirne is iarger numba of batches per year, which results in 
srnalier plant size. And a reduction in plant size results in highcr ROI. For a fixed plant 
she, reduction of tum amund time increases the revenue h m  the plant by allowing more 
batches to be canied out per year. This suved as one of the major motivations for process 
improvement by CeIItech for theh 1000 L airlift bioreactm which rcsuited in rcduced tum 
around timc of 1.5 days instead of 4 days (Wilkinson, 1987). 
Sensitivity. study (Figure 4.3.1 1) of case A fed-batch process shows that a 5046 reduction 
in batch t h  would rcsuit in about 10% inrnasc in ROI for the process. This is a huge 
incentive to d u c e  the culture tim of fed-batch operation to reach the same product 
concemation by manipulating other variables such as mctaboîic pathways of the same 
ceU line or switching to differcnt ccll line etc. Howcvcr, larger number of batches per 
year WU require more muent replacement of matenals such as chromatographie resins, 
uhf3tration and miaofïitration membranes etc. This wiü also r q u k  mDre raw 
mataials, media. hbor force, operathg supplies, u ~ t s  etc., which will incrrase the 
annuai operating COS. This incrrased COS was also coosidtrcd in this study. 
Figure 4.3.10: distribution of batch time for the fed- 
batch processes 
4.4. Process Alternative: Airlift Bioreactor 
4.4.1. INTRODUCTION 
This altemate process to the base case uses airlift bioreactor instead of the stirred tank 
type used in the base case. The airlift type of bioreactor has been used for many years for 
the cultivation of microbial cells and lately for hybndoma (Rhodes and Birch, 1988) and 
CHO cells (Arathoon and Birch, 1986). It produces a gentle, low shear environment 
suitable for tissue culture and genetically engineered rnicroorganisms (Chisti, 1 989). The 
main advantage of the airlift design is its simplicity in construction and operation. It 
removes the need for motors and agitators associated with stirred reacton. In addition, 
hydrodynarnic and mass transfer characteristics of the airlift reactor are predictable with 
increase in scale (Arathoon and Birch, 1986) and therefore it is relatively easy to scale 
UP* 
The basic principle of aidi% bioreactor is that, it uses gas mixtures to provide mixing. 
Gas mixtures are introduced into the culture fiom a sparge tube at the base of a central 
draught tube. This causes a reduction in the bulk density of the liquid in the draught tube 
compared with the outer zone of the vessel, which sets the culture in circulation. In 
addition to providing mixing, the gas mixturrs also supply oxygen to the culture!. Means 
of directing flow other than draught tubes are also used Ceiltech developed airlift 
bioreacton up to 1000 L scaie for production of monoclonal antibody (Rhodes and 
Birch, 1988). A 10,000 L %ale airlift bioreactor was also designed for the same purpose. 
4.4.2. PROCESS DESCRIPTION 
The downstrearn processes of this fiowsheet consist of the same steps used in the base 
case flowsheet, two altemate steps of ultrafiltration and affin@ chromatography, 
followed by a final step of gel filtration. The required process information and operating 
conditions, required as input for simulation, were gathered h m  literature. These are the 
same as described for the base case and can be found under Section 4.1.2. 
The simulated bioreactor is an internal loop, draft tube type airlift reactor with the CHO 
cells grown in suspension culture. It is hoculated with 1000 L of inoculum having a 
concentration of 2x10' cells/ml. A concentric draft tube internal loop airlifi reactor was 
simulated for the process since the 1000 L airlift reactor operated by Celltech for 
hybridoma culture is of the same type. Table 4.4.1 compares the performance of the 
internal loop airlift reacton with external loop reactoa. The external loop configuration 
results in high shear, which could be detrimental to animal cells. 
The presence of a drafl tube in the internai loop airlift reactors and the ratio of 
downcomer area to riser area (Ad&) was found to have no effect, in general, on the 
overall gas holdup (E) in the bioreactor (Chisti, 1989). However, the ratio (A&) is 
found to influence the liquid circulation apd mixing in airlift reactors. This ratio is the 
principal factor, which was found to control the total circulation path flow resistance in 
airlift reactoa. There was no dennite general agreement on the influence of this 
geometric tem on circulation except that interstitial liquid velocity, VL was found to be 
dependent on (Wb) in the foliowing manner: 
where v was found to Vary baween 0.2 and 0.77 (Chisti, 1989). For the bioreactor 
simulated, the ratio of downcomer area (AJ to riser m a  (4) was assumed to be 1.25 
(Chisti, 1996). This ratio resuits in a downcomer diameter (d,) to column diameter (dJ 
ratio of about 0.53. For intemal loop bioreactors, Iargest liquid circulation rates are 
reported for diameter ratio of between 0.6 and 0.5 (Weiland, 1984; Miyahara et ai., 1986; 
Jones, 1985) and efficient mixhg and oxygen tramfer between 0.8 and 0.9 (Weiland, 
1984). The diameter ratio for the simulated bioreactor, therefore, is withui the range for 
large liquid circulation rate but below the range for high oxygen transfer. For animal 
cells, since oxygen demand is low in cornparison to rnicrobial cells (Fleischaker and 
Sinske y, 1 98 1 ) the specified diameter ratio should be satisfactory . 
Table 4.4.1 .Relative performance of extemal and intemal loop airlift bioreactors (Chisti, 
19891 ,
The liquid height (hJ to total diameter (dJ ratio is found to effect the liquid circulation 
velocity and mixing time in airlift bioreactors (Ganzeveld et al., 1995). A higher aspect 
ratio results in higher liquid circulation velocity and longer mixing tirne. Shce the 
diameter ratio for the simulated bioreactor is chosen to give a high liquid circulation 
velocity, the aspect ratio was assumed to be 3.0 to achieve better mixing (Chisti, 1996). 
This resulted in a total diameter (4) of 1.36m and liquid height (hJ of 4.lm for the 
reactor. The relationship [4 + A,., = n(dJ2/4] yielded a downcomer area (4 of 0.81 m2 
and a riser area (4) of 0.65 m2. The riser height to riser diarneter ratio was assurneci to be 
3.5. A higher ratio (5) was used in the concentric draft tube airlift reactor described by 
Chisti (1 989). This ratio results in a higher riser height than the liquid height, h, for the 
simulated bioreactor and therefore, had to be lowered. 
Parameter 
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An estimate of the superficial gas velocity in the riser (U,) was obtained h m  the 


















probably higher 1 probably lower 
where KL was assumed to be 5 KI as in the base case. This gave a value of 0.00287 mls 
for U, The above equation is applicable up to a gas-liquid dispersion height &,) of 1.8 
m. For the simulated bioreactor h, is m e r  than 4m (exact height to be calculated 
later). However, none of the other equations was found to be more suitable for the 
simulated case and therefore the a b v e  equation was chosen for U, calculation. 
The volumetric flowrate was cdculated to be: 
Which is equivaient to (1 12L/min)/(6000L) = 0.01 86 W. Birch et al. (1987) have 
measured oxygen transfer coefficients in airlift reactors and shown that the transfer rate 
needed to support a hybndoma culture of average maximum population density (ca. 2 
x1 O' celldml) at 1 O00 L scale is about 2.5 h" which corresponds to about 0.01 WM. 
In airlift reactoa power supply originates fiom two sources: i) isothermai expansion of 
the gas as it moves up the reactor and ii) the kinetic energy of the gas injected into the 
reactor. It has been demonstrated that the contribution of kinetic energy to total power 
input is a very small percentage and for most practical situations does not exceed t .5% 
(Chisti, 1989). The power delivered to the fluid, therefore, was calculated fiom the 
foilowing relationship : 
and found to be 12.5 W/m3. This quantity mis calculated to be 13 W/m3 for the stimd 
bioreactor of the base case. 
The heat transfer coefficient (hJ was obtained fiom the following correlation proposed 
by Chisti (1989) for concentric draft tube intemal lwp systems: 
and found to be 1.4 kw/m2-"c. For the base case the heat transfer coefficient was found to 
be 540 kc&m2-hr-0~. 
The total gas holdup, E and the gas holdup in the downcomer (EJ and the riser area (q) 
were calculated following a trial and error approach using the following equations: 
The pas holdup comlation due to Hills (1976): 
which can be used to cdculate q for any given gas velocity using an assumed value for 
liquid velocity. The downcomer gas holdup is then obtained using the following 
equation for draft tube intemal loop airlift (Bello et al., 1985): 
The superficial liquid velocity, U, can be calculated fiom the following simplified 
equation (Chisti et al., 1988; Kubota et al., 1978) for the concentnc tube type internal 
loop airlift devices once estimate of the gas holdups are obtained: 
in the above equation, 4 is the free area for liquid flow under the drafi tube, h, is the 
gas-liquid-solid dispersion height and &, is the fiictional loss coefficient for botîom zone 
of the reactor. The coefficient &, for aimost ai i  the severai cliffixent types of internal- 
loop aùlift can be calculated fiom the following comlation (Chisti, 1989): 
and the gas-liquid-solid dispersion height, b, can be obtained h m  the following 
relationship: 
h, = h,/(l-e) (4.4. 1 O) 
An initial value of zero was assumed for U, the superficial liquid velocity in the nser, 
and then it was incremented by a mal1 number (0.01) and compand to the updated 
value obtained from the above equation. This procedure was continued until no 
significanî (tolerance of 0.001) Merence was found between the two. The final values 
obtained are the following: 
n ie  values of q and q, obtained are found to be within the range observed for hybridoma 
culture in an interna1 loop airlift bioreactor (Ganzeveld et al., 1995). 
4.43. SIMULATION AND RESULTS 
BioProcess SimulatorN does not have any model for airlift bioreactor. Therefore, the 
model in the Superko Designer@ was w d  to simulate the bioreactor for this flowsheet. 
This model simulates an airlift bioreactor using a simple stoichiometric reactor model. 
The user has to specify the stoichiometry and the extent of the overall reaction. The 
modehg equations of the airlift bioreactor in SuperPm Designa are identical to the 
stirrpd tank bioreactor. The specifïc input data required to simulate the airMt bioreactor 
are the ratios of riser height to riser diameter and the riser a m i  to downcomer area. The 
outputs h m  the model are nser height and diameter and downcomer volume. 
Ushg the above mode1 a singie 6000 L bioreactor was simulated in rating mode. 
Glutamine was defined as the limiting reactant with the stoichiometries king the values 
that would result in the nnal concentrations of the reactants and products in the broth, as 
observai with the BioProcess Simulatorm simulation. 
The reporteci outputs of simulation are as following: 
Riser Height, & = 3.81 m 
Riser Diameter, & = 1.09 m 
Riser Volume, & = 3.56 rn3 
Downcomer Volume, D, = 4.44 m3 
Total Volume, V, = 8.0 m3 
Liquid Volume, V = 6.0 m3 
The details of the flowsheet can then be summarized in the following table, where the 
downstream uni& are simulated using BioRocess Simulatorm and are the sarne as for 
the base case. 
Table 4.4.2: Simulation results for airlift reactor flowsheet 





Affinity Chrom. , 
Ultrafilter 
M h i t y  Chrom. 
Ultrafilter 
Gel Filtration 
The overall economics of the process is summarized in Table 4.4.3. Of the purchased 
equipment cost (Figure 4.4+1), the aff?nity chromatography columns and the gel filtration 





























separation units are prctty cbse (11% aod lû% ~tsptctkly), W& the a- 
quipmtnt acmumtd for 24%. 
Total Capital CZ = (5.SXW I 74.8 I 
Tabk 4.4.3: Econodc d y s i s  of the v s s  (in minions of doliars) 
Revenue, R I 176 I 
Purchased Eqiiipmtnt Cost, CPe 




Net Profit, NP (40% tax) I 45 I 
Annual ûpcratiug Cost, AOC 





Net Cash Flow, (NP + Dep.) 
R e m  on Investrnent, ROI 
Cross Margin, GM = (GPB) 





Calcuiation of the annual operating cost is the same as for the base case. The ROI of the 
process is 68% with a gros  margin of 43%. 
4 - 4 5  COMPARISON WTH BASE CASE 
The effect of replacing the stirred tank bioreactor of the base case with an airlift type 
reactor was observed in the lower purchase equipment cost for this flowsheet The 
purchase cost of an equd shed airiift bioreactor was found to be 75% of the s h e d  tank 
bioreactor according to the SuperPro Designefi built-in cost mode1 because of the 
simplicity in its construction. The lower C, resulted in 4.4% lower total capital 
investment for this flowsheet, which improved the ROI by an almost equal arnount, other 
costs remaining unchanged. 
Table 4.4.4: Comparative economic analysis (in millions of dollars) 
With airlift bioreactors, the reactor type per se, had no effect on growth kiwtics or 
antibody production rate (Birch et al., 1987; Aratbwn and Birch, 1986). However, 
because of its simple construction airiift bioreactors help to maintain aseptic condition 
and operation of the bioreactor, the effect of which mis not possible to compare with that 
of a stirred tank bioreactor. Power and labor cost are also e-d to be cheaper for this 
type of reactor compared to a stined tank type. 
Purchased Equipment Cost, C, 
Fixed Capital, C, = (4.6XCa 
Total Capital, C, = (5.5XCa 
Revenue, R 
&mual Operating Cost, AOC 
Gross Profit, GP = (R-AOC) 
Net Profit, NP (40% tax) 
Ne$ Cash Flow, (NP + Dep.) 
Retum on Investment, ROI 























On the other hand, the presence of bubbles in the medium in an au lift bioreactot was 
found to cause more ce11 damage to some ce11 line then providing a gentie environment 
in the absence of agitators. Numerous hybridoma ce11 lines have been successfùlly grown 
in airlift bioreactoa while others could not be. Han& et ai. (1987) tried to elucidate the 
relationship between gas-liquid interface and the survival of mammalian cells. They 
found that ce11 viability and survival in the presence of air bubbles depended on three 
factors- ce11 type, bubble size and superficial gas velocity. Some ce11 lines were found to 
be more sensitive to the presence of gas bubbles than others, even though no gros 
morphologicd difference was observed. Increasing the superficial gas velocity, as well 
as the presence of small bubbles, were found to be detrimental to ce11 survival. A later 
study by the sarne authors (Handa et al., 1989) revealed two mechanisms of ce11 damage. 
One due to rapid oscillations caused by bursting bubbles and the other due to damage 
caused by shearing in draining liquid films (or lamellae) in foams. They aiso established 
that ce11 death was associated with the region of bubble disengagement at the medium 
surface and therefore, short bubble columns, as well as mal1 bubbles and high bubble 
frequencies were detrimental to cells. 
However, it was also verified by the same authors (Handa et al. 1988) that increasing 
bubble column height, which reduces the proportion of the tirne spent by the cells in the 
bbdestructive zone" at the medium d a c e ,  caused a progressively increased xtention of 
cell viability. Addition of several non-ionic &actant nich as Pluriol PE 6800 had 
concentration dependent protective effect on decreasing ce1 growth caused by the 
presence of bubbles. Therefore, with a linle modification it should stili be possible to use 
airlift bioreactors for large sale culture of mammalian cells. However, the removal of 
the dac tan t  fiom the broth and its subsequent effect on downstream pmcessing needs 
to be investigated. 
4.5. Process Alternative: Single versus Multiple Bioreactor 
4 .S. 1. INTRODUCTION 
An issue that has received Mxed opinion in the scaling up of bioreactors is whether to 
increase the size or the number when moving to industrial scale. Celltech designed a 
10,000 L bioreactor for production of monoclonal antibody from animal ce11 where it 
was decided to increase the size rather than the nurnber of the bioreactor. The 
justification king to benefit h m  the economies of sale (Birch et al., 1987). If scale-up 
consists of increasing the number of units without increasing the unit-size, then both 
capital and labor costs increase linearly with increase in scaie. However, if scale up is 
achieved by increasing the unit-sire the capital cost increases approximately to the 0.6 
power (Figure 4.5.1). 
In contrast, Horvath (1989) pointed out that having several large bioreacton rather than 
one or two very large ones couid be advantageous due to several reasons. Multiple 
bioreactors offer fiexibility of o p t i o n ,  ease of start up, inoculum preparation, cleaning, 
sterilization etc. Manufactuers are able to match production with market demand 
adopting a modular approach. In large-scale batch culture, contamination or equipment 
mdfunction can ruin an entire run and waste s e v d  days as downtime for maintenance 
and repair. The modular design will minimize production disruption because the 
operation of the contaminated bioreactor can be temllnated without disturbing the others. 
In the above discussions the effect of bioreactor sale up on downstream units, which for 
high value products account for about 80% of the production cost, was not considered. A 
major advantage of a moddar approach to scale up could be the size reduction of the 
downstream processing equipment. Proper scheduling of the downstrram unîts would 
aiiow the same sets to be used with the diffant bioreactors and this should result in 
major savings in capital c o n  It was also pointed out by Hanhbarger et al. (1995) that, 
since a ce11 culture bioreactor cycle can last up to a week, multiple bioreactor trains can 
be used to feed an economically sized, single purification train. In the absence of 
dedicated faciiities or excess facility capacity, the production of even more than one 
product using the same equipment, which requires additional cost for validateci cleaning 
and sanitking procedures between each product manufacturing run, has been found 
econornically feasible (Sofer and Nystrom, 1991). In USA, approximately 80% of the 
new biotherapeutics are expected to corne fiom companies setking approval for multi- 
product fafilities that will use the same purification equipment for purification of 
mdtiple products (McCormick, 1991). The labor cost can also be kept low using 
multiple bioreactoa by sequencing the operation of the bioreactoa so that the same labor 
force can be used to operate the bioreacton at different points of tirne of the same batch. 




Figure 4.5.1 : Effect of scale on relative cost of components 
4.5.2. PROCESS DESCRIPTION 
The downstream processes of this flowsheet consist of two altemate steps of 
ultrafiltration and affinity chromatography, followed by a f ia l  step of gel 
chromatography. The simulated bioreactor was stirred tank type with the CHO cells 
grown in suspension culture. Serurn fk medium was used in the bio-or, which 
consists of HB-CHO basal mixture and a proprietary supplement (Immucor Canada 
Inc.). This 
with 160 L 
medium contains 320 mg/L of total protein. The bioreactor was inoculated 
of inoculum hawig a concentration of 2x1 Os celWml. 
The operating conditions for the membrane filtration units were the same as demibed 
for the base case (Section 4.1 -2). Simulation of affinity chmatography was carried out 
for an 85 L column having a height to diameter ratio of 0.5 and at a superficial loading 
velocity of about 40 cdh .  A 30 L column was used for the second chromatography. Gel 
filtration was simulated in a 75 L colurnn having a length to diameter ratio of 1.5. The 
sample volume was taken as 5% of  column volume as recommended (Wheelwright, 
1991) and the flow velocity was 16 cm/h. 
4.5.3. SIMULATION AND RESULTS 
The 6000L bioreactor of the base case flowsheet was divided into six equal sized 
bioreactor for this flowsheet and one of the six bioreactors with its associated 
downstream units was simulated using BioProcess Simulatorm. The simulation results 
for the flowsheet is presented in Table 4.5.1. 
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The overall recovery for this flowsheet was found to be 43.4% with a batch time of 215 
hours and a ha1 product punty of 99.9998%. In the dowmtream train longest time is 
taken to polish the product with gel filtration. To utilize the same sets of domsimm 
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equipment by the six bioreactors, the operation of the bioreactoa has to be scheduled so 
that there is no overlap in the usage of equipment. 
4.5.4. SCHEDULING 
Simulation results have shown that the bioreactor requirrs 200 hours to complete one 
batch compared to 15 hours to purify the product. Therefore, product h m  al1 the 
bioreactors will be ready for purification well before the purification of the broth from 
the first bioreactor is complete. This will cause a lineup in the purification section while 
the products from the other bioreactors in storage tanks await purification. This kind of 
operation has several disadvantages. First of dl, large volumes (at least 5000 L in this 
case) of expensive storage tanks will be required to maintain the broth in aseptic 
condition for a long tirne (60 hours for the sixth bioreactor). Possibilities of product 
degradation will be high in presence of protesses and other compounds in the stored 
unpurified broth. This type of operation will also increase the batch tirne significantly 
(275 hours in con- to 2 1 5 hours) to exceed the tirne pre-set in the design basis. 
An alternative approach would be to schedule the operation of the bioreactor so that 
there is no lineup for the downstream units. If the bioreactors are inoculated every five 
hours (or every four hours with an hour ailocated to cool d o m  the broth), the different 
units will be occupied for the time interval as shown in Figure 4.5.2. Al1 the membrane 
separation uilits (1,2,4 and 6) will be ready for the next batch well ahead of tirne. For the 
affinity chromatography columns, the cycle time s h o w  includes time for loading, 
washing and elution of the column. After that there wilî be about an hour and 45 minutes 
(1.7 hours) lefi to regenerate the first column (unit 3) for the next batch. This tirne should 
be nifncient to regenerate a single 85 L column. For the second chromatography 
O 5 10 15 20 25 30 35 40 45 50 55 60 65 70 
time (hour) 
Figure 4.5.2: Scheduling of the unit 
operation blocks 
1 O0 150 
time (hour) 
Figure 4.5.3: Scheduling of the Bioreactors 
I 
column (unit 5) there will be an hour and 30 minutes to regenerate the column, which 
again should be sufficient for a 30 L column. However, polishing (unit 7) of the first 
batch of product from the fht biomctor would not be complete when the second batch 
of product gets nady for gel filtration (Figure 4.5.3). There would be about 40 minutes 
left of the polishing step for the fint batch. There could be two solutions to this problem 
depending on the situation. An additional gel filtration column can be dded to the 
flowsheet so that the product fiom the second bioreactor can use the unoccupied column. 
Altematively if there is no nstriction on the batch tirne, the small volume (3.2 L in this 
case) of almost pure product fiom the ultrafiltration step can be stored and later purified 
using the sarne gel filtration colurnn. 
II III IV v 
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4.5.4: Flowsheet for first approach 
The second approach above would be considered under sensitivity (Section 4.5.7) as an 
alternative. If the first approach is adopted, the batch tirne will be 240 hours (21 5 +25). 
In laboratory, t-PA has been found to be stable for more than 350 hours in senun-fke 
medium and up to 250 hours in medium containing 5% fetal calf s e m  (FCS) @ y k g  et 
al., 1994). The flowsheet for this case is shown in Figure 4.5.4. 
Scheduling was simple for the above process where overlapping occurred in only one 
unit at the end of the process. For more complex situations, optimization packages such 
as GAMS/Minos (Brooke and Kendrick, 1992) can be used. SuperPro Designer@ 
(version 3.0) allows simulation of process steps to share equipment in batch recipes. This 
feature could be used to schedule the downstream section under more complicated cases 
of overlapping. The new Gantt charts of SuperPro Designer@ (v 4.0) (to be released in 
early 1999) would also lend itself for scheduling calculation of multiple batches 
(Petrides, 1 998). 
455. ECONOMIC EVALUATION 
The overall econornics of this process has k e n  summarized in Table 4.5.2. The revenue 
in this case is one fifth of that for the base case which requires five of the 6000 L 
bioreactors simulated. 
Table 4.5.2: Economic aaalysis of the process (in millions of dollars) 
Purchased Equipment Cost, C, 
FUted Capital, C, = (4.6XCA 
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Annual Operathg Cost, AOC 
Gross Pro& GP = (R-AOC) 
Net Profit, NP (40% tax) 
Net Cash Flow, (NP + Dep.) 
R e m  on Investment, ROI 
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Figure 45.5: Breakdown of equipment purchase 
cost 
The equipment purchase cost for this flowsheet is dominated (36.3%) by the cos  of six 
1000 L bioreacton followed by chromatography (18.3%) and gel filtration (15%) 
c o l u m ~  (Figure 4.5.5). The contribution of upstrram units, nich as inoculum bioreactors, 
air compmsors, filters, blending tank for media preparation etc. and other awiliary 
equipment such as purnps, heat exchangers, storage tanks etc. contribute by 21%. 
Process chernicals and media contribute by 41.6% to the annual operating cost (Figure 
4.5.6) whereas, labor costs account for 10%. Fermentation media for the six bioreactors is 
found to be the major contributor (79%) to the raw matenal c o a  Affinity and gel 
filtration columns contribute almost equally (1 0.4% each), whereas, contribution fiom the 
membrane separation units is negligible. A more practical approach to the calculation of 
the resources (Le. utilities, raw matenals, labor) for this multiple and overlapping batch 
process would be by using the new feature of version 4.0 of SuperPro Designer@ to be 
released in early 1999. This feature will allow elimination of resource bottienecks for 
mdtiple/overIapping batch processes by calculating resource demand (Petrides, 1998). 
The retum on investment (ROI) of the process is 137% with a gross margin (GM) of 
54%. 
4.5.6. COMPARISON WTH BASE CASE 
The multiple bioreactor case is a scaled down version of the base case where a single 
6000 L bioreactor out of the five bioreactors of the base case was further divideci into six 
1000 L bioreactors. The combined performance of the multiple bioreactors, is therefore, 
compared to the pedormance of a single bioreactor of the base case. 
The high ROI for the multiple bioreactor case resulted h m  swings in the equipment 
purchase COB The ability to share the same set of equipment by the six bioreacton 
resulted in the greatly reduced size of the dowmtream units. A cornparison of the 
contribution fiom the different sources of the equipment purchase cost shows that 
bioreactoa contribute by only 14% for single bioreactor case compareci to 36.3% for the 
multiple bioreactor case. The major contributors for the single bioreactor case are the 
chromatography columas (52%) which in the latter case contribute by about only 33.3%. 
Table 4.5.3: Com~arative Economic Analvsis (in millions of dollars) 
1 1 Multi~le Bioreactors 1 Sinde Bioreactor 1 
1 Purchased Equipment Cost, C, 1 1.63 1 2.84 1 
Fixed Capital, C, = (4.6XCA 
Total Capital, C, = (5.SXCa 
Revenue. R 
The contribution of labor costs to annual operating c o s  is doubled (10%) for the multiple 
bioreactor case. This is due to the extra labor required to operate and maintain the six 
bioreactors. It might be possible to schedule the labor in such a way so as to use the sarne 
force to maintain the different bioreactoa and achieve some savings fiom this source. 
The contribution fiom raw matenal was found to be similar for both the cases (about 
42%). Of the raw material, media accounts for about 79% for the multiple bioreactor case 
compared to 62% for the other. BufTers and resin for the affinity cbromatography 
columns of the base case accounts for twice as much as for the multiple bioreactor case 
(20%). Contribution from gel filtration is also higher for the base case (17.5%) compared 
to this case (1 0.45%)). 
Annual Operating Cost, AOC 
Gross Profit, GP = (R-AOC) 
Net Profit, NP (40% tax) 
Net Cash Flow, (NP + Dep.) 
Retum on Investment, ROI 
Gross Margin, GM = (GPR) 
The multiple bioreactor case would require more fiequent replacement of the 
chromatographie resins and membranes since it carries out six times the cycles with the 
columns and six times longer operation with the membranes. A sensitivity study to the 
replacement fkquency (Section 4.1.6) was camed out for the base case where it was 



















place every five years instead of every year. Therefore, even with the much higher (five 
times) replacement frequency, the ROI of the multiple case would remain high enough 
compared to the base case. 
An alternative to the two-gel filtration column flowsheet show in Figure 4.5.4 was 
outlined in Section 4.5.4. According to this alternate approach, retentate fiom the fuial 
ultraNtration unit has to be stored until the column becomes available for processing the 
broth fiom the successive bioreactors. The retentate fiom the second bioreactor has to be 
stored for 0.65 hour and therefore the retentate fiom the last bioreactor has to be stored 
for a total of 3.25 hours. This will increase the batch t h e  by the same amount and for 
350 operating days per year, the number of batches that can be carried out will be 34 
instead of 35 (Section 3.5). The completion of an additional batch would require 5 more 
days of operation with this flowsheet. 
The flowsheet for this process is shown in Figure 4.5.7. The economy of the process 
under this situation have k e n  summarized in Table 4.5.4, 
Table 4.5.4: Economic analysis of the alternative flowsheet for the 
multiple bioreactor process (in millions of dollars) 
- - - .  
1 R e m  on investment. ROI 1 1 144% 1 
Purchased Equipment Cost, C, 
Fixed Capital, C, = (4.6 X C d  
Total Capital, C, = (5.5 X C d  
Revenue, R 
' Annual Operating Cost, AOC 
Gros Profit, GP = (R-AOC) 
Net Profit, NP (40% tax) 
Net Cash Flow, (NP + Dm-)
Replacement of one of the gel filtration column by a storage tank in the alteniate 











cost accounting for bufFer for one of the columns and its media replacement, teduces the 
annual operating cost by 0.6 million dollars. The revenue on the other hand is also lower 
for this case since the longer batch t h e  does not allow the 35 batches set in the original 
design basis. The overall effect is 5% improvement of the ROI of the process with almost 
unchanged gross margin. 
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at, t = 5.65 h 
t =  11.3h 
t = 16.95 h 
t = 22.6 h 
Storage Tiie: 
n: t = 0.65 h 
III: t =  1.3 h 
IV: t = 1.95 h 
V: t = 2.6 h 
VI: t = 3 Z  h 
t = 28.25 h 
Figure 4.5.7: Fiowsheet for alternate approach 
Therefore, if storing the product for a maximum of up to 3.25 hours before gel filtration 
does not resuit in any deleterious effect, this flowsheet becomes aa attractive alternative 
to the fîrst case. 
4.6. Summary of Results 
The simulation results for the flowsheets and results of economic evaluation are 
summarized in this section so that they can be easily compared. 
4.6.1. Flowsheet Simulation 
The following tables compare the size of the wlividual unit opefation blocks in the 
flowsheeb recoveries therein and batch t h e .  The overail recovery for al1 the flowsheets 
are found to be above the assumed value of 40% and the total batch tirne, less than that 
(1 0 days or 240 houn) specified in the design basis (Section 3.5). 
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Table 4.6.4: Purity in the chromatography columns in the dowastrram train 
1 Units 1 Base 1 Two Stage 1 Fed- 1 Fed- 1 Airlift 1 Multiple 1 
flowsheets 




















































































































4.6.2. Economic Evaluation 
The economic performances of the simulated flowsheets are summarized in this section. 
"Budget authorhion" grade estimates of the total capital investment (CTa for the 
processes were obtained by multiplying the total equipment purchase cost ( C a  by 
appropriate con factor. This estimate was considered satisfactory for cornparison 
purposes. Calculation of annual operating cost (AOC) is explained in Appendix C. The 
overall economics of the process was measured in terms of retum on investment (ROI), 
defined as the ration of (net profit d e r  tax + depreciation) to totd capital investment and 
Gross Margin (GM), defmed as the ratio of pretax profit to annual product sales. Table 
4.6.5 summarizes the economic perfomance of the simulated flowsheets. 










From the table, it is observed that ail the alternate flowsheets have higher ROI than the 
base case. ROI of the process marguiaiiy increases by replacement of the stïrred tank 
bioreactor of the base case with an airiift type. This increase resuîts h m  the lower 
purchase cost of the airlift bioreactor compared to a stirred tank reactor because of the 
simplicity of construction of the former. Two-stage ceii culture process increases the ROI 
of the base case by 77% partiaily due to replacement of the expensive aff?nity 
chromatography columns in the downstrearn train by ion-exchange columns. ROI 































increased most significantly by switching h m  batch to fed-batch mode of operation. 
1 12% increase in ROI is observed for fed-batch case (A) where the product concentration 
is four times of that for the batch process (base case). Highest ROI is calculated for case 
(B) of fed-batch process with eight times the product concentration. The multiple 
bioreactor case is also found to be a very attractive alternative to the base case. Since 
downstrearn processing accounts for about 70 to 80% of the overall production cost for 
biotherapeutics, using an economically sized single purification train for this process 
brought about the huge increase in ROI. 
The contribution fiom fermentation and recovery equipment to total capital investment 
was found to differ depending on the process (Figure 4.6.1 .(a) and 4.6.1 .fi)). 
Fermentation equipment were found to be the major contributors for the two stage ce11 
culture process, that uses separate bioreactoa for growth and production, and multiple 
bioreactor case, with the largest contribution made by the latter (36%). Largest 
contribution (95%) by recovery equipment to total equipment purchase cost was observed 
for fed-batch case (A), followed by airlift bioreactor and fed-batch case (B), for which 
cases the hctions contributed (88%) were very close. Contribution by raw material and 
media coa to the annual operating cost was found to be the most significant for ail the 
flowsheets simulated. As observed for the total equipment purchase cost, contribution 
fiom fermentation media were much higher for the two stage ce11 culture process and 
multiple bioreactor case, compared to raw materials for recovery section (Figure 4.6.2. 
(a)). However, in this case, contribution for the two-stage ce11 culture process was larger 
than the multiple bioreactor case. For the raw materials associated with recovery units, 
contribution was highest (70%) for the fed-batch case (A), as expected, followed by fed- 
batch (B) (Figure 4.6.2. @)). 
Batch Two Stage Fed Batch A Fed Batch B Airiii Muitipie 
Figure 4.6.1 .(a): Comparison of Equipment Purchase Cost 
(Fermentation) 
Batch TM Stage Fed Batch A Fed Batch B AiKi Multiple 
Figure 4.6.1 .(b): Corn parison of Equipment Purchase Cost 
(Recovery) 
Batch Two Stage Fed Batch A Fed Batch B Mulüple 
Figure 4.6.2.(a): Cornparison of Raw Material Cost 
(Fermentation) 
Batch Two Stage Feâ Batch A Fed Batch B Multiple 
Figure 4.6.2.(b): Comparison of Raw Material Cost 
(Recovery) 
This chapta presents nsults of sensitbity study of the simuiated processes to uncertain 
paranicttrs and variabîes. This paraineeic sensitivity study was camtd out using BPS. 
Som uncertainty was also involveû in the calculation of overail economics of the 
processes. In the second part of this chapter, seasitivity of o v d  economics, m e d  in
terms of ROI, to uncenain quatities in its caicuiation an prcsented. 
5.1. UNIT OPERATlON BLOCKS 
The paramters and operating variables used to simulate the unit operation biocks were 
mostly obtained h m  iitcraturc. For all the cases a range of values rathcr than a nxcd 
numkr was obtained and in some cases estimates wcn used due to lack of knowltdge. 
Om of the advantagts of designhg a proccss using BPS is that it &ws snidy of 
scDstivity of a Simulated process to unceriam paramctm. The flowskt anal@ f é a m  
of BPS abws Whiany ail th variables and paramtas of the models to be snidied that 
are sptcincd as input, This katurc of BPS was utiiized in the following sections to 
idtntify the critical paranmers of the -nt unit operation b k k s  and to &termine to 
what extent process performance will be afTected due to masonable variation in the value 
of the panuneter. In this study, ody  those parameters were selected that are relevant to 
the specific mode1 chosen for each block. The parameters were varied over a range o f f  
50% where a range could not be found fiorn literature. AI1 the sensitivity study was 
carried out for the unit operation blocks of the base case (Section 4.1). 
5.1.1. Bioreactor 
The parameters and variables allowed to vaiy for sensitivity study of this mode1 are: 
1. Oxygen Transfer: minimum dissolved oxygen, maximum VVM, minimum k,a, h a 1  
dissolved oxygen, initial oxygen saturation, dissolved oxygen conceneation, percent of 
dissolved oxygen etc. 
2. Agitation: power, maximum agitation power, power by volume, driver efficiency, 
length of impellers, nurnber of impellers, rotational speed, impeller diameter, impeller 
width, number of blades, nurnbet of baffles, baffle width etc. 
3. Reaction rate: nitrogenhh usage, C, H, O, N imbalance, substrate, carbon dioxide, 
oxygen, hydrogen and nitrogen source utilization rate, mumax, K, K, K, etc. 
4. Geometry: maximum volume, final volume, bioreactor diameter. 
5. Heat Transfêr: cooling duty, coolant temperature, heat transfer coefficient, heat 
transfer area. 
6. Inocdum: concentration, volume, volume charge. 
7. Time: cycle time, batch time, idle tirne, dom tirne. 
The variables studied for the bioreactor are biomass/substrate/N source rate and 
biomasshbstrate concentration by varying the following pararneters and variables: 
Table 5.1.1. Variables studied for sensitivity of the bioreactor block 
Varied Variables 
Inoculum Concentration 
Sensitivity study for the bioreactor was not very informative. The results showed changes 
that occur at the initial conditions or at a certain point of the fermentation cycle. With 




Minimum Oxygen Level 
Kinetic Parameters 
Inoculum Concentration: The inocuium concentration was v&ed between 3 ~ 1 0 ' ~  
and 8X1W2 gm/L. In BPS the available unit for ce11 concentration is mass concentration 
(e.g. mg/L, gmR. etc.). The achial inocuium concentration in cells/ml for mammalian ce11 
was therefore, converted to mass concentration for simulation by assuming that the 
weight of 3.8X109 cells is equal to one gram (Zeng and Deckwer, 1995). Variation in the 
inocuium concentration had signifiant effect on the growth rate and concentration of the 
biomass (Appendix F). 43% reduction in inoculum concentration brought about similar 
magnitude of reduction in biomass production rate and biomass concentration. 
Suggested Range 
1 X 1 Os - 2 ~ 1  Os cells/ml 
Inoculum Volume: n i e  inoculum usually constitute between 5025% of the working 
volume of the bioreactor (Chisti, 1992). The inoculum volume was varied between 500 L 
(8.3%) to 1500 L (25%) for sensitivity snidy. The result of variation in inoculum volume 
was similar to inoculum concentration. However, in this case the substnite (glucose) 
concentration was also aected. 50% reduction in inoculum voiume increased the 
substrate concentration by 9%. 
Re ference 
I 




Chisti, (1 992) - 
Hansen and Emborg. 
(1 994) 
- 
Volume Charge: The volume charge or the batch charge to the bioreactor was varied 
between 2000 L to 5000 L. 20% reduction in charge volume resulted in an equal amount 
of reduction in both glucose and glutamine collsumption rate, since according to the 
supplied kinetics (Appendix G) these rates are dependent on the initial concentration of 
the substrates. The reduced consumption rate increased glucose concentration by 4%. Due 
to concentration effect at smailer volume, biomass growth rate increased slightly while 
the ce11 concentration increased by 20%. 
Minimum Oxygen Level: The minimum dissolved oxygen level required in the 
bioreactor was specified as a hction of solubility at the fermentation temperature of 
37°C. The bioreactor model, BFERM was supposed to calculate the minimum air flow 
rate required to keep the dissolved oxygen concentration above this level. At 37'C. the 
soiubility of oxygen is found to be 0.195 m o l  Of i  Pailey and Ollis, 1986). The 
dissolved oxygen concentration maintained in the labonitory scde bioreactors (2 litres) 
for CHO ce11 culture is found to be between 40% and 60% (Hansen and Emborg, 1994; 
Kurano et al., IWO, Lakhotia et al.. 1992). The oxygen concentration therefore, should be 
between 0.078 and 0.1 17 mm01 OJL. However, it was found that the simulation of the 
bioreactor does not converge at oxygen concentrations even as high as 0.715 mm01 OJL. 
The input file, that simulates the bioreactor successfully, was only modified by changhg 
the oxygen flowrate to reduce the dissolved oxygen level h m  6.4 mm01 OJL. The 
simulation would not converge after this single modification. The sensitivity study by 
varying the minimum oxygen level in the bioreactor, therefore had no efféct on the 
dissolved oxygen percentage which was at 100% (Appendix F). 
K,a: For reasons aiready explained in the previous section, sensitivity study with &a 
had no effect on the related variables ofthe bioreactor (Appendix F). 
f i e t i c  Parameten: Among the kinetic parameters, the preferential substrate 
utilkation constant (Gd, specific death rate Oh) and specific growth rate (u were 
varied. The simulator was able to vary the user defined kinetic panuneters and the 
response to sensitivity study was deterrnined by the kinetics supplied to the simulator as 
subroutine. 80% increase in GS resulted in 23% reduction in glucose uptake rate, which in 
tum increased the glucose concentration by 38%. Biomass growth rate fell by 18% and 
the ce11 concentration by 13% when the specific death rate became 3.5 times the base 
value (1.0 X 1 p  NI). A 25% increase in the specific growth rate over the base value on 
the other hanci, increased the biomass growth rate by 120% and the ce11 concentration by 
75%. 
5.13. Membrane Separaton 
The parameters and variables of the membrane separator mode1 that can be varied for 
sensitivity study are the following: 
1. Membrane (circular type): total membrane area, fiber or tube length, fiber or tube 
diameter, nurnber of channels in parallel, nurnber of cartridges in series, membrane 
resistance. 
2. Pressure: pump pressure, permeate side pressure, retentate pressure, retentate pressure 
&op. 
3. Pump: pump efficiency, drive efficiency, pump horse power, electric home power. 
4. Cooler: temperature at cwler outlet, cooler duty, maximum duty. 
5. Physical Property: viscosity, diffusivity, density. 
6. Flow: fiction factor, setpoint velocity, Reynolds number, Reynolds number for 
transition fiom laminar to turbulent region, Schmidt nurnber. 
7. Operation: ~jection coefficient of key component, rejection coefficients for other 
components, hction of key component denatureâ, volume ratio (concentration factor), 
gel-resistance, exponents on tmsmembnine pressure, Reynolds number and key 
component concentration in the equation for gel mistance calculation Crr,=b(Py (Re)b 
(CJ), gel resistance parameter R O )  and decay coefficient (K) in the fouling equation (J 
= JO X e -9 .  
8. Tank: temperature and pressure in tank, initial and maximum tank volume, retentate 
concentration in tank. 
Of the above parameters and variables the following were studied for sensitivity shidy of 
the microfilter block: 
Table 5.1.2. Variables studied for sensitivity of the microfilter block 
Varied Variables 
Setpoint Velocity 










0.8 - 1 .O 
1% to 5% 
1 to 1.65 cp 
0.55 to 4.7X107 ?/cm2 
3.51- 1 .53~10~  Pa-sh 
0.746 and 0.692 
-0.77 
0.18 and 02 
Reference 
Cheryan, (1986) 
Lee, (1989); Wood, (1988) 




Tamer (1 995) 
Setpoint Velocity: The setpoint velocity through the tube of the membrane was 
varied between 0.8 m/3 and 2.4 m/s which represents a range of 50% to 150% of the 
velocity (1.6 m/s) defhed for the design case. A 50% reduction in the velocity resdted in 
10% reduction of the permeate flux (Figure 5.1.1) and 45% reduction of the volume ratio 
(feed volume/retentate volume) or in 0 t h  words the volume of the retentate incnased by 
80% over the design case. The fiaction of key component (CHO cells) retained by the 
membrane, as a result, increased and this inmased the gel resistance by 50% due to the 
dependence of gel resistance on Reynolds number and key component concentration, C, 
(R,=qO(AP)' (CJ). The shear rate, however, remained d e c t e d  by variation in 
set point velocity. The model for microfiltration uses an average velocity through the unit 
for calcuiation of shear rate, which may not have changed significantly within the range 
employed for sensitivity study to affect the shear rate. 
Key Component Rejection: Rejection coefficient (r) for the key component was set 
to 1 .O for the design case. For sensitivity study, this coefficient was varied baween 80% 
and 100% of the value. At r = 0.8, the volume ratio increased by 40% (or the volume of 
the retentate becarne 70% of the design case) and the gel resistance improved (decreased) 
by 16% over the design case. 
Denaturation Fraction: The optionai feature of MEMBRANE model was used to 
study the effect of including a pmtein denaturation fiaction for t-PA in the simulation. 
Surprisingiy enough, no effect was observed on the material balance of t-PA by inclusion 
of the hction protein denatured. The key component concentration also remained 
unaffected (Appendk F). 
Viscosity: Sensitivity study was used to explore the effect of changing viscosity due 
to incrrased protein concentration during filtration. The upper l h i t  of viscosity was 
chosen as the highest value observed in simulation, which was around 1.65 cP. At the 
upper b i t ,  pexxneate flow reduced to about 48% of the value observed for a viscosity of 
IcP (Figure 5.1.1) and the shear rate (y = APr/2Lp) varïed between 3.93X107 hr " to 
1 S ~ X I  O' hr -' between the viscosities of 0.8 cP and 2.0 cP. Since the range of shear rate 
observed with hollow fiber membranes covas 1.44X 1 O' hr '' to s.O~X 1O' hr -' (Cheryan, 
1986), the operation of the simulated membranes were within the range. 
Membrane Reshtance: A wide range of membrane resistance is observed for hollow 
fiber membranes depending on the material of construction. The materials that have been 
used for micro and ultra filtration membranes are maidy polymers such as polysulfone, 
cellulose acetate, cellulose nitrate, polyamide, polypropylene, acrylonitrile copolymer, 
nitrocellulose etc. Depending on the matenal, these membranes differ in thermal 
resistance, operating pH range, resistance to sanitizing chernicals etc. The range of 
membrane resistance reportecl by Cheryan (1 986) for hollow fiber membranes is found to 
Vary by an order of magnitude. For sensitivity study the base case resistance was varied 
between 10 times and 0.1 times of the design case resistance (2.0 X 10" m'l or 0.5 1 X 10' 
s2/cm3. Ten fold increase in the membrane resistance reduced the permeate flux to 12.5% 
of its base case value. A similar decline was observed in the volume ratio (feed 
volumehetentate volume) resulting fiom higher retentate volume due to reduced penneate 
flux. A 3-fold increase reduced the pemeate flux to 42.5% of the base case value. 
O 0.5 1 1.5 2 2.5 3 
Relative values of vanables and parameters 
Figure 5.1.1 : Sensitivity study for 
microfiltration 
Rgelo: Rgelo is a parameter in the gel resistance equation R, = R&îP)' (Re)b (CJ. 
The value of this parameter was assumed to be 4.5 X10" m-' for the base case. For this 
valw the gel resistance was found to be S.42X1010 m". Rgelo was v d e d  between l x  10" 
and 9x10'~ m.'. An 80% reduction in Rgelo reduced the gel resistance by 50% and this 
increased permeate flux by about 12% (Figure 5.1.1). A 100% increase in Rgelo 
increased the gel resistance by 72% and reduced permeate flw by 13%. The value 
assumed for Rgelo in the base case is a bit higher than that reported for E. coli (Lee, 
1989). The combined mistance from gel aud membrane (2.54X101' mal), however, was 
found to be of similar magnitude (6.6X10t' mm') as reported by Reis et al. (1991) for t-PA 
containing broth. 
a: The dependence of gel resistance on transmembrane pressure is described by the 
equation R, = &(LW)' (Re)b (CJ. The values obtained for the exponent 'a' fiom 
literahve are 0.746 and 0.692 for filtration of E. coli (Lee, 1989). In absence of an 
estimate for CHO ce11 or t-PA, a value of 0.7 was used in the simulation. This value, 
however, was reported for the case where pressure was measured in kPa. For simulation, 
this value had to be converted to pressure units of Nlm2, the unit used by BPS for this 
particular variable. The converted value (0.13) was varied between 0.05 and 0.2 for 
sensitivity study. A 50% increase in 'a' brought about a sirnilar scale of incrwise in the 
gel resistance and permeate flux was reduced to 90% of its base value (Figure 5.1.1). 
b: The exponent 'b' relates the dependence of gel resistance on Reynolds Number in 
the equation &= R&îP)' (Re)b (CJ. The value of exponent 'b' obtained fiom literature 
for filtration of E. coli is -0.77 (Tamer, 1995). Since an estimate could not be found for 
CHO celi or t-P& a sensitivity study was d e d  out by varying 'b' between -0.5 and - 
0.85. Simulation did not converge o v a  the f 50% range initiaily intended The gel 
resistance was found to be very sensitive to the value of 'b'. At the upper k t  of -0.85, 
which represents a 10% increase, gel resistance was reduced to 70% of its base value. 
c: The exponent 'c' relates the dependence of gel resistance on key compownt 
concentration in the equaîion \=R&P)' (Re)b (CZ. The values obtained for exponent 
'c' fiom literature are 0.18 (Lee, 1989) and 0.20 (Wood, 198%) again for filtration of E. 
d i .  In absence of an estimate for CHO ce11 or t-PA, a value of 0.2 was used in the 
simulation. For sensitivity study this value was varied between 0.1 and 0.3 with a step 
size of 0.05. The process was found to be relatively insensitive to variations in 'c'. 
For the ultrafiltration block, the batch model for membrane separation BMEMBRANE 
was employed. This model has a holàhg tank for the batch charge where continuous 
feeds (e.g. diafiltration strearn) if present, are added, and part of the retentate recycled. It 
is necessary to recirculate the retentate in order to maintain a signifïcantiy higher flow 
rate of the process feed than permeate. High velocity paralle1 to the filtration surface 
prevents accumulation of the retained components on the surface. The following variables 
and parameters were studied for sensitivity of this block. 
Table 5.1.3. Variables sniàied for sensitivity of the ultrafilter block 
Decay Coefficient: Decay coefficient (K) is a parameter in the fouling model J = JO 
X e'" proposed by Shepard and Thomas (1970), where JO is the initial flw before 
fouling. In batch ultrafiltration and microfiltration, typical flux-time data show a steady 
decline in flux. Part of this decline is attniuted to an increase in viscosity but part is due 
to fouling of the membrane pores. Fouüng is caused by the deposition and accumulation 
of submicron particle on the membrane d a c e  andlor the crystallization and 
precipitation of solutes on the surface and within the membrane pores. Fouling is a t h e  
dependent phenornenon and is also partiaüy concentration dependent. Fouling of 
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pretreatment of feed and adjustment of operating conditions such as feed velocity and 
pressure etc. Fouled membranes can be cleaned by either physical meam (e.g. water 
rinsing, gas-liquid cleaning, electric vibration etc.) or chemical means (treatment with 
detergents, alkali, acids, oxidants etc.). 
Three stages of flux decline have been identified by Fane and Radovich (1986) for the 
lifetirne of an ultrafiltration membrane. Stage 1 is associated with solvent (water)-flux 
decline, where low concentrations of contaminants, dust, bacteria etc. obstruct the largest 
pores of the membrane. The second stage is due to concentration polabtion and 
initiation of fouling. Stage III is the period when solute molecules bhd to the membrane 
fomiing a deposit that results in irreversible flux decline. BPS has three built-in models 
for fouling. The above model was chosen for this simulation because it is easy to obtain 
an estimate of the fouling coefficient (K) for this model although this model is a 
simplistic representation of a complex phenornenon 
J (flux) vernis t (time) data is generated by the BMEMBRANE model of BPS and an 
estimate of decay coefficient (K) was obtained by simply plotting ln J versus t For the 
ultrafdten of the base case, K was found to Vary between 0.12 to 0.64 hr ". Sensitivity 
study revealed that about 70% variation in K changed the flux by about 6% only. 
Reeyele Ratio: Both the batch and continuous models for membrane separation units 
in BPS has a recycle stream that recycles a portion of the retentate. This is necessary to 
maintain a high liquid velocity parallel to the filtration surface that prevents accumulation 
of retained components. Recycle ratio of 15 was specified for the design case. 33% 
increase in this value had insignificant effect on tank volume and tank concentration. 
However, friction factor, f went d o m  by 43% and power of the recycle pump increased 
by about 45%. Permeate flux was found to incrrase by about 10Y0. 
Pump Capacity: lncrrased pump capacity reduces the filtration time for batch ulea 
and micro filtration blocks. The capacity of the recycle pump was varied over a range of 
75% to 150% of the base value of 100 Lhr. A 50% increase in the pump capacity 
increased pump power by about the same magnitude as expected. This variation in pump 
capacity reduced the tank volume by 15% and increased pemeate flux by about 22%. 
The reduced tank volume incnased the concentration of the key component in the tank by 
15%. 
5.13. Affmity Chromatography 
The variables and parameters of the mode1 which are ailowed ta Vary for sensitivity study 
are the following: 
1. Column: length and diameter, total volume, number of column and void fiaction. 
2. Resin: diameter, porosity, tortuosity. 
3. Rate theory parameters: difhivity, mass tramfer coefficient, capacity, isothenn 
adsorption constant kload. 
4. Operation: cycle t h e ,  superficial velocity, linear velocity, pressure &op, regeneration 
time, volume, concentration, molarity and pH of eluant etc. 
The foliowing parameters and variables were studied for this block: 
Table 5.1.4. Variables studied for sensitivity of the affbity chromatography block 
1 Varied Variables 1 Suggested Range 1 Reference 1 
Capacity 
Kload 
Capacity: Lysine Sepharose 4B has been used in laboratory sale purification (E* uiarsson 
et ai., 1985; Dodd et al., 1986) of t-PA among other aff?nity ligands (Table 22.4). Clonis 
(1990) pointed out that Lysine Sepharose 4B found application in the above process 
because of its biospecificity for t-PA. The major chromatographie material supplier 
Pharmacia lists only Lysine Sephamse 4B as a ligand for plasninogen and quotes a 
M.6 mg plasminogdmi gel 
1 62X 1 d cm3/a 
Pharmacia LKB Biotechnology 
Arnold et ai. (1989 
capacity of >0.6 mg plasmlliogen/ml gel. Since plasminogen advator functions by 
binding to plasminogen (Figure 2.2.2) and the binding efficiency has to be less than 
100%, a conservative estimate of 0.5 mg plasminogen activator/ml gel was assumed in dl 
the simulations. However, since the achial capacity of the ligand is not known, in the 
sensitivity study carried out, the capacity was varied over a range of 50% to 150% of the 
design case capacity. A strong dependence of recovery in the a t y  chromatography 
column was observed on the capacity of the ligand for t-PA. 60% reduction in the 
capacity over the design case reduced the recovery in the column by about 63%. The 
purity also went down by 0.2%, which is significant since the purity level dealt with in 
the column is greater than 99.9%. A 20% i n c m e  multed in 17% higher recovery. This 
result has significant impact on the overall economics (ROI) of the process. 20% increase 
in the capacity will increase the overall recovery of the process fiom 40% to 47%. This 
will improve the ROI of the process by 28% as shown in Figure 5.1.2. 
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capacity 
Figure 5.1.2: Sensitivity of ROI to capacity of affinity 
ligand 
0.5 O.? 0.9 1.1 1.3 1.5 
kload 
Figure 5.1.3: Sensitivity of ROI to kload (Langmuir 
isotherm constant) 
Kload: kload is the equilibriurn constant at load conditions for the Langmuir 
isothm. The only value of kload reported in the literature for a similar system is 
162x1 d cm3/g for anti-benzenearsonate monoclonai antibody on Sepharose 4B (Arnold 
et al., 1985). In base case this value for t-PA on Lysine Sepharose 4B was asmmed to be 
120 cm3/g . For sensitivity study a range of 75 cm3/g to 175 cm3/g was investigated. 45% 
increase in kload improved the recovery in the column by 14% over the base case. 
Therefore the column perfomance is also sensitive to kload. However, the response was 
not as signifiant as the change in capacity of the ligand (Figure 5.1.3). 
Cycle: Mity adsorbents lose their initial capacity with increasing number of cycles 
with the column. Hamman and Calton (1985) proposed the following equation that 
accounts for the loss of capacity of affuiity adsorbents: 
Total Protein lsolated = Co Il - e 4.693*1Rl 
[l - e 4.*3'n'" 1 
where, C, is the capacity of first cycle, n is the number of cycles and n,, is the nurnber of 
cycles at which the column capacity is one-half the initiai capacity. For n,, = 8, Figure 
5.1.4 shows how the column capacity decrease with increasing number of cycles (n). 
Cycle haif-life (nid can Vary over a wide range for affinity adsorbents. It is usually found 
to be a fûnction of the method w d  to immobilize the adsorbent on to the ma- the 
reagents w d  to elute the adsorbeci species and bufTers to wash and regenerate the 
column, proteolytic and denaturing agents in the process stream and thermal denahiration 
with time (Hamman and Calton, 1985). Figure 5.1.5 shows the total amount of protein 
p d e d  as a h c t i o n  of wlife for n = 2 X n, 
O 
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number of cycles 
Figure 5.1.4: Loss of capacity with number of 
cycles 
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han-Me 
Figure 5.1.5: Protein purified as a function of 
cycle half-life 
5.1.4. Ion-Exchange Chromatography 
The parameters and variables allowed to vary by BPS for the ion-exchange 
chromatography model are the same as for the aflhity chromatography column except for 
the resin. The panuneters allowed to Vary for the min in this case are specific d a c e  
area, total ionic capacity, charge and charge slope. 
The following table lists the parameters studied for the ion-exchange block. 
Table 5.1 .S. Variables studied for sensitivity of the ion exchange block 
Varied Variable 
Specific Surface Area 











Aspen Plus, User's Guide (1995) 
Pharmacia LKB Biotechnology (1 99OB 1) 
Appendix H (Scharer, 1996) 
Specific Surface Area: For specific surface area, a value of 1 cm2/cm3 was used in 
the simulation of the ion-exchange colurnn. In BPS this is defined as the ratio of the total 
internai and extemal surface area of the adsorbent to column volume. This vaiue was 
obtained fiom the example problem for the same model included in the BPS m m d  
(Aspen Plus, Release 9.2). Since estimate of this parameter for the particular resin (SP 
Sephadex) could not be found h m  any other source, a sensitivity midy was canied out 
by varyhg specific d a c e  area over a range of 3 to 0.05 cm2/cm3. Variation in the value 
of the specinc d a c e  area was found to have no effect on the recovery, purity end point 
concentration (at a specinc point in the elution curve) of t-PA in the column (Appendix 
F). Specific d i e  area is most probably used to get an estirnate of d a c e  potential 
(wJ, which is required to calculate the equilibrium constant (Y) for this model. 
Total Ionie Capacity: The total ionic capacity for SP Sephadex has been quoted 
between 2.0 to 2.6 mmoVg by Phamiacia LKB Biotechnology (Catalogue, l99O/9 1). The 
capacity quoted in manufacturer's catalogue (usually expresseci in terms of density of 
charged groups per unit weight of the medium), is not necessarily an indicator of the 
protein binding capacity. Only a s d l  proportion of this capacity may be actuaiiy 
accessible to the protein depending on the hydrodynamic size of the protein and the 
support pore diameter (Chisti and Moo-Young, 1990). In BPS model, this quantity is 
defined as total ionic capacity of adsorbent per unit column volume, in units of kmol/m3. 
A value of 1.3 kmoVm3 was used for total ionic capacity in the simulation, which was 
calculated aîsuming a voidage of 60%. Again no effkct of this parameter was observed on 
recovery, purity and point concentration of t-PA with sensitivity study (Appendix F). 
Instead, the solute capacity was found to be a critical parameta for the model. 
Solute Capacity: No estimate was found in the literature for adsorption isotherm 
constants for t-PA and SP Sephadex system. Loading capacity is found to Vary with ionic 
strength and pH of solution because these panuneters affect the dimensions of the 
hydrophillic, porous support media Yamamoto et al. (1988) List protein adsorption 
capacity for some anionic exchangers which were found to lie between 22 to 116 rng/ml 
and Vary significantiy depending on pH. The total capacity reported for BSA (127 mghl  
Sephadex A50 and 12 mg/& DEAE Sepharose) were found to m e r  largely dependhg 
on the resins (Oraham et al., 1987). A conservative estimate of 7 m g / d  was used in the 
simulation for t-PA. Mute capacity, which is a panuneter in the multi-component 
Langmuir equilibrium isotherm model, was found to be a critical parameter in 
detennining the recovery in the column. The base capacity was varied between a range of 
k 50% for sensitivity study. A 50% change in the solute capacity resulted in about 17% 
decrease in the recovery of t-PA in the ion-exchange column. Therefore, as already 
observed for the afbity chromatography column, the performance of the ion-exchange 
column is also found to be very sensitive to solute capacity. 
Kload: Unlike solute capacity the other isotherm parameter, kload, was found to 
create no effect on the recovery, purity or point concentration in the columa For kload, a 
value of 45 m'kg for t-PA was used in the simulation. This value has been reporteci as 
33g/mg Sephadex A50 and 35 g/mg DEAE Sepharose for BSA. For sensitivity study, 
kload for t-PA was vaned between 5 and 100 m'/kg (Appendix F). 
Charge: An estimate for charge on t-PA molecule at pH 5 was obtained following the 
rnethod recommended by Scharer (1996) (Appendix Fi). For BSA, the operating pH of 
the column is very close to its isoelectnc point and therefore, an estimate of -0.8 was 
used. However, the charges on these molecules are very sensitive to the ionic strength of 
the solution and therefore a sensitivity study was performed. The recovery in the column 
was found to be reasonably sensitive to the charge on t-PA molecule. A 50% decrease 
reduced the recovery by 7% whereas a 50% increase in the charge increased the recovery 
by oniy 3.5%. 
5.1.5. Gel Chromatography 
For this model the panuneters and variables for sensitivity study are: 
1. Column: length and diameter, total volume, void volume and column voidage. 
2. Gel: diameter, pomsity and void fiaction. 
3. Plate theory parameters: HETP, A, B, C, V, KA", N, Lambda, 2, alpha and beta. 
4. Operation: superficial velocity, linear velocity, pressure drop, cycle the, load 
volume, cycle volume and flow rate. 
The parameters and variables studied for this model are the foliowing: 





1 % to 10% of column 
volume 
Length: Resolution of gel filtration column is a bc t ion  of column length among 
other variables. On a process scale, individual colurnns of up to 1 meter in length are 
feasible with modem gels that have some ngidity (Bomerjea and Terras, 1994). In these 
cases, the diameter (to about 20 cm) and linear flow velocities are restricted to avoid 
compression of the gel bed. If a greater column length is requkd in order to achieve the 
necessary resolution, or a wider diameter column is necessary to obtain a high 
throughput, colurnns co~ec ted  in series (stacked colurnns) are used. For sensitivity study 
column lengths between 0.2 to 1 meter were considered. Resolution droppcd by 63% at a 
column length of 0.2 m (Figure 5.1.6). which is about 27% of the length (0.75m) for the 
design case. For the other extreme (Le. 1 m), resolution increased by 22% and the 
pressure drop became about 0.4 atm compared to 0.3 atm for the design case. 
Wheelwright, 199 1 ; Bonnerjea and 
Terras, 1994 
3-30 cm/h 
Load Volume: Load volume is another variable that dictates molution of a gel 
filtration column. The load volume or the ratio of sample volume to column volume is 
usually between 1 to 5% for gel filtration columns (Wheelwright, 1991)- For impUnties of 
largely differing molecdar weights, the sample volume can be increased up to 10% of the 
c o h ~  vohme (Bomerjea and Terras, 1994). At 2% load volume, the resolution is 
found to improve by 32% and for the upper limit of IO%, it cirops to 33% of the 
resolution for the b a ~  case (load volume of 5%) (Figure 5.1 -6). 
Bomerjea and 'ïems, 1994 
Flow Rate: The resolution of gel filtration column is also a fiuiction of flow rate. The 
recomrnended flow velocity for gel filtration column is within 3-30 c d  (Bonnejea and 
Terras, 1994). According to Wheelwright (1991), the optimal fiowrate for maximum 
resolution is approximately 2 dcm2-h. Sofer (1986) maintained a velocity of 13cdh for 
large-scale gel filtration of insulin in a 96L c o l u r ~ .  The flowrate for this simulation was 
assurned to be 16 cmh. For the sirnulated gel filtration column (50 cm diameter), this 
flow velocity corresponds to 32 M. The range for sensitivity study was between 7.5L/h 
to 75 LI'. Towards the lower Iimit, resolution is found to improve by about 38% over the 
design case and it drops by 17% as the 80w rate is increased to reach the upper limit 
(Figure 5.1.6). However, at the Iower bound the t h e  required for filtration becomes too 
large. 36.6 hours of gel filtration tirne is required at the flow rate of 6.0 Wh which is 5.3 
times of the cycle time (6.9 hour) for the design case. 
I + load volume + length 
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Relative values of variables 
Figure 5.1.6: Sensitivity study for gel filtration 
column 
Sensitivity Study of Combineci Variables: 
BPS allows a combination of maximum five variables or parameters for sensitivity study. 
This feature of BPS was utiiized to study the combined effect of the variables on the 
resolution of the gel filtration column. The following table nimmarizes the effect 
obsemed with the variables set at values resdting in poorest resolution. 
Table 5.1.7. Combined effect of the variables of the gel filtration column on resolution 
Length 1 Load Volume 1 Flow Rate 1 Resoiution 1 
For the above case and with the range of variables studied, the length of the column is 
found to effect the resolution most significantly. The effect of flow rate is found to be 
least cntical. A combination of length and load volume reduced the resolution by about 
40% than length alone. Inclusion of flow rate reduced the resolution by ficher 12%. 
(ml 
0.2 
5.2. ECONOMIC EVALUATION 
In economic evaluation of the process, uncertainty was involved in some eshates. 
Ambiguity was present with some cost factors utilized in the calculation and above all, 
the specific nature of the process r e q M  fùrther analysis with respect to some critical 
issues. 
(% of Column Volume) 
O 
Labor Cost: For economic evaluation of the simulated processes, estimate of labor cos  
was obtained fkom the built-in estimator of SuperPro Designer@. It was later pointed out 
that labor reqwtement values used in the first few versions of SuperPm Designer@ were 
( L W  
O 0.28 
on the low side, which were conected to reflect more redistic h a t e s  in the subsequent 
versions (Intelligen Inc., 1996). 
In addition, it is found that labor cost is the largest cost component, in general, 
accounting for more than 50%, for bioreactors (Wilkinson, 1987). Also for 
chromatography columns, labor cost tends to run far ahead of supplies and amortized 
equipment (Wheelwright, 1987). Therefore, a sensitivity study of the overall economics 
of the base process to labor cost was carried out. In this study, in addition to cost for 
supervision (A), maintenance (B) and operatug labor (C), cost of other labor dependent 
items of annual operating cost such as operating supplies (10% of C), laboratory charges 
(25% of C), plant overhead (60% of (A+B+C)) and administration (25% of plant 
overhead) were also included @atm and Rosen, IWO). 
Although, labor cost accounts for only about 5.2% of the annual operating cost for the 
base case, it was found that a 50% increase in the labor cost will bring about 5% 
reduction in ROI of the process (Figure 5.2.1). Therefore, increase in the base unit labor 
rate (Sl8hour) or the labor-hour may have significant effect on the econornics of the 
process and the prospect of minimizing labor cost by automation of the process should be 
investigated. 
Waste Treatment and Environmental Regulations: For plants producing biochemicals 
fiom recombinant organisms, safety mesures to prevent release of the recombinant cells 
to the environment have to be considered. Discharges containing viable recombinant 
organisms m u t  be inactivateci by a validated inactivation process prior to release fiom a 
closed system. The two most fiequent techniques used for this purpose are thermal 
inactivation and chemicd inactivation. Ali the thee stream h m  the plant are routed to 
a contained drain kill tank system. These streams inciude condensate fiom the vessel, all 
process Luies and associateci steam traps. Exhaust gas fbm the biomctor is cyclone 
separated and sterile filtered using 0.22 micron membranes before being released to the 
atmosphere. National Institutes of Hedth 0 has defked four physicai containment 
levels in the 'Guidelines for Research Involving Recombinant DNA Molecules' (NiH, 
199 1). The containment boundary for extraceliular product encornpasses the bioreactor, 
kill taok and ce11 harvesting followed by cross flow microfiltration through 0.22 micron 
membrane (Giorgio and Wu, 1986). For plants producing pharrnaceuticals fiom 
recombinant animal cells, a containment level of at least GLSP (Good Large Scale 
Practice) is recommended (Miller and Bergmann, 1993). Each of the physicai 
containment level has specific design requirement regarding facility design (e.g. 
architecturai finishes, washing facilities, gannents, ventilation etc.), equipment design 
(e.g. for biological d e t y  cabinets, exhaust gases, rotating seals, systems for monitoring 
integrity of containment, transfer steps etc.) and response plans for accidentai spills. The 
maintenance of this safety level will add up to the waste treatment cost mbstantiaily. 
Waste treatment cost is caiculated as 5% of the annual operating cost for the simulated 
processes as suggested by Datar and Rosen (1990). 50% increase in this cost component 
will reduce the ROI of the process by about 2% and 100% increase by about 3% (Figure 
5.2.1). Therefore, the process is found to be faKly insensitive to this cost for the 
calculation strategy adopted to obtain annuai operating cost 
Utiiities: Pharmaceutical plants require special kind of process utilities such as water for 
injection (WFI), pharmaceuticai water, clean steam, different classes of air etc. WFI has 
low limits of ionic, microbial and endotoxin contamination. It is used prirnarily for 
purification buffers and for any final clean-in-place (CIP) rinse. It is also wd to prepare 
ceii culture media to minimize trace components. Process air is classified accordbg to the 
number of 0.5 pm diameter particle tolerable per ft). Class 10,000 air is recommended for 
purification suites whereas class 1000 and c l w  100 air for n1l and finish areas 
(Harshbarger et ai. 1995). The cost of production of these pmess utilities and 
distribution through special piping (e-g. process piping, hygienic utility piping etc.) will 
be significantly higher than those nomally required plant utilities. For the simulated 
processes, cost of utility was calculated as a k e d  percentage (10%) of the annuai 
operating cost (Datar and Rosen, 1 990). A sensitivity study (Figure 5 1.1) revealed that 
50% increase in this coa would bring down the ROI of the process by about 3% and 
100% increase by about 6%. 
Equipment Porchase Cost: Estimates of equipment purchase cost for the sllnulated 
processes were obtained fkom the built-in models of SuperPm Designer@. Sensitivity 
study was carried out to observe the effect of change in this price on the ROI of the 
process. Even a 25% increase in this price will lower the ROI of the process by almost 
21%. 50% increase by 35% and 75% increase by 45% (Figure 5.2.1). Therefore, as 
anticipated, the process is fond  to be very sensitive to this pice and any change in the 
price of the major contributors to this cost should be readily included for economic 
evaluation. 
Cost of Rnw Material: price of raw material and media was found to be the major 
contributor to the annual operating cost for al1 the processes. Therefore, sensitivity to this 
price was deemed important. 25% increase in this price was found to reduce ROI of the 
process by 9% and 50% increase by 18% (Figure 5.2.1). Therefore, the process is ais0 
faVly sensitive to the pnce of raw materiai and media 
Overnii Yield: The design of the simulated processes is based on an overall recovery of 
40%. Sensitivity study was carried out to tind how much improvement in ROI of the 
process could be expected if opthkation of operation of the downstream uni6 and 
development of novel purification methods increase the overali recovery. If overall 
recovery increa~s to 50%, the ROI of the proces will improve by 37%. ROI increase by 
74% if the overall recovery becomes 60% (Figure 52.2). Therefore, there is a huge 
incentive for o p t h h i o n  of the downstream units for new plants before they are put to 
operation. However, for the existing plants, revalidation of the process steps can offset 
the gain in ROI. 
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Figure 5.2.1 : Sensitivity to Economic Variables 
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Figure 5.2.2: Sensitivity to overall yield 
Ciinicai Studics and FDA Approvai: Chical Shidies for achieving FDA approval 
represents a major cost in bringing a recombinant therapeutic, like t-PA, into the market. 
$32 million was raised by Genentech for clinical test and development of t-PA (Elander, 
1989). In the five phase conceptuai layout described by Bliem (1988) for establishing an 
induseid scaie ce11 culture process, the major cost was shown to be associated with the 
final phase, accounting for clinical studies and marketing pro-. The cumulative cost 
for the development of a therapeutic product in 1988 was likely to lie in the region of $50 
to 16 150 million (Bliem, 1988). The high cost and consequentiy, the high nsk associated 
with the development and cornmercialization of pharmaceuticals was emphasized in 
another report, where values of up to $350 million have k e n  reported as the average cost 
of a successful drug substance (Business Week, October 17, 1994, p.204). 
For production of porcine growth hormone f?om E. coli this cost was estimated to be $25 
million by Petrides et al. (1989), which they amortized over ten years. For the processes 
simulated, this enormous cost was amortized over the life of the product and was handled 
simply by calculating it (R & D COS) as a nominal percentage (7%) of the overail cost. 
The effect of R&D cost on the selling pnce is shown in Figure 5.2.4. For a total coa of 
$150 million, the selling price of t-PA has to be increased by about $800 per gram. For a 
more realistic figure of $250 million dollar, the selling price is increased by $1,700 per 
gram to maintain the same ROI. If the selling pnce is held constant on the other han& 
ROI of the process will be reduced to 94.6% of its base value for R&D cost of $150 
million and fiirther to 88.5% for $250 W o n  (Figure 5.2.3). 
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Figure 5.2.3: Sensitivity to research and 
development cost 
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Figure 5.2.4: Sensitivity to research and 
development cost at fixed ROI for base case 
MAMMALIAN CELL 
Several unstrucnacd kinetic modcls for animai cclls w m  investigated using Aspen 
BioProcess SianilatorN (BPS). The kinetic cquations were added as subroutines to the 
'Tcmicntef' modeL The smnilator solves the systems of di&nntial tquations and 
generates concentration profiles for substrates and product. Since BioRocess 
Simulatorm ailows the parameters of the models to bc vaxied over spen'ncd range, it is 
v a y  convenient to carry out kinetic modelling study using this siizailator. ModeIs with 
d i a i n t  spccinc growth rate and rate expressions wac sciccted for this smdy. 
6.1 .SPECIFIC GROWTH RATES 
The fokwing specinc growth rate (p) expressions wcre obtained h m  iiterature and 
considcred for the kinctic study 
when, S rcprcscnts the concennation of Glucose in the mrAium, 
G is concentration of Glutamine, 
X is biornass concentration, 
A is concentration of Annnonia and 
L is concentration of Lactate 
In the above expresions the limitïng substrates CO- are glucose, glutamine and 
s e m  coqntnts (Dalili and O b ,  1989). Differcnt combinations of the i;miring 
substrates have been assumtd in di&nnt cases. The expressions also include inhibition by 
mctaboüc waste products iactate and amrmnia and in one case even by the substnite 
glucose (Kurano et aï., 1990). Lactate inhibiton, howmr, was not obsemd up to 
concentrations of 40 m M  for a hybridoma ce1 1M (Gkken et al., 1988) and up to 28 
mM for CHO cclls (Kufa~)  a ai., 1990). Monod mOdt1 was used to t q m s s  substratt 
lirr?itation in ail the cases. The above specific growth rate expressions wcre a?ï developed 
for différent ceïï liw of hybpidorrra except for expression (g), which was devebpcd for 
CHO. 
The specific growth rate &l (d) proposcd by Bret et ai. (1988) was anaiyzed ushg 
BioProcess SmmlatorN. The e k t  of adcihg each tam to the growth expression was 





Figure 6.1.1: Anaiysis of growth rate 
expression using BPS 
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Figure 6.1 2: Cell concentration for different 
specific growth rate expressions 
slightly stronger than lactate inhibition and including both the temis reduced the specific 
growth rate significantiy. This type of study can be usefbl to develop appropriate growth 
rate expressions. 
Altematively, the simulator can also be beed to screen growth rate expressions. The rate 
expression in the subrouthe can be easily replaced with another and the concentration 
profile thus generated can be compared to the experimental data. Three different growth 
rate expressions were considered for the kinetic model proposed by Newland et al. 
(1994). Replacement of the growth rate expression of this model by that f o d a t e d  by 
Tremblay et al. (1993) reduced the maximum ce11 concentration since this model 
considers glutamine as a limiting substrate in addition to glucose (Figure 6.1.2). When 
the rate expression for JL was replaced with the one used by Kurokawa et al. (1994), ce11 
concentration went down significantly. This model includes lactate inhibition in addition 
to limitation by glucose. The lactate inhibition constant is large while the yield 
coefficient, Y, is very large and the yield coefficient, Y, is very small compared to 
others (Tables 6.1.4 and 6.2.1). 
When the kinetic parameters JL , and the different saturation and inhibition constants 
(K, KL, KA, &) for the above expressions were compared, they were found to Vary over a 
wide range (Table 6.1). Maximum value of C,  (3.0 6') was observed for model (d) that 
is about four folds higher than the reported minimum (0.8 6' for (b)). 
A sensitivity study was carried out using BioProcess SimulatorTM to observe the effect of 
change in C, ,. Simulation did not converge with wide variations in this parameter since 
the performance of the bioreactor was very sensitive to this change and the ordinary 
dBerential equation solver of BioRocess Simulatorm could not converge due to large 
variations of bioreactor performance. Table 6.1.2 shows the result obtained with a 
smailer range. 





Table 6.1.2: Result of sensitivity study to maximum specific growth rate 
Reference 
Kurokawa et al., (1994) 
Newland et al., (1994) 





Bree and Dhurjati (1988) 
Glacken et al., (1  989) 
1 
Ddili and Ollis (1989) 
1 
Kurano et al., (1990) 
Sensitivity midy was also carried out to midy the changes in K, saturation constant for 
glucose. Results are presented in the table below. 
P ma,v ( l w  
1 .O E-06 
Xrate (kgni) 
2.OE-04 
Table 6.1.3: Resuit of sensitivity study to saturation constant for glucose (IW 
Srate (kg/h) 
-6.7E-03 

































Table 6.1.4. Reported saturation and inhibition constants for the différent models 
Saturation Constant for Glucose (K& 
0.0s gfL I Kurokawa et al., (1 994) 
Saturation Constant for Glutamine (Q: 
0.18 g/L 
0.0876 g/L  I Newland et al., (1994) 
Tremblay et al.,(1993) 
0.0438 g/L Tremblay et al.,(1993) 
0.1 168 g/L, 
r 
Inhibition Constant for Lactate (KJ: 
Bree et ai., (1988) 
0.02 19 g/L, 
1.25 g/L I Kwokawa et al., (1 994) 
Glacken et ai., (1989) 
I 
Inhibition Constant for Ammonia (KJ: 
0.72 gfL Bree et al., (1 988) 
0.0 1785 g/L 
1 
Saturation Constant for S e m  (m: 
Bree et ai., (1 988) 
0.135 g/L 
26.5% 1 GIacken et ai., (1989) 
Kurano et ai., (1990) 
1 
1.59% Dalili and Ollis (1989) 
The different rate expressions used in the above models are shown below. For the 
substnite glucose, two rate expressions were found, the Merence behg the maintenance 
t m .  Maintenance was considered in only two cases (Kurokawa et al., 1994; Bree et al., 
1988), however, contribution h m  this term was very smaii in both the fases. A wide 
variation in the yield coefficient, Y, was observed. Figure 6.2.1 shows the glucose 
profile for different values of the yield coefficient for the kinetic mode1 (c) (Kurokawa et 
al., 1994). 
a) Glucose: i) dS/dt = -(pc)Nm (6.2.1) 
ii) dSldt = -(PX)& - mx (6.2.2) 
In dl the models considered, lactate production rate was expressed in tenns of the yield 
coefficient, Y,. Again, the yield coefficient was found to Vary over a wide range, the 
maximum being 125 times (Kurokawa et al., 1994) the smallest reported (Bree et al., 
1988). 
b) Lactate: i) dudt = ( p x ) N ,  (6.2.3) 
Three different rate expressions were observed for glutamine and ammonia The reported 
yield coefficients, Y, and Y, and the specific production rate q, and q, were found to 
be more or less congruent. 
C) Glutamine: i) dG /dt= - (p)N, ,  (6.2 -4) 
ii) dG/dt = qGa x - k.G (6.2.5) 
iii) dG/dt = <w)NwG - (1 Np)dP/dt (6.2.6) 
- (1 NA3dA/dt 
O 50 IO0 1 50 200 
time (II) 
Figure 6.2.1 : Glucose profile for batch 
fermentation as a function of yield constant 
( Y W  
Table 6.2.1 : Reporteci kinetic panuneters for mammaiian ce11 cultures 
O 1 0.393 i B ~ W  et al., (1988) - I 
Reported Value 1 In Units of g/g 1 Refance 
Yield (CelYGlucose), Y,: 
I 1 . I 
Yield (AmrnonialCell), Y,: 
Kurokawa et al., (1994) 
Newland et al., (1994) 
Tremblay et al.,(1993) 
Bree et al., (1988) 
1.39 X 1 0' celldg 1 0.0365 
Y ield (Cell/Glutamine), Y ,:




1 .O9 X 10' cells/rnmol 
2.9 X IO5 cells/mVrnM 
0.36 celVpmol 
3.8 X 1 O8 cells/mmol 
9.434 X 10' cellslmi/mM 




Yield (LactateICell), Y,: 
Specific Glutamine Degradation Constant 0<3: 
4.8 X 10'~ IfL 1 -  1 Glacken et al., (1989) 






1 2.7 X 10-' h.' 1 - / Newland et al.. ( 1994) 1 
Kurokawa et al., (1994) 
Tremblay et al.,(1993) 
Bree et ai., (1988) 





Kurokawa et al., (1994) 
Tremblay et ai.,(1993) 
-- - 





Specific Ammonia Production Rate (a: 
Trernblay et al.,(1993) 
Bree et al.. (1 988) 
3.23 X 1 O-3 g/g-h 
L 
8.33 X l(r g/g-h 
- 
- Glacken et al., (1 989) Kurano et al., (1990) 
- 
- 
Glacken et al., (1989) 
Kurano et al., (1 990) 
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CONCLUSIONS AND RECOMMENDATIONS 
7.1. CONCLUSIONS 
7.1.1. f lo wsheet Analysls 
A large macase in ROI was obmed for th flowsheets where the bioreactors were 
operatcd in f&batch modt. Two cases of fd-batch opcracion w a t  simulatecl assunilig 
the product concentration to be four tinits and cight timts the concentration for the base 
case. Anothcr fiowsheet, which also rtsuucd in a high ROI is the mnltiple bioreactor 
fiowsheet. Since ceii cuiturc biowtor cycles cm last up to a week, an economicaiiy 
aztd single purikation train can be used to process the product h m  nniltipie 
bionactors. The single biorcactor of thc base case was divided into rmiltipk equal s k i  
bioreactors and the downs~eam train was designcd to handlc h t h  h m  one of the 
bionxctm. In this case, the b of the do- train was much smaltr than the base 
case. Since for high vaiuc products likc t-PA, dow~lstztam proccssing accounts for about 
70 to 80% of the overali production cost, sigdicant saviag was realized h m  the snrmlkr 
d o w n s ~ t a m h  
Although thcrc arc smiplifyiog essump&ns and ~ M c a t i o n s  invoIVtd with any 
simulation, the dintrtnce in economic perfôrmancc obsaved fbr thcsc flowsheets were so 
signScant that it was rcasonabk to draw conclusions based on the omnibrinn nsults. 
7.1.2. Simulation 
Simulation experience with BioProcess Simulatorm and SuperPro Design- led to the 
conclusion that these two simulators should be used in conjunction to develop a new 
process. Since simulation of most of the units is sirnpler with SuperPro, it can be used 
initially to screen process alternatives in a shoa tirne and minimum effort. Once a 
process has k e n  chosen, it can be analyzed using the more complex approach of 
BioProcess SimulatorT"< to fmd the optimum operating conditions and predict the process 
performance with changing parameters. 
Simulation with SuperPro Designer@ was straightforward once the required input 
information were obtained. Some simulation problems were, however, encountered 
while working with BioProcess Simulatorm as highlighted below. 
Bioreactor: The simulation for the bioreactor was found not to converge at low air 
flowrates. Simulation converged with air flowrates corresponding to dissolved oxygen 
levels of 6.4 mrnol/L. This is much higher than the solubility of oxygen (0.224 mmoUL) 
at the fermentation temperature of 3pC. In laboratory studies reported, the dissolved 
oxygen concentrations maintained for t-PA production were between 25% to 40% of 
saturation, i.e. 0.056 to 0.089 rnmoYL. The simulation did not converge even at 
dissolved oxygen concentrations as high as 0.715 mmoVL. Therefore, with the fermenter 
mode1 of BioProcess Simulatorm, it was not possible to investigate the effect of ka, air 
flow rate or dissolved oxygen concentration. 
Afenity Chromatography: The presence of a split elution peak for t-PA and the 
increase in the area of the nnaller interfering peak with higher concentration could be an 
artifact of the simulator. For the simulated fed-batch processes, this behavior aected the 
pe~omance of the affinity columns very sîgnincantly. Since t-PA is required at very 
hi& purity, the t-PA associated with the first peak is wasted and therefore although the 
fed-batch process increased concentration of t-PA, the recovery was low. The rrsults 
reported in literatwe for afkity chromatography are camied out for d y t i c a l  purposes 
using small sarnple size and low concentration. Therefore, it was not possible to ver@ 
these observations and it remains to be investigated experïmentally. 
Ion-Exchange Chromatography: The elution profile of t-PA fiom the ion-exchange 
column was found to have an elongated tail. According to chromatography theory, 
tailing of elution peaks can occur as a result of large particle diameter, high fiow rate and 
low molecular difhivity of the solute (Yamamoto, 1978; 1979). Tailing of the elution 
curve was also observed with ion-exchange chromatography when increased sarnple 
concentration causes the column to operate in the nonlinear region of the isotherm (Kato 
et ai., 1982). Simulations with lower t-PA concentrations, however, did not improve the 
elution profile. The peaks were found to have longer tails and lower heights at 
progressively lower concentrations (50% and 25% of the design case) and sharpening of 
the peak was observed at higher concentrations (125% and 225% of the design case). 
Elution profile remained unchanged for simulations with lower (half of the design case 
flow rate) and higher flow rates (double of the design case flow rate). Although 
simulation with smaller particle diameter (up to 60 pm of particle diameter) changed the 
reported mass tramfer coefficient, the elution profile did not change. To test for higher 
molecular miVit ies ,  simulation was carried out with a lower molecular weight (one- 
tenth of the acnial molecdar weight) of t-PA for observation purposes. Again, the 
elution curve was d t e r e d .  These observations led to the conclusion that the tailing t- 
PA peak couid be due to limitation of the ion-exchange model in BioProcess 
SimulatorM. This may also have resulted nom the choice of parameters. Solute capacity 
was found to be a critical parameter for this model for which no close estimate was 
avaiiable fiom literature. 
Membrane Sepiration: In the two-stage ce11 culture flowsheet, the cells h m  the 
senun containing media of the growth bioreactor are washed to get rid of the senmi 
proteins before king tninsferred to the production bioreactor. Simulation of the ceil 
wash stage was attempted using the diafiltration option of the batch membrane 
separation model of BioProcess Simulatorm. However, the model with diafiltration 
never converged. The model performed without difficulties until the diafiltration step 
was reached and then stopped. The enor message h m  the history file reported that the 
solver encounters divisions by zero with M e r  calculation. Repeated trials with this 
model were unniccessful. (The support group of Aspen Technology was informed of 
this. The problem was followed up for six months, but they were unable to provide any 
solution). 
7.1.3. Economic Evaluation 
Economic evaluation with SuperPro Designer@ was found to be simple and satisfactory 
for flowsheet comparison purposes. The economic evaluator of BioProcess Simulatorm 
requires detailed information, which were not available at the conception level. "Budget 
Authonzation" grade estimate of the total capital investment was obtained by 
multipiying the total equipment purchase cost by appropriate cost factors. The 
contribution from fementation and recovery equipment to the total equipment purchase 
cost was found to Vary depending on the flowsheet Fermentation equipment was found 
to be the major contributors for the two-stage ce11 culture and the multiple bioreactor 
case. However, for annual operating cost, the major contributor for al1 the cases was raw 
material cost, although contributions fiom media and recovery material were found to 
Vary signincandy. The media c o s  was found to be the largest contributor for the two- 
stage and multiple bioreactor case. Economic performances of the flowsheet were 
meanired in terms of Retum on Investment (ROI) and Gros  Margin (GM). The highest 
ROI and GM were caiculated for case B fed-batch process (8 X product concentration 
for batch), followed by multiple bioreactor case and case A fed-batch having almost 
equal ROI. 
7. f.4. SensitiVity Analysls 
Conclusions of sensitivity analysis of uncertain parameters and variables for the 
following units are given below. 
Membrane Seporation Unib: The cntical variable identified for this unit is set 
point velocity. A 50% reduction in velocity reduced pemeate flux by 10%. This was a 
result of increased gel resistance estimated by the equation (I(, = %O(@)' (Re)b (CJ). 
Gel resistance (RJ increased as a result of both lower Reynolds numbers (Re) and higher 
key component concentration (CJ. Arnong the uncertain parameters, the exponent 'b' 
denoting the dependence of gel resistance on Reynolds nurnber was found to be the most 
critical one. Over I 50% range of 'b', the changes in operating conditions were so 
significant that simulation did not converge. At the upper Iirnit of -0.85, which represents 
only a 10% inmase, gel resistance was reduced by 30% of its base value. For other 
parameten, e.g. %O and 'a', 80% and 50% reduction respectively, reduced the gel 
resistance by 50%. Enhancing fiw by increasing tangential velocity can result in 
undesirable effects. Large pressure drops are generated at higher velocity in common 
membrane modules resulting in higher trammembrane pressure (TMP). This can cause 
compaction of the layer of cells retained at membrane d a c e .  Another drawback of high 
velocity is the higher shear rate which a e c t s  the thickness of the boundary layer, but on 
the other hand can damage sensitive mammalian cells (Nagata et al., 1989). Using shear 
filters or rotary nIters is one way of decoupling shear generation and TMP with minor 
damage to shear sensitive ceiis (Frenander and Jonsson, 1996). In these filters, high 
tangential flow rates are achieved by rotating metal disks. These rotary fiIters not only 
impmve the flux but also the protein trammission. 
Aninity Chromatogmphy Column: The most critical parameter was found to be 
the solute capacity followed by Langmuir isotherm constant. A 20% increase in capacity 
resulted in 17% higher recovery whereas 45% increase in Langmuir isotherm constant 
(kload) improved the recovery in the column by 14% over the base case. 
Ion-exchange Ch romatogrnp hy : For this column the critical parameters were 
solute capacity and charge on t-PA molecule. A 50% change in the solute capacity 
resulted in about 17% decrease in the recovery of t-PA in the ion-exchange columa. 50% 
increase in the charge increased the recovery by 3.5%. However, 50% reduction reduced 
the recovery by 7%. 
Gel Filtration: The variable that was found to result in most significant effect, 
within the range studied, on the resolution of the gel filtration column is column length. 
This was followed by load volume (as a percent of column volume) and flow rate 
respective1 y. 
Economics: The overall economics of the processes was found to be most sensitive 
to equipment purchase cost, raw material cos  and overall recovery yield of the process. 
Among other variables, labor cost and coa of utility reduced the ROI of the processes by 
about 5%. The effect of research and development (R & D) cost on ROI was not simple 
to determine since this coa can Vary over a wide range. For R & D cost of 250 million 
dollars (US), the ROI was found to be reduced by 10% fiom its base value. 
Individuai Processes: The b w  case process was found to be very sensitive to the 
percentage of bovine serum albumin (BSA) in the medium. ROI of the fed-batch 
processes were very sensitive to the batch time, a major part of which is occupied by the 
bioreactor. 
7.2. RECOMMENDATIONS 
Experiments should be carried out to validate the performance of the individual unit 
operation blocks. Although overd congruency of economics of the simulated processes 
with published trends indirectly validated the results, validation of the performance of 
the individual models will place more confidence on the results obtained. 
Performances of some of the models in BioProcess Simulatorm were not 
satisfactory. These models should be reviewed and the solution algorithm checked. 
Besides the problems already mentioned, the ion-exchange chromatography model was 
found to be insensitive to eluant molarity, elution volume, specific surface area and total 
ionic capacity. Similarly, the membrane separation model was not able to register the 
inclusion of denaturation fiaction in simulation. 
Since fed-batch mode of operation was found to possess very high economic 
potential, the possibility of using other high-density culture systwis, such as perfusion 
culture for large scale production of high value products should be invenigated. 
The possibility of using novel methods such as perfusion chromatography. 
membrane affinity separation (Asenjo, 1 994; Spalding, 199 1), dynamic membrane 
filtration (DMF) (Fremder and Jonsson, 1996) and new materiais such as HyperD 
Wty matrix (Boschetti, 1994) for large scde purification of proteins should be 
considered. 
Finally, the mitical process parameters and variables shouid be determined 
experimentdy for a paaicuiar system to confer more significance to the simulation 
results. The assumptions and the choice of correlation and equations can only be justined 
by cornparison with practical situations. Similarly chrornatographic media, ligand, 
microfiltration and ultrafiltration membrane, etc. should be chosen by carrying out 
experirnents with the actuai system. For example, Sephadex A50 has very high capacity 
for BSA, which is about ten times of that for DEAE Sepharose. However, due to the very 
open gel-like structure of this resin it is found unsuitable for large-scale operation 
(Graham et ai., 1987). Therefore, experimentation and simulation shodd be considered 
complementary ratber than independent approaches to reliable process design. 
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Appendix A 
Aspen BPS Input File for Simulation of Base Case 
This Appendix contains Aspen BPS input file used to simulate the base case. The flowsheet was 
simuhted in two sections - bionactcr and down~tfearn processiag. Resuits of the simulation nm are 
snmwhd in Chapter 4 and detaüed resuits are presented in Appeildix B. For breity. input files for 
the other simuiated fiowsheets are orni& The simulation nias were paf<amed using d o n  9.2. 
A.1. SIMULATION OF BIOREACTOR 
TITLE 'Simulation for t-PA production' 
I'N-UMTS MET VOLUME-FLOW='WHR' ENTHALPY-FLwKCAL/HR' & 
HEAT-TRANS-Cz'KCALMR-SQM-R TEMPERATURE< DELTA-T=C & 
HEAD=METER UA='KCAL/HR-R HEAT=KCAL FLUX='L/SQM-KR' & 
MOLE-CONC='MOL/L' 
DEF-STREAMS MIXNC ALL 
RUN-CONTROL MAX-TIME+I 0000 
DATABANKS PURECOMP 1 AQUEOUS / SOLIDS / INORGANIC 1 BPS & 
1 NOASPENPCD 
PROP-SOURCES PURECOMP 1 AQUEOUS 1 SOLIDS / INORGANIC I & 
BPS 
COMPONENTS 
GLUCOSE C6H1206 GLUCOSE / 
GLUTAMIE BSA GLUTAMlE / 
FBS BSA FBS 1 
T-PA BSA T-PA 1 
OXYGEN 02 OXYGEN 1 
CO2 CO2 CO2 / 
NITROGEN N2 NITROGEN 1 
WATER H20 WATER / 
HAM NACL HAM / 
CHOCELL CHOCELL 
BIO-COMPS GLUTAMIE FBS T-PA 
FLO WSHEET 
BLOCK FERMENT NEF-1 F-2 OUT=F-4 F-3 
PROPERTIES BPSIDEAL 
NC-COMPS CHOCELL BIOSTATE BIOCOMP 
NC-PROPS CHOCELL ENTHALPY BIOENTH / DENSITY BIODEN 
PROP-DATA 
PROP-LIST ATOMNO / NOATOM 
PVALGLUTAMIE6 1 7 8 1 5 10 2 3 
PROP-DATA 
PROP-LIST ATOMNO / NOATOM 
PVAL T-PA 6 1 8 7 16 / 2486 4950 1365 775 40 
STREAM F-1 
SUBSTREAM MIXED TEMP=37 PRES4 VOLUME-FLO W=EO SOLVENT=WATER & 
NPHASE=l PHASE=L 
MOLE-CONC GLUCOSE 10.OE-03 / GLUTAMIE 5.10E-03 / FBS & 
0.00 15 / HAM 0.2 
STREAM F-2 
SUBSTREAM MIXED TEMP=25 PRES=l 
MOLE-FLOW OXYGEN 0.029 / CO2 7.35E-03 / NITROGEN 0.21 
BLOCK FERMENT BFERM 
PARAM METHOD=USER-RATES INOC-CONC=0.0526 & 
INOC-VOL=1000 VOL-CHARGE=5000 KLAe7.0 POWER=30 <WATT/CUM> & 
FERM-TEMP=37 PRES=1 NfRODUCTS=l DOWN-TIME4 MIN-02=0.40 & 








REAL-KINET 1.67 0.0008 0.00026 7.2E-07 -1.94E-06 0.006 7.79 & 
4.167E-06 1.138E-05 0.025 20.0 25.5 
STOP-l'NT CRITNO=l N - N O = 1  VARIABLE=ABS-TIUE & 
STOP-VALUE=200 
COOLANT TEMP=lO U425 <WATT/SQM-K> AREA=l3.78 
PLOT PLOTNO4 COMP-LIST=GLUCOSE GLUTAMIE 
PLOT PLOTNO=2 COMP-LIST=CHOCELL 
PLOT PLOTNO=3 COMP-LIST=OXYGEN 
PLOT P L O T N M  COMP-LIST=T-PA 
COMP-ATTR, 1 CHOCELL BIOSTATE ( 0.75 0.25) 
COMP-ATTR 2 CHOCELL BIOCOMP (53 7.3 19 12 8.7 80 ) 
STREAM-REPOR NOMOLEFLOW MASSFLOW BPS-REPORTzYES 
A.2. SIMULATION OF DOWSTREAM PROCESSING 
TITLE 'Purification of t-PA ' 
IN-UNITS MET VOLUME-FLOW='L/tIR' ENTHALPY-FLO='KCAL/HR' & 
HEAT-TRANS-C-KCAWHR-SQM-R TEMPERATURE=C DELTA-T=C & 
HEAD=METER HEAT=KCAL MOLE-CONC='MOL/L' 
DEF-STREAMS MIXNC ALL 
DATABANKS PURECOMP 1 AQUEOUS 1 SOLIDS / INORGANIC / BPS Br 
/ ASPENPCD 
PROP-SOURCES PURECOMP / AQUEOUS 1 SOLIDS / INORGANIC / & 
BPS 1 ASPENPCD 
COMPONENTS 
CHOCELL * CHOCELL / 
WATER H20 WATER 1 
TPA BSA TPA 1 
HAM NACL HAM 1 
BSA BSA BSA / 
GLUC C6H1206 GLUC / 
ELUENTl HCL ELUENTl / 
ELUEN'IZ HCL ELUENTî 1 
ELUENT3 NH4HS04 ELUENT3/ 
WASH NACL WASH 
BIO-COMPS TPA BSA 
FLOWSHEET 
BLOCK MICROF IN=FEED OUT=PERMl RETl 
BLOCK UF IN=PERMI OUT=PERM2 RET2 
BLOCK AFFl IN=RET2 ELUTEl WASH OUT=PRODl WASTEI 
BLOCK UFl IN=PRODl OUT=PERMB 1 RETB 1 
BLOCK AFF2 IN=RETB 1 WASH2 ELUTE2 OUT=PROD2 WASTE2 
BLOCK UF2 IN=PROD2 OUT=PERMB2 RETB2 
BLOCK GEL IN=RETB2 ELUANT O W R O D  WMTE 
PROPERTIES BPSIDEAL 
PROPERTIES NRTL 
NC-COMPS CHOCELL BIOCOMP 
NC-PROPS CHOCELL ENTHALP Y BIOENTH / DENSITY BIODEN 
PROP-DATA 
PROP-LIST ATOMNO 1 NOATOM 
PVAL TPA 6 1 8 7 16 / 2486 4950 1365 775 40 
PROP-DATA 
PROP-LIST ATOMNO / NOATOM 
PVAL ELUENTl6 1 8 7 35.5 1 19 18 O 3 1 
PROP-DATA 
PROP-LIST ATOMNO 1 NOATOM 
PVALELUENT261 8735.5/191803 1 
PROP-DATA 
PROP-LIST ATOMNO 1 NOATOM 
PVALWASH61871153 1 
PROP-SET MASSCONC MASSCONC UNITS='GM/Lt SUBSTREAM=MIXED PHASE=L 
STREAM ELUTE 1 
SUBSTREAM MUCED TEMP=4 PRES=1.2 
MASS-FLOW WATER 375 1 ELUENTl 120 
STREAM ELUTE2 
SUBSTREAM MIXED TEMP4 PRES=1.2 
MASS-FLOW WATER 375 / ELUENT2 120 
STREAM ELUANT 
SUBSTREAM MIXED TEMP=4 PRES4.2 MASS-FLOW=5.5 SOLVENT=WATER & 
NPHASE=l PHASE=L 
MASS-CONC ELUENT3 3.5 
STREAM WASH 
SUBSTREAM MUCED TEMP4 PRES=1.2 
MASS-FLOW WATER 247.5 / WASH 2.0 
STREAM WASH2 
SUBSTREAM MIXED TEMP=4 PRES=12 
MASS-FLOW WATER 247.5 / WASH 2.0 
STREAM FEED 
SUBSTREAM MIXED TEMP-4 <O PRES=l 
MASS-FLOW WATER 5388/TPA 0.192/HAM 62.4/BSA 41 ZGLUC 1.1 
SUBSTREAM NC TEMP=4 <C> PRES=l 
MASS-FLOW CHOCELL 0.24 
COMP-ATTR CHOCELL BIOCOMP ( 53 7.3 19 12 8.7 80 ) 
BLOCK MICROF MEMBRANE 
PARAM PRES=1.25 P-PERM4 .O8 T'COOL4 CC> VISC=l 
GEOMETRY TYPE=CIRCULAR AREA=80.0 LENGTH=.435 DIAW6.E-04 & 
NSERIES=l NMEM=2 





RESIS-SERIES RESIS-MEM=2.0E+ I 1 RGELWSE+12 RGELAzO. 13 & 
RGELB=-0.77 RGELG0.2 
BLOCK UF MEMBRANE 
PARAM P R E W  .275 P-PERM=l .O8 TCOOL4 <C> VISC=l 
GEOMETRY TYPE=CIRCULAR AREA=60.0 LENGTH=.435 DIAM=6.E-04 & 
NSERIES=l NMEM=2 
PDROP MODEL=FIXED P-RET=l .O 
FLUX MODEL=RESIS-SERIES 
KEY-COMP C I M A  REJECT=0.99 
SOLVENT CIPWATER 
CONV-RECYCLE SETPOINT-VEL=1.6 
RESIS-SERIES RESIS-MEM=2.0E+ll RGELO=4SE+12 RGELAzO. 13 & 
RGELB-0.77 RGELC=0.2 
BLOCK AFFl CHROM 
TYPE TYPE=AFF 
PARAM LENGTH4.4 DIAMETER=.8 REGEN-TIME=1.5 PART-DIAM=lOE-05 & 
PROFILE=STEP 
PARAMB NELPROF=l NSPLIT=l 
STAGE STAGE-ID=LOAD FLOWe200 REL-VOLz0.4 STAGE-PH=7 
STAGE STAGE-IWASH FLOW=250 EL-VOL=0,85 STAGE-PH=7 
STAGE STAGE-ID=ELUTE FLOW=200 MAXVOL=500 STAGE-PH=7 & 
END-CDTPA END-CONC=O.OO 1 
SOLUTES SOLUTE-CID=TPA MW=68000 CAPACITY=OS KLOAD=120 & 
WON=-1  0 
SOLUTES SOLUTE-CID=FBS MW=65000 CAPACITY=O-O0 1 KLOAD=5 & 
FXPON4.0 
PLOT-CONC PLOTNCbI PLOT-CWTPA FBS PLOT-STAGE=LOAD 
PLOT-CONC PLOTNCk2 PLOT-CDTPA FBS PLOT-STAGE=WASH 
PLOT-CONC PLOT-3 PLOT-CDTPA FBS PLOT-STAGE=ELlUTE 
PROFILE PROF-NO=l ELUANT-CID=ELuEJVI"I' ELUTE-VOL4 & 
ELUANT-CONCz226.7 
SPLIT-BASE SPLIT-BASIS=VOLUME 
SPLIT-VOL SPLIT-VOL-NO=l SPL-VOL-SID=PRODl VOL-STARTz380 & 
VOL-STOP--450 
BLOCK UF1 BMEMBRANE 
DESCRIPTION 
OPER-SEQ NMODULES=l 
TANK-PARAMS TANKT4 MAX-VOLUME=225 VINTANK=200 
MODEL-PAR MODULE-ID=l P-PERM=l .O8 PUMP-PRESz1.25 TCOOL4 
GEOMETRY GEO-MODULEID=l TYPEKIRCULAR AREA40 LENGTW0.43 5 & 
DIAM=6E-4 NSERIES=3 NMEMBRANE=1 
PDROP PRES-MOD-ID=1 MODEL=FIXED P-RET=l .O 
FLUX FLUX-MOD-ID=l FLUX-MODEL=RESIS-SERIES KEY-CID=TPA & 
REJECT=O-98 SOLWD=WATER RESIS-MEMe2E11 RESIS-GEL=4.5EI2 & 
RGEL A=O. 1 3 RGELB=-0.77 RGELCz0.2 
PROFILE PEUNT-TIME4 <MIN> MAX-NPOINT=25 MAX-TIME=l .O 
SEQ-PARAM STAGE-IBl START=VOL START-VALz200 STOP-VAR=TIME Br 
STOP-VAb0.5 PUMP-CAPACTY4OO.O 
INTG-PARAM MT-TOL4.O 1 
SPLIT SP-STAGE-ID=l SPLIT-ROWID= 1 SPLIT-FRACz1 .O 
MODULE-REC VEL-STAGE-ID=l MODULE-NO=1 XRECYCLE=I 5 .O 
CONNECTIVITY CONN-ROWID=l MODULE-LISTz1 
PLOT-BMEM 1 PLOTN* 1 OPTIONS= ACONCK RFOUL MT-LIST=l 
BLOCK AFF2 CHROM 
TYPE TYPE=AFF 
PARAM LENGTH4.3 DIAMETER=.6 REGEN-TIME=1.5 PART-DIAM=lOE-05 & 
PROFTLE=STEP 
PARAMB NELPROF=l NSPLIT=l 
STAGE STAGE-ID=LOAD FLO W=100 REL-VOL44 STAGE-PH=7 
STAGE STAGE-ID=WASH FLOW=l50 REL-VOL=0,20 STAGE-PH=7 
STAGE STAGE-IDzELUTE FLO W=100 MAXVOL=500 STAGE-PH=7 & 
END-CID=TPA END-CONC--0.00 1 
SOLUTES SOLUTE-CID=TPA MW=68000 CAPACITY=O. IO KLOAD=80 & 
EXPON=IO 
SOLUTES SOLUTE-CIBFBS MW=65000 CAPACITYz0.00 KLOAD=O-O0 & 
EXPON=O.O 1 
PLOT-CONC PLOTNO=l PLOT-CID=TPA FBS PLOT-STAGE=LOAD 
PLOT-CONC PLO-2 PLOT-CID=TPA FBS PLOT-STAGE=WASH 
PLOT-CONC PLOTNO=3 PLOT-CID=FBS PLOT-STAGE=WASH 
PLOT-CONC PLOTNO4 PLOT-CDTPA FBS PLOT-STAGEzELUTE 
PLOT-CONC PLOTNO=5 PLOT-CDFBS PLOT-STAGE=ELUTE 
PROFILE PROF-N-1 ELUANT-CDELUENT2 ELUTE-VOL4 & 
ELUANT-CONCz226.7 
SPLIT-BASE SPLIT-BASIS=VOLUME 
SPLIT-VOL SPLIT-VOL-N-1 SPL-VOL-SID=PROD2 VOL-START45 & 
VOL-STOP= 1 1 O 
BLOCK UF2 BMEMBRANE 
DESCRIPTION 
OPER-SEQ NMODULEStl 
TANK-PARAMS TANKT4 MAX-VOLUME=75 VINTANK45 
MODEL-PAR MODULE-ID=l P-PEM=1 .O8 PUMP-PRES=1.275 TCOOL4 
GEOMETRY GEO-MODULEID= 1 TWE=CIRCULAR AREA=2.S LENGTH50.435 & 
DIAM=6E-4 NSERIES=l NMEMBRANE=l 
PDROP PRES-MOD-ID=1 MODEkFIXED P-RET=l .O 
FLUX FLUX-MOD-ID=1 FLUX-MODEL=RESIS-SERIES KEY-CID=TPA & 
REJECT=0.98 SOLVID=WATER RESIS-MEM=2E I 1 RESIS-GEL=4.5E+ 12 & 
RGELA=O. 13 RGELBz0.77 RGELC=O.S 
PROFILE PEUNT-TIME=5 <MIN> MAX-NPOINT=25 MAX-TIME=l 
SEQ-PARAM STAGE-ID=l STARTzVOL START-VAL4 STOP-VAR=TIME & 
STOP-VAk0.5 PW-CAPACTY=l l  O 
INTG-PARAM MT-TOL=O.O 1 
SPLIT SP-STAGE-ID=l SPLIT-ROWID=l SPLIT-FRAGI .O 
MODULE-REC VEL-STAGE-ID=1 MODULE-NO=1 XRECYCLE=2S.O 
CONNECTMTY CONN-ROWID=l MODULE-LIST=l 
PLOT-BMEMl PLOTNO=l OPTIONS= ACONCK RFOUL UNIT-LISTz1 
BLOCK GEL GELCHROM 
PARAM FLOW-RATE=32 LOAD-VOL=7 LENGW=0.75 DIAMETER=.S & 
GEL-NM=S-200HR 
SOLUTE CID=TPA MW=68000 
SOLUTE CID=FBS MW=96000 
SOLUTE CMLUC MW=l80 
SOLUTE CID=HAM MW=SS 
SOLUTE CID=ELUENTl MW=236 
SOLUTE CID=ELüENT2 MW=236 
SOLUTE CID=ELUENT3 MW47 
SPLIT SPLIT-N-1 STREAM-DPROD CID=TPA GTLT43T CONC=.00 1 
SPLIT SPLIT-Ne2 STREAM-ID=PROD C D F B S  GTLT=LT CONC=.000008 
PLOT PLOTNO=l CID=TPA FBS 
STREAM-REPOR NOMOLEFLOW MASSFLOW PROPERTIES=MASSCON 
Appendix B 
Sumrnary of Result for the Simulation Runs 
This appendix contains report file b m  both Aspen BPS and SupcRo Designer for simulation of the 
base case Qowskr The repart file h m  BPS (*.rep) was edited to retain only the relevant design 
information The report file for SuperPm hcluded in this appcndix is for saam report (*.sr) oaly. 
B.1.Aspen BPS 
BLOCK: AFFl MODEL: CHROM ----------------.----------.- 
PROCESS STREAM: W T 2  
BUFFER STREAM: ELUTE1 
ELUANT STREAM: WASH 
OUTLET STREAM(S) : PRODl WASTEl 
PROPERTY OPTION SET: BPSIDEAL 
INPUT DATA *** 
COLUMN AND GEL PARAMETERS: 
TYPE OF CHROMATOGRAPHY 
COLüMN LENGTH METER 
COLUMN DIAMETER METER 
VOID FRACTION 
GEL DIAMETER METER 
GEL POROSITY 
GEL TORTOUSITY 
REGENERATION TIME HR 









NUMBER OF POINTS 
ELUTION PROFILE: 
ELUTION COMPONENT 
























O. 5000 120.0000 














SPLIT NO. OUTLET STREAM VOL START 
L 




*** DATA EROM DATA BANK **+ 
GEL CHARACTERISTXCS: 
VOID FRACTION 
GEL DIAMETER METER 
GEL POROSITY 
GEL TORTOUSITY 
BED VOLUME L 
CYCLE TIME HR 
TIME FRACTION IN USE 











SUPERFICIAL VELOC. CM/HR 
LINEAR VELOCITY CM/HR 





COMPONENT TRANS -LOAD TRANS-WASH TRANS-ELUTE 
TPA 
E'BS 





*** BATCH RESWLTS FOR SOLUTES *** 
STREAM 
RET2 








SPLIT NO. OUTLET STREAM VOL START VOL STOP 
L L 
1 PROD2 55 , . llE+03 
*** DATA E'ROM DATA BANK *** 
GEL CHARACTERISTICS : 
VOID FRACTION ,35000 
GEL DIAMETER METER .10000E-03 
GEL POROSITY .60000 
GEL TORTOUSITY 2.0000 
*** RESULTS *** 
BED VOLUME L 
CYCLE TIME HR 
TI= E'RACTION IN USE 
NûMBER OF COLUMNS 
STAGE RESULTS: 
LOAD WASH ELUTE 
VOLUME L 33.9292 17.5000 105.0000 
SUPERFICIAL VELOC. CM/HR 35.3677 53.0516 35,3677 
LIN= VELOCITY CM/HR 101.0507 151.5361 101 . 0507 
PRESSURE DROP ATM 6.6610-02 9.9920-02 6.6610-02 
SOLUTE CHARACTERISTICS: 
COMPONENT BüLK-DIFF PORE-DI FE' 
sqcri~sec SQCM/SEC 
TPA 3.6558-07 1.0967-07 










*** BATCH RESIJLTS FOR SOLUTES **+ 
VOLUME 
L 




BLOCK: GEL MODEL: GELCHROM -------------------------------- 
PROCESS STREAM: NT82 
E L W T  STREAM: ELUANT 
OUTLET STREAM (S) : PROD WASTE 
PROPERTY OPTION SET: BPSIDW 
*** INPUT DATA *** 
ELUTION FLOW RATE L/HR 
LOADING VOLUME L 
COLUMN LENGTH METER 
COLUMN DIAMETER METER 























SEPHACRYL S-ZOO HR 
COMPONENT SPECIFICATION CONC 
GM/L 
TPA GREATER THAN .10000E-02 
E'BS LESS THAN .80000E-05 
*** DATA FROM GEL DATA BANK **+ 
SEPHACRYL 5-200 HR 
.36000 
.47OOOE-O4 
A B C KAV 
METER SQCM/SEC HR 
.92120E-04 .45210E-06 -14295E-02 -2204 6 
.92120E-04 ,401123-06 -18196E-02 .16606 
.92120B-04 ,679903-05 .16707€-O4 1.0000 
.92120E-04 -643423-05 .17654E-04 1.0000 
*** RESULTS *** 
SUPERFICIAL VEWXITY CM/HR 
LINEAR VELOCI TY CM/= 
PRESSURE DROP ATM 
TOTAL GEL VOLUME L 
VOID VOLtfME L 
INJECTION FREQüENCY L 
CYCLE TIME BR 
TIME FRACTION I N  USE 
NüMBER OF COLOMNS 



































** CONCENTRATION PROFILE ** 
ELUTION VOLUME L 
************+** 
A: TPA 
B: FBS * 
********+****** 
BLOCK: MICROF MODEL: MEMBRANE -------------------------------- 
INLET STREAM: FEED 
RETENTATE STREAM: RETl 
PERMEATE STREAM: PERM1 
PROPERTY OPTION SET: BPSIDEAL 
** MASS AND ENERGY BALANCE *** 
REAL COMPONENTS (KGIHR ) IN OUT PRODUCED 
TOTAL 5493.13 5493.13 .000000E+00 
ENTHALPY (KCAL/HR ) 
DUTY (KCALIHR 1 
*** INPUT DATA **+ 
MEMBRANE GEOMETRY 
TYPE OF MEMBRANE 
-RANE AREA W H  
MEMBRANE LENGTFi METER 
NO CHANNELS IN SERIES 
FIBER DIAMETER METER 
OPERATING CONDITIONS 
PüMP PRESSURE ATM 
PERMEATE PRESSüRE ATM 
VELOCITY SETPOINT MISEC 




E'LOW TRANSITION EL& 
PRESS- DROP SPECIFICATIONS 
SPECIFICATION METHOD 
RETENTATE PRESSURE ATM 
nox MODEL OPTION AND PARAMETERS 
MODEL NAME 
MEMBRANE RESISTANCE l/METER 
GEL RESISTANCE PARAM0 
GEL RESISTANCE PARAMA 
GEZ RESISTANCE PARAMB 
GEL RESISTANCE PARAMC 
KEY COMPONENT PROPERTIES 
KEY COMPONENT 






.13000 -. 77000 
.20000 
REJECTION COEFFICIENTS 
PERFORMANCE RESULTS : 
COMPONENT CONCENTRATIONS CONCENTRATION E'RACTION 
RETENTATE PEEIMEATE FACTOR RETAINED 
GM/L 
CHOCELL -66903 .00000E+00 14.996 1.0000 
CALCULATED FLOW PARAMETERS: 
NUMBER OF CKANNELS 
EXED/RETEN VOL RATIO 
RETENTATE FLOW RATE L/XR 
PERMEATE E'LûW RATE L/HR 
PERMEATE nux L/SQM-SEC 
CALC. RECYCLE RATIO 
REYNOLDS NUMBER 
GEL RESISTANCE 1 /METER 
E'RICTION FACTOR 
CALCULATED PUMP AND COOLER DUTIES: 
PUMP BRAKE HP KW 
PUMP ELECTRIC HP KW 
COOLER DUTY KCAL /HR 
BLOCK: UF MODEL: MEMBRANE 
INLET STREAM: PERM1 
RETENTATE STREAM: RET2 
PERMEATE STREAM: PERM2 
PROPERTY OPTION SET: BPSfDEAL 
**+ MASS AND ENERGY BALANCE *** 
REAL COMPONENTS (KG/HR ) ZN OUT PRODUCED 
TOTAL 5126.83 5126.83 .000000E+00 
ENTHALPY (KCAL/HR ) 
DUTY (KCAL/BR 1 
*** INPUT DATA +** 
MEMBRANE GEOMETRY 
TYPE OF MEMBRANE 
M E M B a  AREA SQM 
MEMBRANE LENGTH METER 
NO CHANNELS ZN SERIES 







PUMP PRESSURE ATM 
PERMEATE PRESSURE ATM 
VELûCITY SETWINT M/SEC 
OUTLET TEMPERATURE C 
PüMP EFFI CIENCY 
DRIVER EFPICIENCY 
VISCOSITY CP 
FLOW TRANSITION RE 
PRESSURE DROP SPECIFICATIONS 
SPECIFICATION METHOD 
RETENTATE PRESSURE ATM 
n u x  MODEL OPTION AND PARAMETERS 
MODEL NAME 
MEMBRANE RESISTANCE l/METER 
GEL RESISTANCE PARAMO 
GEL RESISTANCE PARAMA 
GEL RESISTANCE PARAMB 
GEL RESISTANCE PARAMC 
USER FLüX ROüTINE NAME 
INTEGER VECTOR LENGTH 
REAL VECTOR LENGTH 





*** RESULTS *** 




TPA -63798 -626023-02 
CALCULATED F L O W  PARAMETERS : 
NUMBER OF CHANNELS 
FEED/RETEN VOL RATIO 
RETENTATE PLOW RATE L/HR 
PERMEATE FtOW RATE L/HR 
PEWEATE nm L/SQM-SEC 
CALC. RECYCLE RATIO 
REYNOLDS NIMBER 















CALCULATED PWMP AND COOLER DUTIES: 
PüMP BRAKE HP KW 
PUMP ELECTRIC HP KW 
COOLER DUTY KCAL/HR 
*** INPUT DATA *+* 
OPERATION SEQUENCE 
NUMBER OF MODULES 
NUMBER OF ROWS 
NUMBER OF STEPS 
DOW TIME HR 
MODULE CONNECTIVITY 
ROW 1 MODULE NO 1 
TANK PARAMETERS 
TANK TEMPERATURE C 
TANK PRESSURE ATM 
MAXIMUM TANK VOLUME L 
BATCH VOLttME L 
FEED PüMP SPECIFICATIONS 
E'EED PUMP PRESSURE ATM 
FEED PüMP EFFICIENCY 
MEMBRANE GEOMETRY 
MODULE NO. 
TYPE OF MEMBRANE 
MEMBRANE AREA SQM 
MEMBRANE LENGTH METER 
FIBER DIAMETER METER 
NO OF MEM PER CHANNEf, 
NO CHANNELS I N  SERIES 
NO I N  PARALLEL 
OPERATING CONDITIONS 
MODOLE NO, 
RECYCLE PUMP PRES ATM 
PERMEATE PRESSüRE ATM 
COOLER TEMPERATURE C 




PRESSURE DROP SPECIFICATIONS 
MODCiLE NO. 
SPECIFICATION METHOD 
AXIAL PRESSURE DROP ATM 
MODULE NO. 
MODEL NAME 
MEMBRANE RESISTANCE l/METER 
RGEL COEFFICIENT 
RGEL CONSTANT A 
RGEL CONSTANT B 
RGEL CONSTANT C 







STOP VALUE HR 
BLEED RATIO 
PlfMP CAPACITY L/HR 
RECYCLE RATIO 
MODULE NO 1 
SPLIT FRACTION 
ROW NO 1 
CONTROL 
XNLET STREAM 
PR1 NT ING PARAMETERS 
OUTPUT TIME INTERVAL HR 
MAXIMüM BATCH TIME HR 
















CUM FEED PUMP WOEM KW-BR 
MAX E'EED PMP POWER KW 
CYCLE TIME BR 
MAXIrmM TANK VOLUME L 
INLET VOLüME BALANCE 
BATCH VOLUME L 
CONT DIAFIL VOLUME L 
CONT E'EED VOLOME L 
DISC DIAF VOLüME L 
TOTAL INLET VOL- L 
OUTLET VOLUME BALANCE 
RETENTATE VOLüME L 
PERMEATE VOLOME L 
BLEED VOLüME L 
TOTAL OUTLET VOLUME L 
MODULE NO. 
NO IN PZWULEL 
PERMEATE VOLUME L 
PERMEATE MASS KG 
CUI4 RCYCLE PüMP WORK KW-HR 
MAX RCYCLE PMP POWER KW 
CUM COOLER DUTY KCAL 
MAXIMUM DZITY KCAL/HR 
MINIMUM nux L/SQM-SEC 
INLET MATERIAL BALANCE 




WATER 157.10 45.104 .00000E+00 202 . 21 
TPA .33621E-02 .IO556 .00000E+00 -10892 
E'ES -314133-05 .304743-08 .00000E+00 .31444E-O5 
WASH -97104 -11760 .00000E+00 1.0886 
TOTAL 158.08 45.327 .00000E+00 203.41 
COMPONENT CONCENTRATION RECOVERY 
FACTOR 


















MODULE BASED PROFILES 
MODULE NO. 1 



























BLOCK: UF2 MODEL: BMEMBRANE -----------.--------------.------ 
INLET ST-: PROD2 
RETENTATE STREAM: RETBZ 
PERMEATE STIIEAM: PERMB2 
PROPERTY OPTION SET: BPSfDEAfi 
*** INPUT DATA **+ 
OPERATION SEQUENCE 
NUMBER OF MODULES 
NUMBER OF ROWS 
NUMBER OF STEPS 
DOWN TIME HR 
MODUSE CONNECTIVITY 
ROW 1 MODULE NO 1 
TANK PARAMETERS 
TANK TEMPERATURE C 
TANK PRESSURE ATM 
MAXIMUM TANK VOLUME L 
BATCH VOLUME L 
FEED PUMP SPECIFfCATIONS 
FEED PUMP PRESSURE ATM 
E'EED PUMP EFFICIENCY 
MEMBRANE GEOMETRY 
MODULE NO. 
TYPE OF MEMBRANE 
MEMBRANE ?mm SQM 
MEMBRANE LENGTH METER 
FIBER DfAMETER METER 
NO OF MEM PER CHANNEL 
NO CEIANNELS I N  SEEUES 
NO IN PARALLEL 
OPERATZNG CONDITIONS 
MODüLE NO. 
RECYCLE PUMP PRES ATM 
PERMEATE PRESSURE ATM 
COOLER TEMPERATüRE C 












PRESSORE DROP SPECIFICATIONS 
MODULE NO, 
SPECIFICATION METHOD 
AXIAL PWSSURE DROP ATM 
MODULE NO. 
MODEL NAME 
MEMBRANE RESISTANCE l/METER 
RGEL COEFFICIENT 
RGEL CONSTANT A 
RGEL CONSTANT B 
RGEL CONSTANT C 







STOP VALUE HR 
BLEED RATIO 
PUMP CAPACITY L/HR 
RECYCLE RATIO 
MODULE NO 1 
. SPLIT FRACTION 
ROW NO 1 
CONTROL 
INLET STREAM 
PR1 NTING PARAMETERS 
OUTPUT TIME INTERVAL HR 
MAXIMUM BATCH TIME HR 
MAX NO OF OUTPUT PTS 
* RESULTS +++ 
CüM FEED PüMP WORK KW-HR 
MAX E'EED PMP POWER KW 
CYCLE TIME HR 
MAXIMUM TANK VOLükE L 
INLET VOLUME BALANCE 
BATCH VOLUME L 













CONT FEED VOLüME L 
DISC DIAF VOLCM3 L 
TOTAL INLET VOLUME L 
OUTLET VOLtlME BALANCE 
RETENTATE VOLUME L 
PERMEATE VOLUME L 
BLEED VOLtJME L 
TOTAL OUTLET VOL= L 
MODULE BASED RESULTS 
MODULE NO. 
NO IN PARALLEL 
PERMEATE VOtüME L 
PERMEATE MASS KG 
CUM RCYCLE PUMP WORK KW-HR 
MAX RCYCLE PMP POWER KW 
CUM COOLER DUTY KCAL 
MAXIMUM DUTY KCAL/HR 
MINIMUM nnx L/SQM-SEC 




WATER 40.957 14.560 
TPA -39879E-02 .68537L-O1 
WASH -32736 -12170 
TOTAL 41.289 14.751 
COMPONENT CONCENTRATION 
FACTOR 











MODULE BASED PROFILES 
MODULE NO. 1 
MODULE NO. 1 
TIME 
PROFILES OF TANK PROPERTIES 

























TIME UNIT 1 
ELUANT ELUTEl ELUTE2 FEED PERM1 


















































MX XNC MIXNC 
LIQWID LIQUID 
28.0819 15.3205 
653. SOOO 335.5530 
509.0066 276.1903 
MIXED SUBSTREAM PROPERTIES : 
*** LIQUID PHASE *** 
MASSCONC GM/L 
WATER 1006.0915 978.5847 988.2341 1001,6338 1001.0254 
TPA 0 . 0  O .  O O .  O 3.5693-02 3.5693-02 














































PERM2 PERMBl PERMBZ PROD PRODI 
UF UFl OF2 GEL AE'Fl ---- ---- -0.- ---- UFl 
MIXNC MXXNC MIXNC mXNC MIXNC 
LIQUID LIQUID LIQWID LIQUID LIQWID 











STREAM I D  





















































LIQUID LIQUID L I Q U I D  L I Q U I D  
GM/CC 
AVG MW 
MIXED SUBSTREAM PROPERTIES: 




HAM 0 . 0  
FBS 3.8613-08 
GLUC 0 . 0  
ELUENTl 0.0  
ELUENT2 0 . 0  
ELUENT3 O O O 
STREAM ID PROD2 RETI RETZ RETBl RETB2 


























STRUCTURE: NON CONVENTIONAL 
MISSING 4 . 0000 MISSING 
O .  9000 1.0000 1.0000 
MISSING 0 . 0  MISSING 
MISSING 0 . 0  MISSING 
MISSING 1.0000 MISSING 
MISSING -3108.9182 MISSING 
MISSING -746.1510 MISSING 
MISSING 1 , 0000 MISSING 
1 .  O000 1.0000 1.0000 
MISSING 53.0000 MISSING 
MISSI NG 7,3000 MISSING 
MISSING 19.0000 MISSING 
MISSING 12,0000 MISSING 
MISSING 8.7000 MISSING 
MISSING 80.0000 MISSING 
WASB WH2 WASTE WASTEl WASTES 
MISSING 



































WASH WASH2 WASTE WASTEl =TE2 ---- O--- GEL AFFI MF2 
M F 1  AFF2 ---- ---- ---- 







































0 . O 
0 . O 






















































































MIXED SUBSTREAM PROPERTIES : 
*** LIQUID PHASE +*+ 
MAsSCONC GM/L 
WATER 905.0900 
TPA O. 0 
HAM 0 . O 
FBS O. O 
GLUC O. 0 
ELüENT1 226.7000 
ELWENT2 O. O 




Batch T u e  = 215.5 h 
STREAM NAME S-102 S-111 S-115 S-114 S-105 
SOURCE MF-101 V-102 MF-101 INPUT P-101 
DESTINATION UF-101 P-103 OUTPUT C-101 C-101 
-==-ttOll-..--- ==--ml- 
STREAM PROPERTIES 
ACTIVITY U/ml 0.0 O . O 0.0 O . O 0.0 
TEMP OC 4 .O 4.0 4.0 4.0 6.2 
PRES bar 1. O 1.0 1.0 1. O 2.0 
DENSITY g/l 1000.4 1000. O 1001.5 1000. O 1000.4 
COMPONENT FLOWRATES (kg/Batch) 
Biomass 
















- - - - - - - - - - - - - - - - - - - - - - 
S-122 S-101 S-104 
INPUT R-101 V-101 





ACTIVITY U/ml 0.0 O. O 0.0 0.0 O. 0 
TEMP OC 4.0 37. O 4.0 4 . 3 4.0 
PRES bar 1.0 1.0 1.0 1.1 1.0 
DENSITY g/l 1000. O 1000.5 1000.4 1000. O 1000 . O 















--- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -- - 
TOTAL (kg/batch) 1472.6000 5382.3588 232.9962 1938.2022 99.4136 
TOTAL (m3/batch) 1.4726 5.3796 0.2329 1.9382 O. 0994 
STREAM NAME S-118 S-106 S-108 5-119 5-123 
SOURCE INPOT V-103 P-102 INPUT INPUT 
DESTINATION C-101 UF-102 C-102 C-102 C-102 
----m-n- III- 
STREAM PROFERTIES 
ACTXVITY U/ml 0.0 0.0 0.0 0.0 0. O 
TEMP OC 4.0 4.0 4.7 4.0 4.0 
PRES bar 1.0 1.0 1.3 1. O 1.0 
DENSITY g/l 1000. O 1000 . 0 1000.0 1000.0 1000. O 
COMPONENT FLOWRATES ( kg/Batch) 
Biomass 













TOTAL (kg/batch) 2412.0000 201.1099 34.3898 76.4000 382 . O000 





- - - - - - - - - - - 
S-126 S-112 S-125 S-127 S-128 
INPUT P-103 C-103 INPOT R-101 
C-103 C-IO3 OUTPOT R-IO1 OUTPUT 
STREAM PROPERTIES 
ACTIVITY U/ml O. 0 O. O 0.0 O . O 0.0 
TEMP OC 4.0 5.1 4.6 37.0 37.0 
PRES bar 1. O 1.5 1.3 1.0 1.0 
DENSITY g/l 1000.0 1000.0 1000 . O 1000.7 1.2 
COMPONENT E'LOWRATES (kg/Batch) 
Biomass 0 . O000 O. O000 O. O000 O. 0082 O. O000 
Caxb. Dioxide 0 O000 O . O000 O. 0000 O. O000 O. O105 
Elute 1 O. 0000 O . O000 O. 0000 O. O000 0.0000 
Elute 2 O. O000 O. O000 O . 0000 O. O000 O. O000 
Elute 3 0. O000 O. 0000 O. 0000 O. O000 O. O000 
Glucose 0. O000 O. O000 O . O000 5.2400 O. O000 
Glutamine O. O000 O. O000 O. O000 4.3800 O O000 
Ham's F-12 O. O000 O. O000 0.0000 62.4000 O. 0000 
Nitrogen O. O000 0 . O000 O. 0000 O. O000 0.2100 
Oxygen O. O000 O. O000 O. O000 O. O000 O. O700 
Proteins O . O000 O. O000 O. O000 40.2700 O. O000 
t-PA O. O000 O. 0788 O. 0788 O. 0606 0 O000 
Wash 28.3192 O. 9162 11.3277 O . O000 O. O000 
Water 707.9808 22.9060 283.1923 5270.0000 O. O000 
a- -- - 
TOTAL (kg/batch) 736.3000 23.9011 294.5988 5382.3588 0.2905 





S-129 S-130 S-131 S-117 S-132 
G-101 AF-101 INPUT C-101 C-101 
R-101 G-101 AF-101 V-103 OUTPUT 
STREAM PROPERTIES 
ACTIVITY U/ml 0. 0 
TEMP OC 40.0 
PRES bar 1.9 
DENSITY g/l 0.0 
COMPONENT FLOWRATES (kg/Batch) 
Biomass 0 ,0000 
Carb. Dioxide O ,0105 
Elute 1 O. 0000 











TOTAL (kg/batch) 0.2905 O. 2905 0.2905 201.1099 3951.3863 
TOTAL (m3/batch) O. O000 0. 2428 O. 2428 0.2011 3.9513 
STREAM NAME S-109 S-121 S-103 S-116 S-107 
SOURCE C-102 C-102 UF-101 OF-101 OF9102 
DESTINATION V-104 OUTPUT OUTPUT V-101 OUTPUT 
S T W  PROPERTIES 
ACTIVITY U/ml 0.0 
TEMP OC 4.0 
PRES bar 1.0 
DENSITY g/l 1000. O 















TOTAL ( kg/batch) 99.4136 393.3763 4782.4939 232.9962 166.7201 
TOTAL (m3/batch) 0.0994 O. 3934 4.7804 0.2329 0. 1667 
STREAM NAME S-120 S-224 5-133 
SOURCE UF-102 UF-103 UF-103 
DESTINATION P-102 OUTPUT V-102 - 
STREAM PROPERTIES 
ACTIVITY U/ml O. O 
TEMP OC 4.0 
PRES bar 1 . O 
DENSITY g / l  1000. O 
COMPONENT EZOWRATES (kg/Batch) 
Biomass 














TOTAL (kg/batch) 34.3898 75.5125 23.9011 
TOTAL (rn3/batch) 0.0344 O. 0755 O. 0239 
-œ=i- 01 - 
OVERALL MATERIAL BALANCE (kg/Batch) 
(Hours per Batch = 216) 
=-iiPI- -lt 
COMPONENT IN OUT (OUT-IN) 
-Pp
Biomass O. O08230 8.395930 8.387700 
Carb. Dioxide O . 010500 O. 010SQO O. O00000 
Elute I 301.500000 301.500000 O. 000000 
Elute 2 12 . 733333 12.733333 0. O00000 
Elute 3 306.791667 306.791667 0 . O00000 
Glucose 5.240000 1 . 100900 -4.139100 
Glutamine 4.380000 O . O00000 -4.380000 
Eiam's F-12 62.400000 62.400000 O. O00000 
Nitrogen O. 210000 O. 210000 0 . O00000 
Oxygen O. O70000 O. 030000 0 . O00000 
Proteins 40.270000 40.270000 -0.000000 
t-PA O. 060600 O. 192000 O. 131400 
Wash 135.780769 135. 780769 0 . O00000 
Water 11099.994231 11099.994231 O .  O00000 
TOTAL 11969.449330 11969.449330 O. O00000 
Appendix C 
Economic Evaluation 
This appendix contains the cost factors used to carry out caiculatioa of total capital investarnt and 
annual operating COS of the simulated processes. The appendix a h  shows the calculation of 
equipment purchase cost and raw materiai and media cost for cach proccss considend in Chapter 4. 
C. 1 .CAPITAL COST (CTC) 
Table CI 1.2: Detailed estimate of fixed capital and com~arison of cost factors 









Auxil iary Facilities 
Total plant direct cost (TPDC) 
Total Purchased Equipment Cost 
Direct Installed Cost, CDi 
Fixed Capital Investment, CF= 
Engineering 
Construction 
Total plant indirect cost (TPIC) 
Total plant cost (TPC) 
CPE 
3.8 X CpE 
4.6 X CpE 
A.Contractor7s fee 
Total Capital Investment, CTc 1 5.5 X CpE 
B.Con~gency 
Direct fixed Capital @FC) 
0.25 x TPDC 
0.35 x TPDC 
0.60 x TPDC 
(TPDC+ TPIC ) 
0.05 x TPC 
0.10 x TPC 
petrides et ai., 
(1 989) 
0.25 x TPDC 
0.35 x TPDC 
0.60 x TPDC 
(TPDC+TPIC 1 
0.05 x TPC 























































79.8 1 8 
I 
TOTAL 
Unlisted Equipment (20%) 
SUBTOTAL 



















































7 1 -690 
10,335 













































Ion Exchange Column 
Holding Tank 
U I ~ L  

























































































1 S5X1 0° 
3 
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Table C. 1.5: Calculation of Total Equipment Purchase Cost for Fed-Batch Case (A) 
Flowsheet 
1 Equipment 1 Size 1 Quantity 1 Unit 1 Pnce 1 
Blending Tanks 
1 1 1 Microfilter 1 80 m' 1 1 
Axial Cornpressor 
Absolute Filter 











Price 1 ($1 
10,335 ) 20,670 



















































8,000 - ' 

























1.55X 1 0" 
2 
2 




S k e  
I 
Production Bioreactor 3745 L 2 146,000 1 292,000 







6500 L 1 2 











Holding Tank 3000 L 2 7,077 14,154 
Ultrafilter 62,565 125,130 
Holding Tank 500 L 2 3,644 7,288 


















Gel Filtration Column 
43,303 
4,154 
1 O00 L 
200 L 
TOTAL 











































Table C. 1.7: Calculation of Total Equipment Purchase Cost for Airlift Bioreactor 
Equipment 
Blending Tanks 
Production Bioreactor 8000 L 1 
Micro filter 80 m' 1 
Holding Tank 5500 L 1 
Ultrafilter 60 m' 1 
Holding Tank 300 L 1 
Atfinity Chromatography Column 200 L 3 
Holding Tank 250 L 1 
U ltrafilter 10 rnL 1 
Holding Tank 40 L 1 
Afhity Chromatography Column 85 L 1 
Holding Tank 100 L 1 





1 TOTAL I I 1 1 1 1 $2.266X 10' 1 
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133, 








































Gel Filtration Column 
10 L 
75 L 
C.2.ANNUAL OPERATING COST (AOC) 
Table C.2.1: Estimation of Operating Cost (AOC) (Datar et al., 1990) 
1 Raw Material and Media 1 1 





Operating Labor (A) 
Maintenance Labor (B) 














0.25 X A 





Opearting Labor + Supervision Labor + Maintenance Labor = C 
$l9/hour 
0.03 x DFC 
0.40x(A+B) 
0.20 x ( A  + B ) 
0.10 x A 












R & D  
0.10 x DFC 
0.03 x DFC 
0.01 x DFC 
0.02 x DFC 
0.05 x DFC 
0.60 x ( A+B+C) 
0.10 X A 
0.04 X CFc 
0.25 X A 
0.07 X AOC 
0.05 X AOC 
0.6 X C 
0.02 X CFc 
0.005 X CFc 
O. IO X CFc 
0.25 X D 
O. IO X AOC 
0.07 X AOC 
0.01 x AOC 
0.02 x AOC 
0.11 x AOC 
0.10 x DFC 
0.06 x DFC 
0.01 x DFC 
0-02 x DFC 
0.05 x DFC 
0.01 x AOC 
0.05 x AOC 
O. 14 x AOC 
Datar and 
Rosen ( 1 990) 




0.10 x AOC 
0-05 x AOC 
0.07 x AOC 
C.2.1 .Calculation of Raw Material and Media Cost for Base Case: 
1. Media: 6000 L X $25L X 5 X 35 = $26.25 X 106 
11. Buffers: 
a) Aninity elution buffe~: (3x1 54.2 + 105) X 5 X 35 X $lO/L 
= $0.993 X 106 
b) Affmity equilibration bufTer: (3 X 243.3 + 17.5) X 5 X 35 
x $5.5/~=0.72xl o6 
C) Gel elution buffer: (225 X 6) X 5 X 35 X $28.75/L = $6.8 X 106 
TOTAL = 8.512 X 106 
III. Replacement: 
a) Affinity Chromatography media: (200L X 5 X 3 + 85 X 5) X S2000L 
= $6.85 X 106 
b) Gel filter media: (147 L X 4 X 5 X $200/L = $588,000 
c 
1 Membranes: (8O+6O+ 1 (n2.5) m X 5 X $200/m2 = $152,500 
TOTAL = $7.6 X 106 
SUBTOTAL = $42.35 X 1o6 
1 Patent I 1 0.07 X AOC 1 1 
Table C.2.3: Estimation of Operating Cost (AOC) @atm et al., 1990) 





R&D 1 0.07 X AOC 1 I 
A 
0.25 X A 
0.06 X CF= 
3.124 
L 
1 - - I 
0.39 AOC + 61.58 = AOC 














Opearting Labor + Supervision Labor + Maintenance Labor = C 
0.05 X AOC 





0.10 X A 
0.04 X CFc 
0.25 X A 
0.10 X CF= 
0.25 X D 
0.10 X AOC 
6.0 
0.78 
C.Z.2.Calcdation of Raw Material and Media Con for Two-stage Fermentation: 
1. Bioreactor: 
a) Growth Bioreactor: 6000 L X $1 8/L X 5 X 35 = $18.9 X 106 
b) Production Bioreactor: 5000 L X 625L X 3 X 35 = $13.125 X 106 
c) Diafiltration Stream: 1000 L X 5 X 35 X $5/L = $0.875 X 106 
TOTAL = 32.9 X 106 
II. Buffers: 
a) Ion-exchange elution bufEer: (2 X 500 + 30 1.2) X 3 X 35 X $ lOL 
= $1.366 X 106 
b) Ion-exchange equilibration bufTer. (2 X 83.3 + 24) X 3 X 35 
x $5.5/L = 0.11 x 106 
c) Gel elution buffer: (197 X 4) X 3 X 35 X $28.75/L = $2.38 X 106 
TOTAL = 3.856 X 1o6 
In. Replacement: 
a) Ion-exchange Chromatography media: (200L X 2 X 3 + 1 13 X 3) 
X $400/L= $6.85 X 1 o6 
b) Gel filtration media: (147 L X 5 X 3) X $200/L = $440,000 
c ) ~ e m b r a n e s : ( 8 0 ~ 5 + 7 0 ~ 3 + 5 0 ~ 3 + 1 5 ~ 3 + 5 ~ 3 ) m ~  
x$200/m2 = $164,000 
TOTAL = $1.22 X 106 
SUBTOTAL = $37.98 X 106 
Table C .2.4: Estimation of Operating Cost (AOC) (Datar et al., 1 990) 










Plant ûverhead, D 
37-98 
1.8 
0-07 X AOC 
0.05 X AOC 





Opearting Labor + Supervision Labor + Maintenance Labor = C 
0.25 X A 






0.10 X A 
0.04 X CFc 
0.25 X A 
1 Depreciation 1 0.10 X CFC 1 6.0 1 
0.39 AOC + 56.67 = AOC 
AOC = $92.9 X 106 
C.2.3.Calculation of Raw Material and Media Cost for Fed-batch Case A: 




a) Media: 4000 L X S25L X 2 X 35 = $7.0 X 106 
a) Inoculum: 800 X 2 X 35 X $lO/L = $560,000 
b) Continuous feed: (300 X 2 X 35 X $10/L) = $21 0,000 
Distri bution 
R & D  
TOTAL = 7.77 X 106 
0.10 X AOC 
0.07 X AOC 
II. BufTers: 
a) Aninity elution buffer: (3750 + 580) X 2 X 35 X $lO/L = $3.03 X 106 
b) Minity equilibration bufTer: (2267 + 162.5) X 2 X 35 
X $5.5/L = 0.935~10~ 
c) Gel elution buffer: (120 X 6) X 2 X 35 X $28.75/L = $2.656 X 106 
TOTAL = 6.62 X 1 o6 
III. Replacement: 
a) Affinity Chromatography media: (1860 + 438) X 2 X $2000/L 
= $9.2 X 106 
a) Gel filter media: (147 L X 6 X 2) X â200L = $352,800 
c) Membranes: (65+65+50+60+20) m2 X 2 X $200/m2 = $104,00 
TOTAL = $9.34 X 1 o6 
SUBTOTAL = $23.73 X 1 o6 
Table C.2.5: Estimation of Operating Cost (AOC) (Datar et al., 1 990) 
1 Raw Material and Media 1 1 23.73 1 
I I 




0.39 AOC + 36-52 = AOC 
AOC = $59.86 X 106 
C.2.4.Calculation of Raw Material and Media Cost for Fed-batch Case B: 
A 
1 0.25 X A 
0.06 X CFc 
LBioreactor 
a) Media: 3000 L X $25L X 2 X 35 = $5.25 X 106 
b) Inoculurn: 700 L X lE 1 O L  X 2 X 35 = $0.49 X 106 















Opearting Labor + S u p e ~ s i o n  Labor + Maintenance Labor = C 
Operating Supplies 1 0.10 X A 
II. Buffers: 
a) Affinity elution b s e r  (145.8 X 6 + 190) X 2 X 35 X $10L = $745,360 
b) Affinity equilibration bufTer: (236.7 X 6 + 29.17) X 2 X 35 
X $5.5/L = $558,000 











TOTAL = $2.19 X 1 o6 
0.04 X CFc 
0-25 X A 
0.07 X AOC 
0.05 X AOC 
0.6 X C 
0.02 X CFc 
0.005 X CFC 
0.10 X CFc 
0.25 X D 
Distribution 
m. Replacement: 
a) e t y  Cbromatography media: (195L X 6 X 2 + 135 X 2) X $2OOOL 
= â5.22 X 106 
0.10 X AOC 1 
b) Gel filter media: (147 L X 2 X 2) X $ 200lL = $1 17,600 
c) Membranes: (60+60+45+10+5) m2 X 2 X $200/m2 = $72,000 
TOTAL = $5.41 X 106 
SUBTOTAL = $13.44 X 106 
Table C.2.6: Estimation of Operating Cost (AOC) @atm et al., 1990) 
1 I 
. - .. 
1 patent 1 0.07 X AOC 1 1 







~ L t e n a n c e  Labr 
I 
1 0.06 X CFc 
Opearthg Labor + Supe~sion Labor + Maintenance Labor = C 
1 
. - -  
I R ~ L D  I 1 0.07 X AOC 1 1 
A 
0.25 X A 
Operathg Supplies 
Maintenance Supplies 
0.39 AOC + 27.27 = AOC 
AOC = W.7 X 106 
0.10 X A 















0.05 X AOC 
0.6 X C 
0.02 X CFc 
0.005 X CF= 
O. 1 O X CFc 





a) AfKnity elution buffer: (181.3 + 39.42) X 6 X 35 X $10/L = $0.463 X 106 
b) Affmity equiübration buffer: (126.7 + 5.83) X 6 X 35 
X S5.5L-O. 15 X lob 
c) Gel elution buffer: (1 13 X 2) X 3 X 35 X $28.75/L = $0.68 X 106 
TOTAL = 1.298 X 106 
0.25 X D 
0.10 X AOC 
0.50 
III. Replacement: 
a) e t y  Chromatography media: (85 L + 30 L) X $2000/L 
= $230,000 
b) Gel filter media: (75 X 2) X $200/L = $30,000 
c) Membranes: (1 5+15+ll+2+1) m2 X $200/m2 = $8,800 
TOTAL = $0.27 X 106 
1 1 
- 
1 patent 1 0.07 X AOC 1 1 
Table C.2.7: Estimation of Operating Cost (AOC) (Datar et al., 1990) 






Plant Overhead, D 
I R & D  1 1 1 0.07 X AOC 1 , 
A 
0.25 X A 
0.06 X CF= 
0.39 AOC + 11.03 = AOC 





0.05 X AOC 




















0.02 X CFC 
0.005 X CFc 
0.10 X CFc 
0.25 X D 
0.10 X AOC 
0.10 X A 
0.04 X CFc 
0.25 X A 
Appendix D 
KLa, Agitation and Power Input Requirement 
This appendix presents the caiculation of &a aad power requirement used for simulation of the 
bimactor. An estimate of &a is obtained following the basic approach in its calculath. Power 
rtquPcmcnt is caiculated using two appmachcs - simiiar fluid turnover and constant Koimgorov 
length scale. 
Dele Calcuiation of KLa using Basic Approach 
1 .  Determination of Bubble diameter, dB: 
2. Detemination of Bubble type: 
3. Calculation of Re: 
Bubble rise velocity, Ub : 16 C I ~ S  
4. Choose correlation: 
5.  Determination of 'a': 
rigid bubble : d ' ~  - 10 
mobile bubble : d ' ~  - 50 
D.2. Calculation of Agitation and Power Input Requirements 
D.2.1. Approach A: Similar Fluid Turnover (Chisti, 1993) 
If oxygen tramfer rate is not a Iimiting factor scale-up can be carried out by maintainhg a sirnilar 
Table D2.1: Cornparison of aspect ratio 
Buid turnover, that is impeller pumping rate per unit bioreaactr 







300 L bioreactor, (N di3)/V = 0.051 
6000 L bioreactor, 
Length/Diarnter 
( L W  
1 .O 
1.2 
(N' di")^' = 0.05 1 
N' = 1.28 s" = 77 rpm 
Power Input = N ~ ( N ' ) ~ ( ~ ~ ' ) * ~  = 77.5 W
Power Input per Unit Volume = 13 w/m3 








volume, at the two scale. The 
Viscosity, p = 1.2 X 10 " Pa.s 
Density, p = 1000 kg/m3 
a 2 Kinematic Viscosity, v = Np = 1 2 X 10 m Is 
For the base case (Chisti, 1993): 
No = 1.67 s-' 
Rei9o = 61 375 
Np = 0.4 
q = P N = 3 . 3 6 X  l o J  
La = = 130 p 
Agitation rate for sclaed up vessel: 
Power Input =  di')'^ = 6.94 W 
Power Input per Unit Volume = 1.1 5 w/m3 
Table D.2.2: Resuits of trial and error runs 






































KLa, Agitation and Power Input Requirement 
This appeadix prcsents the calculation of &a and powa quiremnt  used for simulation of the 
bioreactor. An esErnate of &a is obtained foliowing the basic approach in its caiculation. Power 
requhmnt is caiculatcd using two appmachcs - similar fluid turnover and constant Kolmogorov 
length scaie. 
E. 1. BIOREACTOR 
SENSITIVITY S-1 
DEFINE XRATE BLOCK-VAR BLOCK=FERMENT VARIABLE=BIOMASS-RATE & 
SENTENCE=BIOMASS-RATE ID 1 4 0  
DEFINE SRATE BLOCK-VAR BLOCK=FERMENT VAR?ABLE=SUBSTRT-RATE & 
SENTENCE=SUBSTRT-RATE ID M O  
DEFINE XCONC BLOCK-VAR BLOCK=FERMENT VARIABLE=BIOMASS-CONC & 
SENTENCE=BIOMASS-CONC ID 1 4 0  
DEFINE SCONC BLOCK-VAR BLOCK=FERMENT VARiABLE=SUBSTRT-CONC & 
SENTENCE=SUBSTRT-CONC ID 1=50 
DEFINE NRATE BLOCK-VAR BLOCK=FERMENT VARIABLE=NSOURCE-RATE & 
SENTENCE=NSOURCE-RATE ID 1=50 
DEFINE MIN02 BLOCK-VAR BLOCK=FERMENT VAR,IABLE=MIN-DISOX & 
SENTENCE=RESULTS 
DEFINE MINKLA BLOCK-VAR BLOCK=FERMENT VARIABLE=MIN-KLA & 
SENTENCE=RESULTS2 
DEFINE F02 BLOCK-VAR BLOCK=FERMENT VARIABLE=FINAL-DISOX & 
SENTENCE=RESULTS2 
DEFINE ISAT02 BLOCK-VAR BLOCK=FERMENT VARIABLE=INIT-SAT-O2 & 
SENTENCE=RESULTS2 
D E F N  D02PER BLOCK-VAR BLOCK=FERMENT VARIABLE=D02-PERCENT & 
SENTENCE=D02-PERCENT ID 1=50 
TABULATE 1 "XRATE" 
TABULATE 2 "SRATE" 
TABULATE 3 "XCONC" 
TABULA= 4 "SCONC" 
TABULATE 5 ''NUTE" 
TABULATE 6 "MIN02" 
TABULATE 7 "-A" 
TABULATE 8 "FOS" 
TABULATE 9 "ISAT02" 
TABULATE 10 "D02PER 
VARY BLOCK-VAR BLOCK=FERMENT VARIABLE=INIT-SAT-VAL & 
SENTENCE=DISSOLVED-O2 
RANGE LOWER="O.O 195E-03" UPPER="O.O975E-03" NPOINT="5" 
VARY BLOCK-VAR BLOCK=FERMENT VARIABLE=INOC-CONC & 
SENTENCE=PARAM 
RANGE LOWER="0.03" UPPER="0.25*' NPOINT="5" 
VARY BLOCK-VAR BLOCKeFERMENT VARIABLE=INOC-VOL & 
SENTENCE=PARAM 
RANGE LOWER="500" UPPER="2000" NPOINT="4" 
VARY BLOCK-VAR BLOCK=FERMENT VARIABLE=VOL-CHARGE & 
SENTENCE=PARAM 
RANGE LOWR="2000" UPPER="400OW NPOINT="3" 
VARY BLOCK-VAR BLOCK=FERMENT VARIABLE=MIN-02 SENTENCE=PARAM 
RANGE LOWER="O. 1 5" UPPER="OSn NPOINT="Sn 
VARY BLOCK-VAR BLOCK=FERMENT VARIABLE=KLA SENTENCE=PARAM 
RANGE LOWER="2" UPPER="8" NPOINT="S" 
VARY BLOCK-VAR BLOCK=FERMENT VARIABLE=VALUE-LIST & 
SENTENCE=REAL-KINET ELEMENT=l 
RANGE LO WER="O.S" UPPER="4.0t' INCR="OS " 
VARY BLOCK-VAR BLOCK=FERMENT VARIABLE=VALUE-LIST & 
SENTENCE4UX.L-KINET ELEMENT=4 
RANGE LOWER="0.001" UPPER="0.003SW NPOINT="5" 
VARY BLOCK-VAR BLOCK=FERMENT VARIABLE=VALUE-LIST & 
SENTENCE=REAL-KINET ELEMENT4 
RANGE LOWER="0.003" UPPER="0.009" NPOINT="SW 
VARY BLOCK-VAR BLOCK=FERMENT VARIABLE=VALUE-LIST & 
SENTENCE=REAL-KINET ELEMENTz7 
RANGE LO WER="Sn UPPER=" 1 O" NPOINT="SW 
VARY BLOCK-VAR BLOCK=FERMENT VARIABLE=VALUE-LIST & 
SENTENCE=REAL-KTNET ELEMENT=8 
W G E  LOWER="O.O 1 " UPPER="0.02" NPOINT="5" 
VARY BLOCK-VAR BLOCK=FERMENT VARIABLE=VALUE-LIST & 
SENTENCE=REAL-KINET ELEMENT=9 
RANGE LOWER="0.03" UPPER="0.05" NPOiNT="S" 
STREAM-REPOR NOMOLEFLOW MASSFLOW BPS-REPORT=YES 
E.2. CONTINUOUS MEMBRANE SEPARATION UNITS 
SENSITIVITY S-l 
DEFINE PF BLOCK-VAR BLOCK=MICROF VARIABLE=PERM-FLUX & 
SENTENCE=RESULTS 
DEFINE SR BLOCK-VAR BLOCK=MICROF VARIABLEeSHEAR-RATE & 
SENTENCE=RESULTS 
DEFINE FP BLOCK-VAR BLOCK=MICROF VARIABLE=FLOW-PERM & 
SENTENCE=RESULTS 
DEFINE VR BLOCK-VAR BLOCK=MICROF VARIABLE=VOL-RATIO & 
SENTENCE=RESULTS 
DEFINE VR BLOCK-VAR BLOCK=MICROF VARIABLE=VOL-RATIO & 
SENTENCE=RSULTS 
DEFINE CF BLOCK-VAR BLOCK=MICROF VARIABLE=CONC-FACTOR & 
SENTENCE=CONC ID l=TPA 
DEFINE FR BLOCK-VAR BLOCK=MICROF VARIABLE=FRAC-RET & 
SENTENCE=RETAINED ID 1 =TPA 
DEFINE RG BLOCK-VAR BLOCK=MICROF VARIABLE=RESIS-GEL & 
SENTENCE=RESULTS2 
DEFINE PC BLOCK-VAR BLOCK=MICROF VARIABLE=PRM-CONC & 
SENTENCE=PERMEATE ID 1 = P A  
DEFINE KC BLOCK-VAR BLOCK=MICROF VARIABLE=KEYCONC & 
SENTENCE=RESULTS 
TABULATE 1 "PF" 
TABULATE 2 "SR" 
TABULATE 3 "FP" 
TABULATE 4 "VR" 
TABULATE 5 "CF'' 
TABULATE 6 "FR 
TABULATE 7 "RG" 
TABULATE 8 "PC" 
VARY BLOCK-VAR BLOCK=MICROF VARIABLE=FRACTION & 
SENTENCE=DENATURE ID 1 = P A  
RANGE LOWER="0.05" UPPER="0.2" NPOINT="2" 
VARY BLOCK-VAR BLOCK=MICROF VARIABLE=RGELB & 
SENTENCE=RESIS-SERIES 
RANGE LO WER="-0.5 " UPPER="-.85" NPOINT="2" 
VARY BLOCK-VAR BLOCK=MICROF VARIABLE=RGELC & 
SENTENCE=RESIS-SERIES 
VARY BLOCK-VAR BLOCK=MICROF VARIABLE=RGELC & 
SENTENCE=RESIS-SERIES 
RANGE LOWER="O. 1 " UPPER="0.3" NFOINT="2" 
VARY BLOCK-VAR BLOCK=MICROF VARIABLE=RGELO & 
SENTENCE=RESIS-SERIES 
RANGE LOWER=" 1 E+12" UPPER="9E+l2" NPOINT="5" 
E.3.BATCH MEMBRANE SEPARAnON UMT 
SENSITMTY S-1 
DEFTNE TV BLOCK-VAR BLOCK=UF VARIABLE=TVOLVALUE & 
SENTENCE=TVOL-ES ID 1=5 
DEFINE F BLOCK-VAR BLOCKzUF VARIABLE=PLUXVALUE & 
SENTENCE=PFLUX ID l=5 D2=I 
DEFINE TC BLOCK-VAR BLOCK=UF VARIABLE=VALUE & 
SENTENCE=TCONC-ES ID l=5 ID2=TPA 
DEFINE PP BLOCK-VAR BLOCKzUF VARIABLE=P2-POWER & 
SENïENCE=RESULTS2 ID1 =I 
DEFINE PP BLOCK-VAR BLOCK4JF VARIASLE=P2-POWER & 
SENTENCE=RESULTS2 ID 1=l 
;; DEFINE VEL BLOCK-VAR BLOCGUF VARIABLE=VEtVALUE & 
;; SENTENCE=VEL-RES ID 1 4  0ID24 
O *  9 7 DEFINE FF BLOCK-VAR BLOCK=UF VARIABLE=FRICFAC & 
;; SENTENCE=PDROP m = 1  
;; DEFINE PRET BLOCK-VAR BLOCK4JF VARIABLEZP-RET & 
;; SENTENCE=PDROP IDI=l 
TABULATE 1 "TV" 
TABULATE 2 "F" 
TABULATE 3 "TC" 
TABULATE 4 "PP" 
; TABULATE 5 "VEL" 
; TABULATE 6 "FF" 
; TABULATE 7 "PRET" 
VARY BLOCK-VAR BLOCK=UF VARIABLE=XRECYCLE & 
SENTENCE=MODULE-REC ID 1 4  ID24 
RANGE LOWER=" 10" UPPER="201' NPOINT="SW 
VARY BLOCK-VAR BLOCKzUF VARIABLE=PUMP-CAPACN & 
SENTENCE=SEQ-PARAM ID 1 = 1 
RANGE LO WER="7Sm UPPER=" 150" INCR="SOn 
VARY BLOCK-VAR BLOCK=UF VARIABLE=DCOEF SENTENCE=FOULING & 
ID1=1 
RANGE LOWER="3.33E-05" UPPER=" 1.766E-04" NPOINT="5" 
;; VARY BLOCK-VAR BLOCK=UF VrUUABLE=VOLUME SENTENCE=SEQ-PARAM & 
* *  IDl=f 9 9 
* *  RANGE LOWER="500" UPPER="2000" INCR="500M 99  
VARY BLOCK-VAR BLOCK=UF VAR.IABLE=RGELC SENTENCE=FLUX & 
ID1=1 
VARY BLOCK-VAR BLOCK=UF VARIABLE=RGELC SENTENCE=FLUX & 
ID1=1 
RANGE LO WER="O. 15" UPPER="0.3" NPOINT="4" 
STREAM-REPOR NOMOLEFLOW MASSFLOW PROPERTIES=MASSCONC 
E.4. AFFINITY CHROMATOGRAPHY COLUMN 
SENSITIVITY S-l 
DEFINE REC BLOCK-VAR BLOCK=AFF VARIABLE=RECOV & 
SENTENCE=PERFORMANCE ID l=PROD ID2=TPA 
DEFINE PP BLOCK-VAR BLOCK=AFF VARIABLE=PERF-PURITY & 
SENTENCE=PERFORMANCE ID 1 =PROD ID2=TPA 
TABULATE 1 "REC" 
TABULATE 2 "PP" 
VARY BLOCK-VAR BLOCK=AFF VARIABLE=CAPACITY SENTENCE=SOLUTES & 
IDl=TFA 
RANGE LOWElW.1" UPPER="0.7" NPON="7" 
VARY BLOCK-VAR BLOCK=AFF VAIUABLE=KLOAD SENTENCE=SOLUTES & 
RANGE LOWER=".lt' UPPER="0.7" NPOINT="7" 
VARY BLOCK-VAR BLOCK=AFF VARIABLE=KLOAD SENTENCE=SOLUTES & 
ID 1 =TPA 
RANGE LOWER="75" UPPER=" 175" NPOINT=" 1 O" 
VARY BLOCK-VAR BLOCK=AFF VARIABLE=KLOAD SENTENCE=SOLUTES & 
ID 1 =FBS 
RANGE LOWER=" 1 .Sn UPPER="SO" NPOINT=" l On 
STREAM-REPOR NOMOLEFLOW MASSFLOW PROPERTIES=MASSCONC 
E.5. ION-EXCHANGE CHROMATOGRAPHY COLUMN 
SENSITIVITY S-l 
DEFINE REC BLOCK-VAR BLOCK=IEX VARIABLE=RECOV & 
SENTENCE=PERFORMANCE ID 1 =PROD ID2=TPA 
DEFINE PP BLOCK-VAR BLOCK=IEX VARIABLE=PERF-PURIT'Y & 
SENTENCE=PERFORMANCE ID 1 =PROD ID2=TPA 
DEFTNE CS BLOCK-VAR BLOCK=IEX VARIABLE=RES-CWSLOPE & 
SENTENCE=SOLUTE-RES IDI=TPA 
DEFINE X BLOCK-VAR BLOCK=IEX VARIABLE=CONCEN & 
SENTENCE=CONC-PROFILE ID 1 =TPA ID2=75 
TABULATE 1 "REC" 
TABULATE 2 "PP" 
TABULATE 3 "CS" 
TABULATE 4 "X" 
VARY BLOCK-VAR BLOCK4EX VARIABLE=KLOAD SENTENCE=SOLUTES & 
ID 1 = T ' A  
RANGE LOWER="SW UPPER=" 100" NPOWT="Sn 
VARY BLOCK-VAR BLOCK=IEX VARIABLE=ELU-MOLARITY & 
SENTENCE=PROFILE ID1 =l 
RANGE LOWER="0.05" UPPER=I1 1 .O" NPOINT="2" 
VARY BLOCK-VAR BLOCK=IEX VARLABLE=ELUTE-VOL SENTENCE=PROFILE & 
IDI=l 
W G E  LOWER="200" UPPER="70OW NPOINT="2" 
STREAM-REPOR NOMOLEFLOW MASSFLOW PROPERTIES=MASSCONC 
E.6. GEL FLTRATION COLUMN 
SENSITIVITY S-l 
DEFINE R BLOCK-VAR BLOCK-GEL VARIABLE=RECOVERY & 
SENTENCE=PERFORMANCE ID 1=PROD ID2=TPA 
DEFINE P BLOCK-VAR BLOCK=GEL VAR.MBLE=PURIY & 
SENTENCE=PERFORMANCE ID l=PROD ID2=TPA 
DEFINE RES BLOCK-VAR BLOCK=GEL VARIABLE=RESOLUTION & 
SENTENCE=RESOLUTION ID l=TPA fD2=FBS 
D E F N  C BLOCK-VAR BLOCKsGEL VAR.IABLE=CONC-FACTOR & 
SENTENCE=RESOLUTION ID 1 =TPA ID2=FBS 
DEFINE C BLOCK-VAR BLOCKeGEL VARIABLE=CONC-FACTOR & 
SENTENCE=PERFORMANCE ID 1 =PROD ID2=TPA 
DEFINE DELP BLOCK-VAR BLOCKzGEL VARIABLE=DELP & 
SENTENCE=RESULTS 
DEFINE N BLOCK-VAR BLOCKzGEL VARJABLE=NCOLUMN & 
SENTENCE=RESULTS 
DEFINE TIME BLOCK-VAR BLOCK=GEL VARIABLE=CYCLE-TIME & 
SENTENCE=RESULTS 
DEFTNE USE BLOCK-VAR BLOCKzGEL VARIABLE=COLUMN-USE & 
SENTENCE=RESULTS 
TABULATE 1 " R  
TABULATE 2 "P" 
TABULATE 3 "RES" 
TABULATE 4 "C" 
TABULATE 5 "DELP" 
TABULATE 6 "N" 
TABULATE 7 "TIME 
TABULATE 8 "USE" 
VARY BLOCK-VAR BLOCK=GEL VARIABLE=LENGTH SENTENCE=PARAM 
RANGE LOWER=''0.2'' üPPER=" 1 .O" INCR="0.2" 
VARY BLOCK-VAR BLOCKzGEL VARIABLE=LOAD-VOL SENTENCE=PARAM 
RANGE LOWER="3" UPPER=" 15" NCR="3" 
VARY BLOCK-VAR BLOCKzGEL VARIABLE=FLOW-RATE SENTENCE=PARAM 
RANGE LOWER="6" UPPER="6OW INCR=" 1 O" 
STREAM-REPOR NOMOLEFLOW MASSFLO W PROPERTIES=MASSCONC 

1 ! ! I ! ! ! 
!= ! ! ! ! ! I 
! 2000,0000 ! 1.5210-02 ! -2.7704-02 ! 0.1327 ! 0.6196 ! -1,1771-02 ! 
!e 3000.0000 ! 1.5210-02 ! -2.7704-02 ! 0.1327 ! 0.6196 ! -1.1771-02 ! 
! 4000.0000 ! 1.4601-02 ! -5,5105-02 ! 7.6319-02 ! 0.7385 ! -2.3236-02 ! 
! 5000,0000 ! 1.4587-02 ! -6.8851-02 ! 6.3512-02 ! 0.7687 ! -2,9023-02 ! -----.------------------------------------------------------------------------- 
e ERRORS OCCURRED FOR VALUES I N  THIS ROW. 
------------------------------------------------------------------------------- 
! VARY 1 ! XRATE ! SRATE ! XCONC ! SCONC ! NRATE I 
! FERMENT ! ! I I I I 
! REAL-KIN ! ! ! I I I 
! VALUS?.-LI ! ! ! I I I 
! ! ! I I I 1 
! (Gd ! KWHR ! KG/HR ! GM/L ! GM/L ! KG/HR I 
! ! ! ! ! I I 
! ! ! ! I I ! 


----------------------O---- ---O ------------------------------------------------ 
! VARY I ! PF ! SR ! FP ! VR ! CF I 
! MfCROF ! I I ! I ! 
! RESIS-SE ! I I ! t ! 
! RGELO I ! I ! ! I 
I I ! I ! ! I 
I ! L/SQM-SE ! l/HR ! L/MIN ! t I 
I ! C ! ! ! ! I 

























Result of sensitivity study for the bioreactor 

























































































































Table F.7.4: Result of sensitivity study for affinity chromatography 
Capacity 
Kioad 
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50% 4 17% ? 11% 'r 
Raw 
Mat. 
50% î 50% 'T' 50% ? 
Recovery M D  
50% 'r 4X 
Appendix G 
Kinetic Mode1 
G.1.Growth and Product formation kinetics: 
whm,  preferential substnut utiiization constant 
extent of non-growth association 
extent of growth association 
spccinc growthrate (h -1) 
maximum specific growth rate ( h - 1 
spccifïc rate of ali Iysis (h-1) 
apparent specifc chth  rate ( h-1) 
specific bios ynthetic energy rate 
spcclfic maintenance energy rate 
glucose oxidation 
product changeover point 
chemicai degradation of glutamine constant h. 0.013 
pcrcentage of oxygcn in the air mimat Pa= 10 
Appendix H 
Charge on t-PA Molecule 
Let KM = Intrinsic dissociation constant; characteristic dissociation 
constant of a specific side chah residue 
ni, nj = nurnber of residues per protein molecule 
ai, aj = fiaction of residue that lost a proton 
Group 
side chain - COOH (Asp, Glu) 
phenoloc - OH (Tyr) 
sulphydryl - 5H (Cysh) 
imidazole (His) 
side chain - NH2 (Lys) 
No. in &PA puw Charge after Type 
molecde proton loss 
The requirrd equations are: 
= 0.5 Zci 2: 
W = 3.57 [ltb - (0.33~*3/(1+(2.5+b) 0.33~O')] 
pH = p L m  + log aJ(1 ai) - 0.868 Z W 
Z = mi ( l a i )  - fij aj 
In this calculation, it was assumed that, b =15 A" and p = 0.05. W was calculated from equation 
A.H.2 and was found to be 0.124. Then a Gtd was assumeci and ai and aj were calculated from 
equation A.H.3. Next, a 2, was caiculated fiom equation A.H.4 using the a values obtained. This 
trial and enor approach was continues until convergence was obtained. Table A. H.l shows the 
result of the various trials. 
So, the charge on t-PA molecule was taken as 14.5 for simulation of the ionexchange columns. 





Z o ~ d  
1 .O 
2.0 
3 .O 
4.0 
Z- 
30.6 
28.3 
26.3 
24.54 
